dalteparin has been researched along with Thrombosis in 474 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with no prophylaxis, the use of low-dose warfarin would be expected to reduce the number of cases of confirmed deep-vein thrombosis from about 1000 (per 10,000 patients) to 420 and the number of thromboembolic deaths from about 250 to 110." | 10.17 | Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. ( Colditz, GA; Menzin, J; Oster, G; Regan, MM; Richner, RE, 1995) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 9.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "6 μg/ml to unfractionated heparin (UFH), enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis under in vitro conditions." | 9.19 | In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis. ( Buerke, M; Drouget, L; Hauroeder, B; Kaeberich, A; Krezel, C; Maedgefessel, L; Neuhart, E; Raaz, U; Schlitt, A; Vogt, A; Werdan, K, 2014) |
| "We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT)." | 9.14 | Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. ( Balestreri, L; Bertuzzi, CA; Bidoli, E; De Cicco, M; Fabiani, F; Fantin, D; Malafronte, M; Matovic, M; Morassut, S; Pacenzia, R; Steffan, A; Veronesi, A, 2009) |
| " The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture." | 9.12 | Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007) |
| "Warfarin at a fixed, very low dose and nadroparin at a fixed, prophylactic dose had comparable benefit-to-risk ratios in the prevention of thrombosis associated with central venous catheters in cancer patients." | 9.10 | Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. ( Buchmüller-Cordier, A; Charlet, V; Decousus, H; Dutrey-Dupagne, C; Fournel, P; Jacquin, JP; Laporte, S; Mille, D; Mismetti, P, 2003) |
| " Although warfarin is usually used for long-term secondary prevention, it is not the drug of choice for a variety of conditions such as antiphospholipid thrombosis syndrome, sticky platelet syndrome, and patients with malignancy and other medical conditions who have failed adequate warfarin doses." | 9.09 | Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety--a preliminary report. ( Bick, RL; Rice, J, 1999) |
| "The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)." | 9.08 | Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997) |
| "Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy." | 9.08 | A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H, 1998) |
| "Bemiparin reduced intimal hyperplasia and prevented thrombosis angiogenesis, but dabigatran did not prevent intimal hyperplasia, and its anticoagulation effect was more than the antithrombotic effect." | 7.91 | Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy. ( Aydin Ozturk, P; Ozturk, U; Yilmaz, T, 2019) |
| "Drug fever caused by dalteparin-sodium (DS), a low-molecular-weight derivative of heparin, is neither listed in the official drug information and nor published as a case report until today." | 7.83 | Dalteparin-sodium induced drug fever in a neonate. ( Nydert, P; Obaya, S; Wackernagel, D, 2016) |
| "To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period." | 7.79 | Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013) |
| "In patients undergoing percutaneous coronary intervention, catheter thrombosis is more frequent with fondaparinux than heparin." | 7.77 | Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. ( Fredenburgh, JC; Liao, P; Roberts, R; Stafford, AR; Weitz, JI; Yau, JW, 2011) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Beginning in 2004, dalteparin doses based on activated clotting time (ACT) were administered for hepatic vessel thrombosis prophylaxis in living donor liver transplantation (LDLT)." | 7.75 | Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation. ( Ikegami, T; Masuda, Y; Mita, A; Miyagawa, S; Nakazawa, Y; Ohno, Y; Terada, M; Uchikawa, Y; Urata, K, 2009) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 7.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| "The antithrombotic effects of direct (ximelagatran and hirudin) and indirect (dalteparin) anticoagulants were compared using a deep venous thrombosis (DVT) treatment model in conscious rats." | 7.71 | Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. ( Carlsson, S; Elg, M; Mattsson, C, 2002) |
| "We investigated the efficacy, safety and relation of dose to plasma anti-Xa activity of the low molecular weight heparin (LMWH) dalteparin in prophylaxis and therapy of arterial and venous thrombosis in pediatric patients." | 7.70 | The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. ( Auberger, K; Flemmer, A; Nohe, N; Praun, M; Rümler, R, 1999) |
| "To test the safety and feasibility of treating deep vein thrombosis (DVT) in an outpatient setting, using the low molecular weight heparin dalteparin, to calculate the potential and actual cost reductions achievable as a result of such a treatment regimen." | 7.69 | Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. ( Holmström, M; Lindmarker, P, 1996) |
| "However, upper limb deep vein thrombosis is poorly studied with scant data on the use of direct oral anticoagulants in noncatheter-related deep vein thrombosis." | 6.82 | Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. ( Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A, 2022) |
| "Catheter thrombosis has never been reported in any trial using bivalirudin." | 6.73 | Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. ( Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K, 2008) |
| "Dalteparin or dextran was used during delivery." | 6.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| "One dalteparin-treated patient had a PE confirmed by V/Q scan; another had progressive thrombosis with swelling in the affected limb." | 6.68 | A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. ( Grankvist, S; Hallert, C; Jauro, I; Ketola, K; Kim, HC; Kiviniemi, H; Koskivirta, H; Luomanmäki, K; Sörskog, L; Vilkko, P, 1996) |
| "Compared with no prophylaxis, the use of low-dose warfarin would be expected to reduce the number of cases of confirmed deep-vein thrombosis from about 1000 (per 10,000 patients) to 420 and the number of thromboembolic deaths from about 250 to 110." | 6.17 | Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. ( Colditz, GA; Menzin, J; Oster, G; Regan, MM; Richner, RE, 1995) |
| "Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT." | 5.72 | An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022) |
| "Dalteparin can be used to treat thrombosis in newborn infants." | 5.62 | Dalteparin in Newborn Thrombosis, Time for a New Starting Dose. ( Bierings, M; Huisman, A; Steenman, F; Vijlbrief, DC, 2021) |
| "Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome." | 5.51 | Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 5.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "Overall thrombus weight, anti-Xa activity and electron microscopic features such as deposits of platelets, erythrocytes and fibrin on the catheter surface were quantified as endpoints." | 5.36 | Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. ( Buerke, M; Busshardt, M; Hauroeder, B; Maegdefessel, L; Plehn, A; Raaz, U; Schlitt, A; Werdan, K, 2010) |
| "Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH." | 5.36 | Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. ( Schiele, F, 2010) |
| "Dysfibrinogenemia is a disorder of fibrinogen structure and is associated with a functional abnormality." | 5.34 | Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis. ( Ganti, AK; Haire, WD; Vose, JM, 2007) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| " Low-molecular-weight heparins prevent venous thrombosis as effectively as heparin and have better bioavailability and a longer plasma half-life, which explains the increased use of low-molecular-weight heparins as substitutes for heparin in clinical practice." | 5.32 | Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. ( Arnljots, B; Dahlbäck, B; Malm, K, 2003) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 5.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "To assess the effect on thrombus growth, we determined the accretion of 125I-labeled fibrinogen onto autologous non-radioactive thrombi preformed in the jugular veins of rabbits." | 5.29 | Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. ( Biemond, BJ; Büller, HR; Levi, M; Nurmohamed, MT; ten Cate, JW, 1994) |
| "6 μg/ml to unfractionated heparin (UFH), enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis under in vitro conditions." | 5.19 | In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis. ( Buerke, M; Drouget, L; Hauroeder, B; Kaeberich, A; Krezel, C; Maedgefessel, L; Neuhart, E; Raaz, U; Schlitt, A; Vogt, A; Werdan, K, 2014) |
| " Patients age > or =75 years treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset." | 5.14 | Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Alexander, KP; Bertrand, ME; Feit, F; Gersh, BJ; Hoekstra, J; Lopes, RD; Manoukian, SV; Ohman, EM; Pollack, CV; Stone, GW; White, HD, 2009) |
| "We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT)." | 5.14 | Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. ( Balestreri, L; Bertuzzi, CA; Bidoli, E; De Cicco, M; Fabiani, F; Fantin, D; Malafronte, M; Matovic, M; Morassut, S; Pacenzia, R; Steffan, A; Veronesi, A, 2009) |
| "In an analysis of the Melagatran Thrombosis Prophylaxis in Orthopedic Surgery (METHRO) III study, we evaluated whether concomitant administration of aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) with the direct thrombin inhibitor melagatran/ximelagatran or the low-molecular-weight heparin enoxaparin increased bleeding in patients undergoing major joint surgery." | 5.12 | Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. ( Agnelli, G; Andersson, M; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Mouret, P; Ogren, M; Panfilov, S; Rosencher, N, 2006) |
| " The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture." | 5.12 | Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007) |
| "Warfarin at a fixed, very low dose and nadroparin at a fixed, prophylactic dose had comparable benefit-to-risk ratios in the prevention of thrombosis associated with central venous catheters in cancer patients." | 5.10 | Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. ( Buchmüller-Cordier, A; Charlet, V; Decousus, H; Dutrey-Dupagne, C; Fournel, P; Jacquin, JP; Laporte, S; Mille, D; Mismetti, P, 2003) |
| "In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure." | 5.09 | Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999) |
| " Although warfarin is usually used for long-term secondary prevention, it is not the drug of choice for a variety of conditions such as antiphospholipid thrombosis syndrome, sticky platelet syndrome, and patients with malignancy and other medical conditions who have failed adequate warfarin doses." | 5.09 | Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety--a preliminary report. ( Bick, RL; Rice, J, 1999) |
| "5, or 10 mg once daily) relative to low-molecular-weight heparin (dalteparin, 100 IU/kg twice daily) in symptomatic proximal deep vein thrombosis." | 5.09 | Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. ( , 2000) |
| "The purpose of this study was to compare the efficacy and safety of treating mobile iliofemoral patients with deep venous thrombosis (DVT) with subcutaneous low-molecular-weight heparin (dalteparin sodium) either 200 IU/kg once-daily (group 1) or 100 IU/kg twice-daily (group 2)." | 5.08 | Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. ( Kechavarz, B; Köhn, H; Lipp, C; Mostbeck, A; Partsch, H, 1996) |
| "The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)." | 5.08 | Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997) |
| "Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy." | 5.08 | A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H, 1998) |
| "Studies reporting vein re-opening, inflammation expressed as Gadolinium enhancement and coagulation parameters were searched in the literature and pooled into a meta-analysis using an inverse variance with random effects." | 4.86 | P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. ( Deatrick, KB; Henke, PK; Londy, FJ; Myers, DD; Ramacciotti, E; Rectenwald, JE; Schaub, RG; Wakefield, TW; Wrobleski, SK, 2010) |
| " Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin." | 4.85 | [The antiphospholipid syndrome in the 21st century]. ( Egurbide, MV; Martinez-Berriotxoa, A; Ruiz-Irastorza, G, 2009) |
| " Although low-molecular-weight heparin and direct oral anticoagulants, such as apixaban and rivaroxaban, have been evaluated for the prevention of catheter thrombosis, their efficacy remains uncertain." | 4.31 | Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. ( Fredenburgh, JC; Guan, Z; Hussain, RH; Jaffer, IH; Wang, R; Weitz, JI, 2023) |
| "ENSURE-AF (NCT02072434) assessed therapy with edoxaban vs enoxaparin-warfarin in patients with nonvalvular atrial fibrillation (AF) undergoing elective electrical cardioversion (ECV)." | 3.96 | Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. ( De Caterina, R; Goette, A; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Merino, JL, 2020) |
| "We report a 35-year old female with no cardiovascular risk factors who presented with thrombotic anterior wall myocardial infarction 6 months after using a third generation low dose combined oral contraceptive pills (Marvelon; ethinylestradiol 30 mcg and desogestrel 150 mcg)." | 3.96 | Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report. ( Adam, M; Al-Suwaidi, J; Aljundi, A; Khir, F; Mohsen, MK; Rahhal, A, 2020) |
| "Bemiparin reduced intimal hyperplasia and prevented thrombosis angiogenesis, but dabigatran did not prevent intimal hyperplasia, and its anticoagulation effect was more than the antithrombotic effect." | 3.91 | Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy. ( Aydin Ozturk, P; Ozturk, U; Yilmaz, T, 2019) |
| "Treatment with rivaroxaban was preferable over standard ACT with enoxaparin/warfarin with regards to the lysis of thrombus when duration of thrombosis did not exceed 10 days." | 3.83 | [Ultrasound dynamics lysis apex thrombus as an objective criterion of effectiveness of anticoagulation therapy in venous thrombosis]. ( Agapov, AB; Kalinin, RE; Pshennikov, AS; Suchkov, IA, 2016) |
| "Drug fever caused by dalteparin-sodium (DS), a low-molecular-weight derivative of heparin, is neither listed in the official drug information and nor published as a case report until today." | 3.83 | Dalteparin-sodium induced drug fever in a neonate. ( Nydert, P; Obaya, S; Wackernagel, D, 2016) |
| " She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding." | 3.81 | Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher? ( Baquero-Salamanca, M; Calderon-Ospina, C; Téllez-Arévalo, AM, 2015) |
| "Deep vein thrombosis was induced by exposure to ferric chloride or ligation of the infrarenal vena cava of C57BL/6 mice after pretreatment with enoxaparin, ticagrelor or vehicle and in P2Y(12-/-) mice." | 3.79 | Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition. ( Bode, C; Boeynaems, JM; Duerschmied, D; Guenther, F; Hein, L; Herr, N; Idzko, M; Mauler, M; Robaye, B; Roming, F; Von Zur Muhlen, C; Witsch, T, 2013) |
| "To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period." | 3.79 | Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013) |
| " Low-molecular-weight heparin (LMWH) has a longer plasma half-life and better bioavailability than standard heparin and can thus be administered as a single daily injection." | 3.78 | Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. ( Ben Maadi, A; Durand-Zaleski, I; Jazaerli, N; Mathieu, D; Petit-Phar, M; Radier, C; Rahmouni, A; Rosso, J; Rostoker, G; Vasile, N, 1995) |
| "A 35-year-old man developed priapism with the use of low-molecular-weight heparin and warfarin following repair of left brachial artery sustained after gunshot injury." | 3.78 | Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication! ( Goel, A; Kumar, A; Nagathan, DS; Pahwa, HS, 2012) |
| " Here, rivaroxaban, an oral, direct factor Xa (FXa) inhibitor, was compared with warfarin and enoxaparin in the prevention of right ventricular (RV) dysfunction and hypertrophy in the monocrotaline (MCT) model of pulmonary hypertension." | 3.77 | A role for coagulation factor Xa in experimental pulmonary arterial hypertension. ( Delbeck, M; Ellinghaus, P; Kast, R; Laux, V; Nickel, KF; Perzborn, E; Schäfer, S; Schermuly, RT; Strassburger, J; von Degenfeld, G, 2011) |
| "In patients undergoing percutaneous coronary intervention, catheter thrombosis is more frequent with fondaparinux than heparin." | 3.77 | Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. ( Fredenburgh, JC; Liao, P; Roberts, R; Stafford, AR; Weitz, JI; Yau, JW, 2011) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Beginning in 2004, dalteparin doses based on activated clotting time (ACT) were administered for hepatic vessel thrombosis prophylaxis in living donor liver transplantation (LDLT)." | 3.75 | Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation. ( Ikegami, T; Masuda, Y; Mita, A; Miyagawa, S; Nakazawa, Y; Ohno, Y; Terada, M; Uchikawa, Y; Urata, K, 2009) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 3.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| " (2) The licence of dalteparin, a low-molecular-weight heparin (LMWH), has been extended in France to cover prophylaxis of deep venous thrombosis in patients confined to bed for heart failure, acute respiratory failure, acute infections or acute rheumatological conditions who have at least one other risk factor for venous thromboembolism." | 3.73 | Dalteparin: new indication. Prophylaxis in medical patients: no advance. ( , 2005) |
| " aspirin (4-30 mg/kg), heparin (100-500 U/kg), enoxaparin (4-30 mg/kg) and clopidogrel (10-20 mg/kg) were studied in a rat Folts-like preparation of carotid arterial thrombosis." | 3.73 | Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. ( Daykin, HJ; Jones, C; Sturgeon, SA; Wright, CE, 2006) |
| " The rate of thrombosis rose to 10% (6/60) if no high-risk dose of dalteparin was applied subcutaneously." | 3.72 | Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing. ( Fung, S; Janssen, D; Kotowa, W; Lersch, C, 2004) |
| "This prospective audit reports pregnancy outcomes, anticoagulation complications, and anti-Xa levels in women with mechanical heart valves who were treated with therapeutic enoxaparin plus aspirin during pregnancy." | 3.71 | Enoxaparin treatment in women with mechanical heart valves during pregnancy. ( McCowan, LM; North, RA; Raudkivi, PJ; Rowan, JA, 2001) |
| "The antithrombotic effects of direct (ximelagatran and hirudin) and indirect (dalteparin) anticoagulants were compared using a deep venous thrombosis (DVT) treatment model in conscious rats." | 3.71 | Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. ( Carlsson, S; Elg, M; Mattsson, C, 2002) |
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "We investigated the efficacy, safety and relation of dose to plasma anti-Xa activity of the low molecular weight heparin (LMWH) dalteparin in prophylaxis and therapy of arterial and venous thrombosis in pediatric patients." | 3.70 | The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. ( Auberger, K; Flemmer, A; Nohe, N; Praun, M; Rümler, R, 1999) |
| "LMWH (Fraxiparine), and NSAIDs (Aspirin, Feldene, Indocid and Profenid) injected together in doses, 1 mg/kg (Aspirin was used at 100 mg/kg), subcutaneously into rats 30 minutes before the thrombosis induction by LASER beams, increased the number of LASER beams required to induce platelet thrombus formation, decreased the number of emboli and reduced the duration of embolization, compared with control (p < or = 0." | 3.69 | Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser. ( Aguejouf, O; Doutremepuich, C; Doutremepuich, F; Imbault, P; Oualane, FA, 1995) |
| "The effect of dalteparin, a low molecular weight heparin, on severely antithrombin III (ATIII)-decreased disseminated intravascular coagulation (DIC) model was compared with that of unfractionated heparin (heparin)." | 3.69 | Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. ( Fukuyama, J; Hamano, S; Ichikawa, K; Misawa, K; Miyata, H; Sakuragawa, N; Tazawa, S, 1995) |
| "To test the safety and feasibility of treating deep vein thrombosis (DVT) in an outpatient setting, using the low molecular weight heparin dalteparin, to calculate the potential and actual cost reductions achievable as a result of such a treatment regimen." | 3.69 | Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. ( Holmström, M; Lindmarker, P, 1996) |
| "Bleeding was predominantly intracranial (n=331 [69%]) or gastrointestinal (n=109 [23%])." | 3.30 | Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Cohen, AT; Connolly, SJ; Coppens, M; Crowther, M; Demchuk, A; Eikelboom, JW; Gibson, CM; Koch, B; Lopez-Sendon, J; Middeldorp, S; Milling, TJ; Schmidt, J; Shoamanesh, A; Verhamme, P; Xu, L, 2023) |
| "Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment." | 3.11 | Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study. ( Charalambakis, N; Kosmas, C; Lianos, E; Liatsos, AN; Mazlimoglou, E; Papageorgiou, G; Pouliakis, A; Simeonidis, D; Xynogalos, S; Ziras, N, 2022) |
| "Adult patients with cancer at the time they develop thrombosis." | 3.01 | Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. ( Eckman, MH; Gulati, S, 2023) |
| "Thromboprophylaxis dosing strategies using enoxaparin in elderly patients with renal disease are limited, while dose adjustments or monitoring of anti-Xa levels are recommended." | 2.90 | Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment. ( Chamoun, N; Dimassi, H; Ghanem, G; Ghanem, H; Hachem, A; Hariri, E; Lteif, C; Mansour, H; Zalloum, R, 2019) |
| "However, upper limb deep vein thrombosis is poorly studied with scant data on the use of direct oral anticoagulants in noncatheter-related deep vein thrombosis." | 2.82 | Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. ( Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A, 2022) |
| "Rivaroxaban is a direct factor Xa inhibitor that prevents thrombus formation." | 2.82 | Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. ( Drabik, A; Eveslage, M; Gerss, J; Goerge, T; Kahle, B; Kreuter, A; Schneider, SW; Strölin, A; Weishaupt, C, 2016) |
| "Bleeding was predominantly gastrointestinal or intracranial." | 2.82 | Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E, 2016) |
| "Left ventricular (LV) thrombus is one of the most common complications in patients with anterior acute myocardial infarction (AMI) and LV dysfunction." | 2.80 | Comparison of the usefulness of enoxaparin versus warfarin for prevention of left ventricular mural thrombus after anterior wall acute myocardial infarction. ( Grines, CL; Grines, LL; Marcovitz, P; Messenger, J; Schreiber, T; White, DC, 2015) |
| " We present 52 patients treated with tinzaparin anticoagulation on HD, confirming that fixed dosing is safe and efficacious with sound pharmacodynamic reason in relation to anti-Xa profiling." | 2.78 | Anti-Xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis. ( Ashman, N; Baig, ZF; Kirwan, CJ; MacCullum, PK; Platton, S, 2013) |
| "Venous thromboembolism is a frequent complication in critically ill patients that has a negative impact on patient outcomes." | 2.77 | Bioactivity of enoxaparin in critically ill patients with normal renal function. ( Gouya, G; Heinz, G; Kapiotis, S; Locker, G; Madl, C; Palkovits, S; Stella, A; Wolzt, M, 2012) |
| "Catheter thrombosis has never been reported in any trial using bivalirudin." | 2.73 | Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. ( Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K, 2008) |
| " In this pilot study 27 children with deep venous thromboses (DVT) were treated with the LMWH enoxaparin at a dosage of 1." | 2.72 | Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. ( Gunther, G; Merkel, N; Schobess, R, 2006) |
| "3% of patients no adverse event was reported." | 2.71 | Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study. ( Eckert, M; Hafner, G; Hohmann, V; Klingel, R; Lotz, J; Schwarting, A, 2004) |
| "Once a diagnosis of left ventricular thrombus has been established, the classical attitude consists in the administration of unfractionated heparin relayed by oral anticoagulation therapy." | 2.71 | Treatment of left ventricular thrombi with a low molecular weight heparin. ( Bourmayan, C; Driss, AB; Grosdemouge, A; Meurin, P; Renaud, N; Tabet, JY; Weber, H, 2005) |
| "Three cases of intraprocedural thrombus occurred among patients who received enoxaparin." | 2.71 | Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). ( Cohen, EA; Fort, S; Godin-Edgecombe, M; Madan, M; Naqvi, SZ; Paradiso-Hardy, FL; Phillips, AM; Radhakrishnan, S; Reis, M; Shanmugasegaram, S; Sparling, C, 2005) |
| "Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition." | 2.70 | Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001) |
| " As the PTT did not reach 40 seconds, the heparin sodium dosage was increased to 7,500 IU 3 times daily." | 2.69 | Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty. ( Eulert, J; Hendrich, C; König, A; Kramer, C; Rader, CP, 1998) |
| "Deep-vein thrombosis was detected in twenty-four (18 per cent) of the patients who used the foot pump compared with eighteen patients (13 per cent) who received enoxaparin (95 per cent confidence interval for the difference in proportions, -3." | 2.69 | Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. ( Donovan, J; Glew, D; Harrison, J; Mitchelmore, A; Peters, TJ; Warwick, D, 1998) |
| "Dalteparin or dextran was used during delivery." | 2.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| " Bleeding complications and other adverse events were registered throughout the study period." | 2.69 | Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. ( Andersen, G; Anderson, BS; Appelquist, E; Borris, LC; Christensen, F; Erin-Madsen, J; Hansen, BR; Hvidt, P; Hørlyck, E; Jensen, BV; Jensen, HP; Jensen, NK; Jørgensen, PS; Lassen, MR; Møller, JC; Nielsen, AB; Nielsen, JB; Paaske, B; Petersen, AO; Rotwitt, L; Siem, P; Skejø Bro, HP; Thomsen, PB; Tjalve, E; Tørholm, C, 1998) |
| " In these clinical studies, Enoxaparin, 30 mg twice daily, was shown to be as effective and safe as low dose unfractionated heparin to prevent deep venous thrombosis after hip arthroplasty." | 2.68 | Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. ( Colwell, CW; Spiro, TE, 1995) |
| " However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use." | 2.68 | A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. ( Anderson, D; Demers, C; Gent, M; Ginsberg, J; Hirsh, J; Kovacs, M; Leclerc, J; Levine, M; Turpie, AG; Weitz, J, 1996) |
| "The incidence of silent pulmonary embolism (PE) (new defect on V/Q scan) was 28% (8 out of 29) in patients with and 5% (2 out of 43) in patients without DVT (chi 2; p < 0." | 2.68 | Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. ( al-Kutoubi, A; Birch, R; Cunningham, DA; Fareed, J; Gill, K; Harris, N; Hoppensteadt, DA; Hunt, D; Johnson, J; Kalodiki, EP; Marx, C; Nicolaides, AN; Regan, F, 1996) |
| "One dalteparin-treated patient had a PE confirmed by V/Q scan; another had progressive thrombosis with swelling in the affected limb." | 2.68 | A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. ( Grankvist, S; Hallert, C; Jauro, I; Ketola, K; Kim, HC; Kiviniemi, H; Koskivirta, H; Luomanmäki, K; Sörskog, L; Vilkko, P, 1996) |
| "In order to define the optimal dosage of a low molecular weight enoxaparine (Lovenox) in the prevention of clotting in extracorporeal circulation during hemodialysis, a multicentre trial was conducted in 72 patients dialysed in seven hemodialysis units." | 2.67 | [Optimization of enoxaparin dose in the prevention of coagulation in the circuits of hemodialysis: results of a multicenter study]. ( Combe, S; de Groc, F; Debure, A; Dupuy, CA; Fievet, P; Küntziger, H; Reach, I; Teboulle, D; Thébaud, HE; Thoumazou, G, 1994) |
| "Two enoxaparin dosage regimens are used as comparators to evaluate new anticoagulants for thromboprophylaxis in patients undergoing major orthopaedic surgery, but so far no satisfactory direct comparison between them has been published." | 2.50 | Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs. ( Bertoletti, L; Chapelle, C; Cucherat, M; Darmon, JY; Laporte, S; Lega, JC; Mismetti, P; Zufferey, PJ, 2014) |
| "An association between cancer and thrombosis has been recognized since 1865." | 2.46 | Bemiparin in oncology. ( Lecumberri Villamediana, R; Monreal Bosch, M; Prandoni, P; Vignoli, A, 2010) |
| "To assess the prescribing practice of enoxaparin in comparison to dosing guidelines." | 2.46 | Current enoxaparin dosing guidelines have dubious credibility. ( Al-Sallami, H; Duffull, S; Ferguson, R; Jordan, S; Medlicott, N; Schollum, J, 2010) |
| " Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs." | 2.41 | Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. ( Vernon, SM, 2001) |
| " The pharmacokinetic and pharmacodynamic differences among LMWHs can be explained by comparing methods of preparation, molecular structures, half-lives, antithrombin- and non-antithrombin-mediated actions, effect on thrombus, and dosing interval." | 2.41 | Differentiation of the low-molecular-weight heparins. ( Racine, E, 2001) |
| " Studies have shown that weight-based dosing influences significantly both the time to reach a therapeutic intensity of anticoagulation and the incidence of thromboembolic recurrence." | 2.39 | Contemporary use of and future roles for heparin in antithrombotic therapy. ( Gibaldi, M; Wittkowsky, AK, 1995) |
| " This agent also showed sustained activity and better bioavailability characteristics than heparin." | 2.38 | Pharmacological profile of reviparin-sodium. ( Fareed, J; Hoppensteadt, D; Jeske, W, 1993) |
| "When guided by thrombus resolution on ultrasound, a four-week or shorter course of anticoagulation does not increase the need for surgical intervention or long-term complications." | 1.91 | Practice patterns in the management of pediatric iliofemoral arterial thrombosis. ( Acker, SN; Diaz-Miron, J; Hall, JK; Harrison, ML; Klein, G; Vaughn, AE; Yi, JA, 2023) |
| "When administered with the purpose of treating a thrombosis, the duration of treatment is six to twelve weeks." | 1.72 | Investigating the experience of parents who have given their infants enoxaparin at home. ( Gilmore, H; Jones, S; Monagle, P; Monagle, S; Newall, F, 2022) |
| "Thrombosis was observed in the PMMA group and ES-PMMA group but not in the sham group." | 1.72 | The mechanism by which enoxaparin sodium-high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells. ( Ding, L; Fu, D; Hao, K; Qi, X; Sang, L; Shen, X; Sun, H, 2022) |
| "Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT." | 1.72 | An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022) |
| " There is no guideline regarding enoxaparin bridging in LVAD patients and a dosing strategy to ensure efficacy and safety is uncertain." | 1.72 | Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution. ( Alvarez, PA; Bernard, AM; Bream-Rouwenhorst, HR; Briasoulis, A; Czerniak, LC; Horner, KE, 2022) |
| "Thrombosis was associated with increasing age (median: 74." | 1.72 | Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study. ( Akinosoglou, K; Chatzistamati, A; Dimakopoulou, V; Efraimidis, G; Golemi, F; Kaiafa, G; Konstantinidou, A; Liontos, A; Markatis, E; Milionis, H; Mitsianis, A; Panagopoulos, P; Papanikolaou, IC; Papazoglou, D; Pavlaki, M; Pouliakis, A; Randou, E; Samaras, V; Savopoulos, C; Savvanis, S; Triantafyllidis, C; Vadala, C; Varela, K; Xarras, P, 2022) |
| "Real word data on the efficacy and safety of long-term use of tinzaparin for the treatment of cancer-associated thrombosis (CAT) are scarce." | 1.72 | Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. ( Cajfinger, F; Crichi, B; Farge, D; Frere, C; Janus, N; Le Maignan, C; Marjanovic, Z; Rueda-Camino, JA; Spiess, N, 2022) |
| "Penile thrombosis has not been reported as a thrombotic complication of SARS-CoV-2 infection with hypercoagulability." | 1.62 | Priapism in a patient with coronavirus disease 2019 (COVID-19). ( Abbad, S; Chebbi, A; Lamamri, M; Legriel, S; Mamane, J; Munuzzolini, M; Sarfati, F, 2021) |
| " Enoxaparin dosing was nearly double the recommended starting doses for secondary thromboprophylaxis." | 1.62 | Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort. ( Dobbie, LJ; Eskell, L; Lamb, A; Ramage, IJ; Reynolds, BC, 2021) |
| "Enoxaparin is commonly used to treat pediatric thrombosis." | 1.62 | Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. ( Abdel-Rasoul, M; Cloyd, C; Dunn, A; Kuhn, A; Steinbrenner, J; Tyrrell, L; Wysocki, EL, 2021) |
| "The Total Thrombus Analysis System (T-TAS), which is a microfluidic assay that simulates conditions in vivo, measures whole blood flow at defined shear rates under conditions designed to assess platelet function (PL-chip) or coagulation and fibrin clot formation (AR-chip)." | 1.62 | Analysis of blood clotting with the total thrombus analysis system in healthy dogs. ( Fukushima, R; Iwanaga, T; Maruyama, I; Miura, N; Nagasato, T, 2021) |
| "Dalteparin can be used to treat thrombosis in newborn infants." | 1.62 | Dalteparin in Newborn Thrombosis, Time for a New Starting Dose. ( Bierings, M; Huisman, A; Steenman, F; Vijlbrief, DC, 2021) |
| "History of prior deep vein thrombosis (HR 2." | 1.62 | Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study - The SeVEN EXTension study. ( Chatzis, D; Giannoukas, AD; Goumas, K; Karathanos, C; Latzios, P; Papakostas, I, 2021) |
| "Hospitalized cancer patients are at increased risk of thrombosis and prophylaxis with heparin is recommended." | 1.56 | Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin. ( Ackerman, S; Haim, N; Keren-Politansky, A; Litvak, M; Maurice-Dror, C; Nadir, Y, 2020) |
| " An antithrombotic prophylaxis at low dosage was immediately started, then increased at prophylactic dosage." | 1.56 | How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. ( Campello, E; Pasca, S; Simioni, P; Spiezia, L; Vettor, R; Zanon, E, 2020) |
| "We present a late presentation of saddle pulmonary embolism and thrombus-in-transit straddle the patent foramen on patient who successfully recovered from severe acute respiratory syndrome coronavirus-2 (COVID-19) pneumonia." | 1.56 | Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset. ( Fontes, JD; Fujikura, K; Taub, CC, 2020) |
| " The purpose of the study was to evaluate the association between initial dosing strategy of thromboprophylaxis in critically ill COVID-19 patients and the risk of death, thromboembolism, and bleeding." | 1.56 | Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. ( Cronhjort, M; Dahlberg, M; Everhov, ÅH; Grip, J; Günther, M; Hollenberg, J; Järnbert-Pettersson, H; Jonmarker, S; Litorell, J; Schandl, A; Söderberg, M; Stackelberg, O, 2020) |
| " Due to the expense associated with ATIII, a capped dosing approach for ATIII was evaluated in this population." | 1.51 | Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis. ( Breese, EH; Jenkins, M; Luchtman-Jones, L; O'Brien, M; Sawyer, J; Young, J, 2019) |
| "Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome." | 1.51 | Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019) |
| "Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)." | 1.48 | Anticoagulation prescribing patterns in patients with cancer. ( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018) |
| " We aimed to determine whether current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations within prophylactic goal ranges in this patient population." | 1.48 | Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD. ( Israel, EN; Mastropietro, CW; Thomas, CA, 2018) |
| "Dalteparin is a safe and effective anticoagulant when used for paediatric home HD." | 1.48 | Dalteparin anticoagulation in paediatric home haemodialysis. ( Hothi, DK; Lutkin, M; Stronach, L; Yadav, P, 2018) |
| " There is limited data comparing anticoagulation efficacy between subtypes of LMWH and dosing regimens in this context." | 1.48 | Mechanical Mitral Valve Thrombosis Secondary to Tinzaparin as an Anticoagulation Bridging Strategy. ( Harten, C; Kent, WDT; Vasanthan, V, 2018) |
| "Essentials The once-daily dosing of tinzaparin provides an advantage over other low molecular weight heparins." | 1.46 | Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis. ( Avery, P; Biss, TT; Murphy, P; Musgrave, KM; Webber, K, 2017) |
| " In the patients of both groups the product dabigatran etexilate in the standard dosage (220 mg/day) was used for specific prevention." | 1.43 | [Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities]. ( Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 1.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "Neonatal myocardial infarction is a rare clinical entity that is associated with high mortality." | 1.42 | A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator. ( Dori, Y; Gillespie, MJ; Hallbergson, A, 2015) |
| "Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates." | 1.42 | Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates. ( Bhatt, MD; Chan, AK; Goldsmith, R; Paes, BA, 2015) |
| "Fondaparinux, was more vulnerable to the presence of cancer cells as compared to apixaban." | 1.42 | Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. ( Elalamy, I; Gerotziafas, GT; Larsen, A; Mbemba, E; Rousseau, A; Van Dreden, P, 2015) |
| "We describe a patient with a giant thrombus on the apical wall of the left ventricle that occurred due to HIT syndrome after anterior myocardial infarction." | 1.40 | Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI. ( Balaban Kocas, B; Coskun, U; Gultekin, N; Gurmen, T; Kucukoglu, S; Sinan, UY, 2014) |
| "Age, critical illness, and timing of AT3 had no effect on time to therapeutic anti-Xa levels." | 1.40 | Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. ( Corder, A; Held, K; Oschman, A, 2014) |
| "Untreated hereditary antithrombin deficiency in pregnancy is associated with maternal venous thromboembolism (VTE) and possibly with fetal loss." | 1.39 | How I treat heterozygous hereditary antithrombin deficiency in pregnancy. ( Bramham, K; Hunt, BJ; Mitchell, M; Moore, GW; Retter, A; Robinson, SE, 2013) |
| " Enoxaparin was administered after caesarean section using the Royal College of Obstetricians and Gynaecologists weight-adjusted dosing guidelines." | 1.39 | Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study. ( Casey, E; Hiscock, RJ; Newell, PA; Simmons, SW; Walker, SP, 2013) |
| "Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication." | 1.39 | Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013) |
| "As major bleeding has modifiable risk factors and is associated with in-hospital mortality, strategies to mitigate these factors should be evaluated in critically ill patients." | 1.39 | Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. ( Albert, M; Arnold, DM; Ashley, BJ; Cook, D; Crowther, M; Dodek, P; Finfer, S; Fowler, R; Heels-Ansdell, D; Karachi, T; Khwaja, K; Lauzier, F; Lopes, RD; McIntyre, L; Nates, JL; Ostermann, M; Rabbat, C; Skrobik, Y; Zarychanski, R; Zytaruk, N, 2013) |
| "Bioprosthetic valve thrombosis is an unexpected complication which has no guidelines for its management." | 1.37 | Successful thrombolysis of late, non-obstructive mitral bioprosthetic valve thrombosis: case report and review of the literature. ( Lengyel, M; Pozsonyi, Z, 2011) |
| "No reductions were observed in the thrombus size or mean mitral gradient on transesophageal echocardiography (TEE) with 1 week of unfractioned heparin therapy." | 1.37 | Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis. ( Akcay, AB; Akcay, M; Davutoglu, V; Sen, N; Soydinc, HE; Yuce, M, 2011) |
| " Inadequate dosage has been pointed out as a potential problem because the use of subjectively estimated weight instead of real measured weight is common practice in the emergency department (ED)." | 1.37 | Error in body weight estimation leads to inadequate parenteral anticoagulation. ( de Oliveira, L; dos Reis Macedo, LG; Garcia, AA; Pazin-Filho, A; Pintão, MC, 2011) |
| "Primary end point was amount of valve thrombus at 30 days." | 1.37 | Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. ( Abel, S; Camp, CL; Ereth, MH; McKellar, SH; Schaff, HV; Suri, RM, 2011) |
| "Darexaban (YM150) is an oral factor Xa inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease." | 1.37 | Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. ( Funatsu, T; Iwatsuki, Y; Kaku, S; Kawasaki, T; Moritani, Y; Sato, T; Shigenaga, T; Suzuki, M, 2011) |
| "Overall thrombus weight, anti-Xa activity and electron microscopic features such as deposits of platelets, erythrocytes and fibrin on the catheter surface were quantified as endpoints." | 1.36 | Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. ( Buerke, M; Busshardt, M; Hauroeder, B; Maegdefessel, L; Plehn, A; Raaz, U; Schlitt, A; Werdan, K, 2010) |
| "Heparin-induced thrombocytopenia is an antibody-mediated disorder exhibiting variable frequency in different clinical settings." | 1.36 | Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. ( Cook, RJ; Greinacher, A; Marder, VJ; Warkentin, TE, 2010) |
| "The prevalence of LAA thrombus among fully anticoagulated patients undergoing AF ablation is unknown." | 1.36 | Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. ( Atwater, BD; Bahnson, TD; Crowley, AL; Daubert, JP; Hranitzky, PM; Voora, D; Wallace, TW, 2010) |
| "Coagulation parameters, overall thrombus weight and electron microscopic features (deposits of platelets and fibrin on the catheter surface) were quantified as endpoints." | 1.36 | The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. ( Buerke, M; Busshardt, M; Ebelt, H; Kaeberich, A; Maegdefessel, L; Plehn, A; Raaz, U; Russ, M; Schlitt, A; Schubert, S; Werdan, K, 2010) |
| "8 dosage adjustments was needed." | 1.36 | Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? ( Berry, D; Chrysostomou, C; Gunawardena, S; Krallman, S; Morell, VO; Munoz, R; Orr, R; Sanchez de Toledo, J; Shiderly, D; Sonderman, S; Wang, L; Wearden, P, 2010) |
| "Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH." | 1.36 | Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. ( Schiele, F, 2010) |
| "We present a rare case of a thrombus at the aortic arch found 1 month after cisplatin-based chemotherapy in a 50-year-old patient with a diagnosis of small cell lung cancer; there were no symptoms related to the thrombus." | 1.36 | Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer. ( Baek, SK; Chin, SO; Choi, CW; Han, JJ; Hwang, YH; Lee, JJ; Maeng, CH, 2010) |
| "This is the first case of renal infarction that developed in the early hours of primary PCI, despite effective anticoagulant and antiplatelet treatment." | 1.36 | Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. ( Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E, 2010) |
| "Dalteparin was used as a reference compound." | 1.36 | Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. ( Elg, M; Johansson, K; Kjaer, M; Pehrsson, S, 2010) |
| "Body weight is an important risk factor for thromboses and is used in algorithms to determine dosages in prophylaxis." | 1.35 | A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. ( Grohs, JG; Lunzer, A; Vavken, P, 2009) |
| "Preprocedural TEE revealed LA thrombus in 12 of 732 cases (1." | 1.35 | Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. ( Abraham, TP; Berger, RD; Calkins, H; Cheng, A; Chilukuri, K; Dalal, D; Dong, J; Henrikson, CA; Marine, JE; Nazarian, S; Scherr, D; Spragg, D, 2009) |
| "Spontaneous aortic thrombosis is rare." | 1.35 | Aortic thrombosis in infancy. ( Mehta, AV; Teixeira, OH, 2009) |
| "Patients with brain tumors including intracranial meningiomas are at increased risk for developing deep vein thrombosis (DVTs) and suffering thromboembolic events (VTEs)." | 1.35 | Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. ( Berger, MS; Cage, TA; Chakalian, L; Frankfurt, A; Lamborn, KR; McDermott, MW; Ware, ML, 2009) |
| " Therefore, we believe that intravenous enoxaparin is a safe alternative to unfractionated heparin in both settings." | 1.35 | Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention. ( Cheong, BY; Díez, JG; Ferguson, JJ; Medina, HM; O'Meallie, L, 2009) |
| "It led to a complete resolution of the thrombus in 4 weeks without the need for a high-risk operation in this patient." | 1.35 | Cardioverter-defibrillator lead-related thrombus treated with prolonged anticoagulation in patient with prothrombotic disorder. ( Chojnowska, L; Hoffman, P; Klopotowski, M; Konka, M; Maczynska, R; Malek, LA; Ruzyllo, W; Skwarek, M, 2008) |
| "Furthermore, thrombus weight and the cell/fibrinogen counts were significantly increased in fonda and fonda+eptifibatide compared with other treatment groups." | 1.35 | In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. ( Buerke, M; Carter, JM; Ebelt, H; Hauroeder, B; Kropff, SS; Maegdefessel, L; Peetz, D; Reindl, I; Rupprecht, HJ; Russ, M; Schlitt, A; Schmidt, H; Schubert, S; Werdan, K, 2008) |
| "Since low molecular weight heparin has greater bioavailability and sustained serum levels in vivo than unfractionated heparin, it has been used to supplant unfractionated heparin to achieve therapeutic anticoagulation in humans." | 1.35 | Enoxaparin does not ameliorate limb ischemia-reperfusion injury. ( Abbruzzese, TA; Albadawi, H; Kang, J; Lamuraglia, GM; Patel, VI; Watkins, MT; Yoo, JH, 2008) |
| "The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered." | 1.35 | The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases. ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009) |
| "Dysfibrinogenemia is a disorder of fibrinogen structure and is associated with a functional abnormality." | 1.34 | Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis. ( Ganti, AK; Haire, WD; Vose, JM, 2007) |
| "The results between cancer-activated and tissue factor-activated blood were similar." | 1.34 | Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. ( Cloonan, ME; DiNapoli, M; Mousa, SA, 2007) |
| "Of these, macroscopic thrombus was observed on PCI equipment in 6 patients (5%) necessitating withdrawal of all catheters and wires." | 1.34 | Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. ( Barbeau, GR; Cloutier, S; Dana, A; Nguyen, CM, 2007) |
| " An initial dosage of 1." | 1.34 | Enoxaparin use in the neonatal intensive care unit: experience over 8 years. ( Chan, AK; Knoppert, DC; Lee, DS; Malowany, JI; Pepelassis, D, 2007) |
| "This study was designed to compare the dose-response of enoxaparin, dalteparin and unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether the ACT or aPTT can be used to monitor intravenous (IV) low molecular weight heparin (LMWH)." | 1.33 | The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. ( Cavusoglu, E; Lakhani, M; Marmur, JD, 2005) |
| " Pharmacokinetic studies determined optimal dosing for clinically relevant anticoagulant levels in mice." | 1.33 | Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. ( Choi, SH; Stevenson, JL; Varki, A, 2005) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "The efficacy of LMWH in resolving thrombus in children is, however, unknown and may differ from what has been observed in adults due to known differences in the hemostatic system." | 1.32 | Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. ( Chan, A; Daneman, A; Dix, D; Marzinotto, V; Massicotte, P; Revel-Vilk, S; Sharathkumar, A, 2004) |
| "To evaluate the ability of published dosage guidelines for enoxaparin to achieve therapeutic anticoagulation and to determine whether the routine monitoring of anti-Xa levels is still necessary at a tertiary care pediatric institution." | 1.32 | An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. ( Dix, DB; Hamilton, DP; Ho, SH; Wadsworth, LD; Wu, JK, 2004) |
| " Low-molecular-weight heparins prevent venous thrombosis as effectively as heparin and have better bioavailability and a longer plasma half-life, which explains the increased use of low-molecular-weight heparins as substitutes for heparin in clinical practice." | 1.32 | Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. ( Arnljots, B; Dahlbäck, B; Malm, K, 2003) |
| "Immediately following, the thrombus was removed, dried and weighed 24 h later." | 1.32 | Orally administered heparins prevent arterial thrombosis in a rat model. ( Hiebert, LM; Pinel, C; Wice, SM, 2004) |
| "In the venous thrombosis model at the maximally effective dose, C921-78 had minimal extension of ex vivo clotting parameters, while enoxaparin and unfractionated heparin demonstrated a two to sevenfold increase in activated partial thromboplastin times, and PPACK had a threefold extension of thrombin clotting times." | 1.31 | Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. ( Hollenbach, SJ; Ku, P; Lin, PH; Malinowski, J; Marlowe, CK; Scarborough, RM; Sinha, U; Wong, PW; Zhu, BY, 2000) |
| "Enoxaparin 1 mg/kg intravenously every eight hours was used safely in this preterm infant with suspected thrombosis, suggesting that more than one dosing regimen may be appropriate in this population." | 1.31 | Use of enoxaparin in a preterm infant. ( Dunaway, KK; Gal, P; Ransom, JL, 2000) |
| "The time to formation of an occlusive thrombus in the femoral arteries averaged 69+/-5 min in the control group compared to 127+/-19, 192+/-33 and 219+/-15 min in the low-, mid- and high-dose CI-1031 groups." | 1.31 | The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. ( Hicks, GW; Janiczek-Dolphin, N; Juneau, PL; Leadley, R; McClanahan, TB; Mertz, TE; Morrison, AL; Morser, J; Peng, YW; Sullivan, ME, 2001) |
| "The aim of this trial, undertaken with the participation of 13 centres, was to establish the minimal effective dosage of nadroparin (Fraxiparin) for the prevention of left ventricular mural thrombosis in acute anterior myocardial infarction which was not treated by thrombolysis." | 1.30 | [Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV Study]. ( Charbonnier, B, 1997) |
| "These cases provide evidence of type IV hypersensitivity and the possibility of crossed-allergenicity among unfractionated heparin and low-molecular-weight heparins." | 1.30 | Delayed-type hypersensitivity to subcutaneous enoxaparin. ( Armentia, A; de la Fuente, R; Fernández, A; Martínez, C; Méndez, J; Sánchez, P; Sanchís, ME; Stolle, R; Vega, JM, 1998) |
| "To assess the effect on thrombus growth, we determined the accretion of 125I-labeled fibrinogen onto autologous non-radioactive thrombi preformed in the jugular veins of rabbits." | 1.29 | Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. ( Biemond, BJ; Büller, HR; Levi, M; Nurmohamed, MT; ten Cate, JW, 1994) |
| "This study compares the pharmacokinetic and the antithrombotic properties of two pentasaccharides with high affinity to antithrombin III with those of a conventional low molecular weight heparin, CY216, in the rabbit." | 1.29 | Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ( Boneu, B; Caranobe, C; Carrie, D; Houin, G; Lormeau, JC; Meuleman, D; Petitou, M; Saivin, S; Van Boeckel, C, 1994) |
| "Aprosulate sodium was the first representative of a new class of synthetic polyanions showing antithrombotic efficacy in different animal models." | 1.29 | Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties. ( Elling, H; Klauser, RJ; Meinetsberger, E; Raake, W; Zeiller, P, 1994) |
| "The relative number of grafts with thrombus free surface was increased in the unrestricted blood flow situation." | 1.29 | Effect of dextran and enoxaparin on early ePTFE graft thrombogenicity in sheep. ( Bergqvist, D; Lindblad, B; Lundell, A; Matthiasson, SE, 1995) |
| "We found evidence of only parietal thrombus formation 3 times (10%) in the arteries and 4 times (13." | 1.29 | [Histologic changes in ligated stumps of ovarian blood vessels in preoperative low-molecular weight preventive heparin administration]. ( Slunsky, R, 1995) |
| "Platelet dependent thrombus deposition was quantified by dedicated image analysis after transillumination of the femoral vein to which a standardised vascular trauma was applied." | 1.29 | Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo. ( Deckmyn, H; Lambeir, AM; Matthyssens, G; Nyström, A; Stassen, JM; Vermylen, J; Vreys, I, 1995) |
| "Histology at day 1 showed that thrombus in the occluded vessels adhered to the exposed adventitia in the crushed area or the adventitia was covered by fibrin, red blood cells, and platelet mesh in the patent vessels." | 1.29 | Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries. ( Chen, LE; Korompilias, AV; Seaber, AV; Urbaniak, JR, 1995) |
| " Fourteen children had a deep vein thrombosis or pulmonary embolism, nine had thrombotic complications in the central nervous system, and two had complex congenital heart disease, for which they received prophylaxis at a lower dosage (0." | 1.29 | Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. ( Adams, M; Andrew, M; Brooker, LA; Marzinotto, V; Massicotte, P, 1996) |
| "Dextran reduced the thrombus weights (p = 0." | 1.29 | Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. ( Bergqvist, D; Holst, J; Lindblad, B; Matthiasson, SE; Mätzsch, T, 1994) |
| " Thirty-three pigs received bolus injections of 300 IU/kg with or without additional dosage during CPB and with or without subsequent protamine sulphate." | 1.29 | Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model. ( Bagge, L; Holmer, E; Malm, T; Nyström, SO; Tydén, H; Wahlberg, T, 1994) |
| " The standard dosage of heparin (1,500 IU, n = 6) was compared with a lower dosage (1,000 IU, n = 3) and several dosages of Fragmin (IU anti-FXa): 750 (n = 1), 1,500 (n = 3), 2,100 (n = 4) and 2,500 (n = 3)." | 1.29 | Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting. ( Bagge, L; Holmer, E; Nyström, SO; Tydén, H; Wahlberg, T, 1994) |
| "During all low-dose treatments, marked thrombus formation occurred in the extracorporeal circuit, and in 2, the circuit clotted within the study period." | 1.29 | Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. ( Davison, AM; Douglas, JT; Jeffrey, RF; Khan, AA; Will, EJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 84 (17.72) | 18.2507 |
| 2000's | 160 (33.76) | 29.6817 |
| 2010's | 154 (32.49) | 24.3611 |
| 2020's | 76 (16.03) | 2.80 |
| Authors | Studies |
|---|---|
| Eck, RJ | 1 |
| van de Leur, JJCM | 1 |
| Wiersema, R | 1 |
| Cox, EGM | 1 |
| Bult, W | 1 |
| Spanjersberg, AJ | 1 |
| van der Horst, ICC | 1 |
| Lukens, MV | 1 |
| Gans, ROB | 1 |
| Meijer, K | 1 |
| Keus, F | 1 |
| Piwowarczyk, P | 1 |
| Borys, M | 1 |
| Kutnik, P | 1 |
| Szczukocka, M | 1 |
| Sysiak-Sławecka, J | 1 |
| Szułdrzyński, K | 1 |
| Ligowski, M | 1 |
| Drobiński, D | 1 |
| Czarnik, T | 1 |
| Czuczwar, M | 1 |
| Atamanova, EA | 1 |
| Andryukhin, MI | 1 |
| Vasilenko, IA | 1 |
| Makarov, OV | 1 |
| Simeone, R | 1 |
| Giacomello, R | 1 |
| Bruno, G | 1 |
| Parco, S | 1 |
| Maximova, N | 1 |
| Martinelli, M | 1 |
| Zito, G | 1 |
| Luppi, S | 1 |
| Cervi, G | 1 |
| Ricci, G | 1 |
| Bulatovic, A | 1 |
| Schlieper, G | 1 |
| Stankovic-Popovic, V | 1 |
| Vujic, D | 1 |
| Floege, J | 1 |
| Dimkovic, N | 1 |
| Enajat, M | 1 |
| Aziz Mohammadi, M | 1 |
| Debeij, J | 1 |
| van der Hulst, RR | 1 |
| Mureau, MA | 1 |
| Duzhyĭ, ID | 1 |
| Kravets', OV | 1 |
| Hres'ko, IIa | 1 |
| Iurchenko, AV | 1 |
| Sandner, SE | 1 |
| Zimpfer, D | 1 |
| Zrunek, P | 1 |
| Steinlechner, B | 1 |
| Rajek, A | 1 |
| Schima, H | 1 |
| Wolner, E | 1 |
| Wieselthaler, GM | 1 |
| Somonova, OV | 1 |
| Madzhuga, AV | 1 |
| Elizarova, AL | 1 |
| Zubrikhina, GN | 1 |
| Vlasin, M | 1 |
| Dvorak, M | 1 |
| Dvorakova, M | 1 |
| Rauser, P | 1 |
| Lexmaulova, L | 1 |
| Gregor, Z | 1 |
| Pozsonyi, Z | 1 |
| Lengyel, M | 1 |
| Leger, P | 1 |
| Cambus, JP | 1 |
| Herault, JP | 1 |
| Herbert, JM | 1 |
| Boneu, B | 2 |
| Betrosian, AP | 1 |
| Theodossiades, G | 1 |
| Lambroulis, G | 1 |
| Kostantonis, D | 1 |
| Balla, M | 1 |
| Papanikolaou, M | 1 |
| Georgiades, G | 1 |
| Mismetti, P | 2 |
| Mille, D | 1 |
| Laporte, S | 2 |
| Charlet, V | 1 |
| Buchmüller-Cordier, A | 1 |
| Jacquin, JP | 1 |
| Fournel, P | 1 |
| Dutrey-Dupagne, C | 1 |
| Decousus, H | 1 |
| Obergfell, A | 1 |
| Langenfeld, H | 1 |
| Hopp, H | 1 |
| Steigerwald, U | 1 |
| Grossmann, R | 1 |
| Benvenuti, L | 1 |
| Gagliardi, R | 1 |
| Peternel, L | 1 |
| Drevensek, G | 1 |
| Cerne, M | 1 |
| Stalc, A | 1 |
| Stegnar, M | 1 |
| Budihna, MV | 1 |
| Lee, JH | 2 |
| Park, NH | 1 |
| Keum, DY | 1 |
| Choi, SY | 1 |
| Kwon, KY | 1 |
| Cho, CH | 1 |
| Doutremepuich, F | 1 |
| Aguejouf, O | 1 |
| Imbault, P | 1 |
| Oualane, FA | 1 |
| Doutremepuich, C | 1 |
| Thomas, L | 1 |
| Tyburn, B | 1 |
| Bucher, B | 1 |
| Pecout, F | 1 |
| Ketterle, J | 1 |
| Rieux, D | 1 |
| Smadja, D | 1 |
| Garnier, D | 1 |
| Plumelle, Y | 1 |
| Biemond, BJ | 1 |
| Levi, M | 2 |
| Nurmohamed, MT | 1 |
| Büller, HR | 1 |
| ten Cate, JW | 1 |
| Carrie, D | 1 |
| Caranobe, C | 1 |
| Saivin, S | 1 |
| Houin, G | 1 |
| Petitou, M | 1 |
| Lormeau, JC | 1 |
| Van Boeckel, C | 1 |
| Meuleman, D | 1 |
| Krupiński, K | 1 |
| Bielawiec, M | 2 |
| Breddin, HK | 3 |
| Raake, W | 1 |
| Klauser, RJ | 1 |
| Elling, H | 1 |
| Zeiller, P | 1 |
| Meinetsberger, E | 1 |
| Tschammler, A | 1 |
| Markert, T | 1 |
| Wittenberg, G | 1 |
| Krahe, T | 1 |
| Bachmann, F | 1 |
| Koopman, MM | 1 |
| Prandoni, P | 3 |
| Piovella, F | 1 |
| Ockelford, PA | 1 |
| Brandjes, DP | 1 |
| van der Meer, J | 1 |
| Gallus, AS | 1 |
| Simonneau, G | 1 |
| Chesterman, CH | 1 |
| Prins, MH | 1 |
| Elikowski, W | 1 |
| Psuja, P | 1 |
| Lewandowski, K | 1 |
| Przybył, M | 1 |
| Wendland, M | 1 |
| Wróblewski, D | 1 |
| Jazienicki, B | 1 |
| Przybył, L | 1 |
| Zawilska, K | 1 |
| Ruiz-Valverde, MP | 1 |
| Barberà, JR | 1 |
| Segarra, A | 1 |
| Capdevila, JA | 1 |
| Evangelista, A | 1 |
| Piera, L | 1 |
| Goldsmith, DJ | 1 |
| Charbonnier, B | 1 |
| Martineau, P | 1 |
| Tawil, N | 1 |
| Giedrojć, J | 1 |
| Klimiuk, M | 1 |
| Radziwon, P | 1 |
| Kłoczko, J | 1 |
| Kobza, II | 1 |
| Lagro, SW | 1 |
| Verdonck, LF | 1 |
| Borel Rinkes, IH | 1 |
| Dekker, AW | 1 |
| Vernon, SM | 1 |
| Hofmann, S | 1 |
| Knoefler, R | 1 |
| Lorenz, N | 1 |
| Siegert, G | 1 |
| Wendisch, J | 1 |
| Mueller, D | 1 |
| Taut-Sack, H | 1 |
| Dinger, J | 1 |
| Kabus, M | 1 |
| Vrij, AA | 1 |
| Jansen, JM | 1 |
| Schoon, EJ | 1 |
| de Bruïne, A | 1 |
| Hemker, HC | 2 |
| Stockbrügger, RW | 1 |
| Kargin, VD | 1 |
| Rzhevskaia, VN | 1 |
| Saltykova, NB | 1 |
| Kapustin, SI | 1 |
| Papaian, LP | 1 |
| Kaplunov, OA | 1 |
| Kaplunov, KO | 1 |
| Trunfio, M | 1 |
| Salvador, E | 1 |
| Cabodi, D | 1 |
| Marinaro, L | 1 |
| Alcantarini, C | 1 |
| Gaviraghi, A | 1 |
| Trentalange, A | 1 |
| Lipani, F | 1 |
| Sciascia, S | 1 |
| Roccatello, D | 1 |
| Bonora, S | 1 |
| Di Perri, G | 1 |
| Calcagno, A | 1 |
| Florian-Kujawski, M | 1 |
| Hoppensteadt, D | 3 |
| Maddineni, J | 1 |
| Ziegler, H | 1 |
| Fareed, J | 5 |
| Sagüillo, K | 1 |
| Pérez-Flecha, F | 1 |
| Almeida, F | 1 |
| Picón, M | 1 |
| Acero, J | 1 |
| Aydin Ozturk, P | 1 |
| Yilmaz, T | 1 |
| Ozturk, U | 1 |
| Vavken, P | 1 |
| Lunzer, A | 1 |
| Grohs, JG | 1 |
| San Juan Alvarez, M | 1 |
| Márquez Garrido, G | 1 |
| Rodríguez Bertos, C | 1 |
| González Pérez, L | 1 |
| Monreal Bosch, M | 1 |
| Vignoli, A | 1 |
| Lecumberri Villamediana, R | 1 |
| Rocha, E | 1 |
| Gómez-Outes, A | 1 |
| Martínez González, J | 1 |
| Kakkar, VV | 3 |
| Kalçık, M | 1 |
| Güner, A | 1 |
| Kalkan, S | 1 |
| Özkan, M | 2 |
| Sarangi, SN | 1 |
| Gaballah, M | 1 |
| Nolfi-Donegan, D | 1 |
| Battaglia, M | 1 |
| Amin, S | 1 |
| Amodio, J | 1 |
| Acharya, SS | 1 |
| Sibai, H | 1 |
| Atenafu, EG | 1 |
| Seki, JT | 1 |
| Belmouaz, M | 1 |
| Goussard, G | 1 |
| Joly, F | 1 |
| Grand, F | 1 |
| Sibille, A | 1 |
| Ecotiere, L | 1 |
| Desport, E | 1 |
| Bauwens, M | 1 |
| Thierry, A | 1 |
| Bridoux, F | 1 |
| Farkouh, ME | 1 |
| Stone, GW | 4 |
| Lala, A | 1 |
| Bagiella, E | 1 |
| Moreno, PR | 1 |
| Nadkarni, GN | 1 |
| Ben-Yehuda, O | 1 |
| Granada, JF | 1 |
| Dressler, O | 1 |
| Tinuoye, EO | 1 |
| Granada, C | 1 |
| Bustamante, J | 1 |
| Peyra, C | 1 |
| Godoy, LC | 1 |
| Palacios, IF | 1 |
| Fuster, V | 2 |
| Cloyd, C | 2 |
| Wysocki, EL | 2 |
| Johnson, H | 1 |
| Miller, JC | 1 |
| Davis, J | 1 |
| Galantowicz, M | 1 |
| Yates, AR | 1 |
| Gilmore, H | 1 |
| Jones, S | 1 |
| Monagle, P | 3 |
| Monagle, S | 1 |
| Newall, F | 1 |
| Saithong, S | 1 |
| Saisorn, W | 1 |
| Tovichayathamrong, P | 1 |
| Filbertine, G | 1 |
| Torvorapanit, P | 1 |
| Wright, HL | 1 |
| Edwards, SW | 1 |
| Leelahavanichkul, A | 1 |
| Hirankarn, N | 1 |
| Chiewchengchol, D | 1 |
| Sang, L | 1 |
| Hao, K | 1 |
| Ding, L | 1 |
| Shen, X | 1 |
| Sun, H | 1 |
| Fu, D | 1 |
| Qi, X | 1 |
| Farasatinasab, M | 1 |
| Balouchzehi, S | 1 |
| Moghaddam, OM | 1 |
| Ansarinejad, N | 1 |
| Mohammadi, M | 1 |
| Nasiripour, S | 1 |
| Centers, GI | 1 |
| Hege, KM | 1 |
| Nitu, ME | 1 |
| Cristea, IA | 1 |
| Yabrodi, M | 1 |
| Schade Willis, TM | 1 |
| Bhai, H | 1 |
| Faustino, EVS | 2 |
| Barco, S | 2 |
| Voci, D | 1 |
| Held, U | 2 |
| Sebastian, T | 2 |
| Bingisser, R | 2 |
| Colucci, G | 2 |
| Duerschmied, D | 2 |
| Frenk, A | 2 |
| Gerber, B | 2 |
| Götschi, A | 1 |
| Konstantinides, SV | 1 |
| Mach, F | 2 |
| Robert-Ebadi, H | 1 |
| Rosemann, T | 2 |
| Simon, NR | 1 |
| Spechbach, H | 1 |
| Spirk, D | 1 |
| Stortecky, S | 2 |
| Vaisnora, L | 1 |
| Righini, M | 2 |
| Kucher, N | 2 |
| Fioretti, AM | 2 |
| Leopizzi, T | 2 |
| Puzzovivo, A | 2 |
| Giotta, F | 2 |
| Lorusso, V | 2 |
| Luzzi, G | 2 |
| Oliva, S | 2 |
| Parker, RI | 1 |
| Saadoun, R | 1 |
| Bengur, FB | 1 |
| Moroni, EA | 1 |
| Surucu, Y | 1 |
| Veit, JA | 1 |
| Khan, NI | 1 |
| Daniels, K | 1 |
| Rothenberger, SD | 1 |
| Kubik, M | 1 |
| Solari, MG | 1 |
| Sridharan, S | 1 |
| Albisinni, R | 2 |
| Vitrone, M | 2 |
| Ursi, MP | 2 |
| Spiezia, S | 2 |
| Salemme, A | 2 |
| Florio, LL | 2 |
| Boccia, F | 2 |
| Iossa, D | 2 |
| Zampino, R | 2 |
| Atripaldi, L | 2 |
| Squillante, F | 2 |
| Maturo, N | 2 |
| Fraganza, F | 2 |
| Severino, S | 2 |
| Punzi, R | 2 |
| Fiorentino, G | 2 |
| Gulati, S | 1 |
| Eckman, MH | 1 |
| Guan, Z | 1 |
| Wang, R | 1 |
| Hussain, RH | 1 |
| Fredenburgh, JC | 2 |
| Jaffer, IH | 1 |
| Weitz, JI | 3 |
| Milling, TJ | 2 |
| Middeldorp, S | 2 |
| Xu, L | 1 |
| Koch, B | 1 |
| Demchuk, A | 1 |
| Eikelboom, JW | 3 |
| Verhamme, P | 3 |
| Cohen, AT | 4 |
| Beyer-Westendorf, J | 3 |
| Gibson, CM | 2 |
| Lopez-Sendon, J | 2 |
| Crowther, M | 3 |
| Shoamanesh, A | 1 |
| Coppens, M | 1 |
| Schmidt, J | 2 |
| Albaladejo, P | 2 |
| Connolly, SJ | 2 |
| Durila, M | 1 |
| Berousek, J | 1 |
| Vlasakova, V | 1 |
| Vymazal, T | 1 |
| Hachenberger, M | 1 |
| Yeniguen, M | 1 |
| Suenner, L | 1 |
| Hinchliffe, D | 1 |
| Mueller, C | 2 |
| Wietelmann, A | 1 |
| Gerriets, T | 1 |
| Tschernatsch, M | 1 |
| Juenemann, M | 1 |
| Gerner, ST | 1 |
| Doeppner, TR | 1 |
| Huttner, HB | 1 |
| Braun, T | 1 |
| Vaughn, AE | 1 |
| Hall, JK | 1 |
| Harrison, ML | 1 |
| Klein, G | 1 |
| Diaz-Miron, J | 1 |
| Yi, JA | 1 |
| Acker, SN | 1 |
| Karahan, F | 1 |
| Ünal, S | 1 |
| Tezol, Ö | 1 |
| Sürmeli Döven, S | 1 |
| Durak, F | 1 |
| Alakaya, M | 1 |
| Mısırlıoğlu, M | 1 |
| Yeşil, E | 1 |
| Kıllı, İ | 1 |
| Kurt, H | 1 |
| Altunköprü, G | 1 |
| Alexander, M | 2 |
| Harris, S | 1 |
| Underhill, C | 1 |
| Torres, J | 1 |
| Sharma, S | 2 |
| Lee, N | 1 |
| Wong, H | 1 |
| Eek, R | 1 |
| Michael, M | 1 |
| Tie, J | 1 |
| Rogers, J | 1 |
| Heriot, AG | 1 |
| Ball, D | 1 |
| MacManus, M | 1 |
| Wolfe, R | 1 |
| Solomon, BJ | 1 |
| Burbury, K | 1 |
| Dziri, C | 1 |
| Ben Hmida, W | 1 |
| Dougaz, W | 1 |
| Khalfallah, M | 1 |
| Samaali, I | 1 |
| Jerraya, H | 1 |
| Bouasker, I | 1 |
| Nouira, R | 1 |
| Chen, S | 1 |
| Schmidt, B | 1 |
| Tohoku, S | 1 |
| Trolese, L | 1 |
| Bordignon, S | 1 |
| Chun, KRJ | 1 |
| Raskob, GE | 1 |
| Spyropoulos, AC | 1 |
| Spiro, TE | 2 |
| De Sanctis, Y | 1 |
| Xu, J | 1 |
| Lu, W | 1 |
| Suh, E | 1 |
| Argenti, D | 1 |
| Yang, H | 1 |
| Albanese, J | 1 |
| Lipardi, C | 1 |
| Barnathan, ES | 1 |
| Sudhakar, D | 1 |
| Kamran, H | 1 |
| Chen, N | 1 |
| Mims, M | 1 |
| Hamzeh, I | 1 |
| Kozieł, M | 1 |
| Merino, JL | 1 |
| De Caterina, R | 2 |
| Huber, K | 1 |
| Jin, J | 1 |
| Melino, M | 1 |
| Goette, A | 1 |
| Lip, GYH | 4 |
| Rahhal, A | 1 |
| Khir, F | 1 |
| Adam, M | 1 |
| Aljundi, A | 1 |
| Mohsen, MK | 1 |
| Al-Suwaidi, J | 1 |
| Maurice-Dror, C | 1 |
| Litvak, M | 1 |
| Keren-Politansky, A | 1 |
| Ackerman, S | 1 |
| Haim, N | 1 |
| Nadir, Y | 2 |
| Cattaneo, M | 1 |
| Morici, N | 1 |
| Singh, N | 1 |
| Singh Lubana, S | 1 |
| Tsai, HM | 1 |
| Zanon, E | 1 |
| Pasca, S | 1 |
| Campello, E | 1 |
| Spiezia, L | 1 |
| Vettor, R | 1 |
| Simioni, P | 1 |
| Lamamri, M | 1 |
| Chebbi, A | 1 |
| Mamane, J | 1 |
| Abbad, S | 1 |
| Munuzzolini, M | 1 |
| Sarfati, F | 1 |
| Legriel, S | 1 |
| Fujikura, K | 1 |
| Fontes, JD | 1 |
| Taub, CC | 1 |
| Ferguson, K | 1 |
| Quail, N | 1 |
| Kewin, P | 1 |
| Blyth, KG | 1 |
| Mattioli, M | 1 |
| Benfaremo, D | 1 |
| Mancini, M | 1 |
| Mucci, L | 1 |
| Mainquà, P | 1 |
| Polenta, A | 1 |
| Baldini, PM | 1 |
| Fulgenzi, F | 1 |
| Dennetta, D | 1 |
| Bedetta, S | 1 |
| Gasperoni, L | 1 |
| Caraffa, A | 1 |
| Frausini, G | 1 |
| Chen, PF | 1 |
| Yi, JL | 1 |
| Pei, JY | 1 |
| Tang, L | 1 |
| Fang, ZF | 1 |
| Zhou, SH | 1 |
| Hu, XQ | 1 |
| Mazzolai, L | 1 |
| Spescha, R | 1 |
| Windecker, S | 1 |
| Lazar, M | 1 |
| Tomey, MI | 1 |
| Ghia, S | 1 |
| Katz, D | 1 |
| Derr, K | 1 |
| Narula, J | 1 |
| Bhatt, HV | 1 |
| Carmo Filho, A | 1 |
| Cunha, BDS | 1 |
| Lemos, ACB | 1 |
| do Espírito Santo, DA | 1 |
| Salvetti, MC | 1 |
| Gilio, RN | 1 |
| Agra, LB | 1 |
| Pazin-Filho, A | 2 |
| Miranda, CH | 1 |
| Bikdeli, B | 3 |
| Talasaz, AH | 3 |
| Rashidi, F | 3 |
| Sharif-Kashani, B | 3 |
| Farrokhpour, M | 3 |
| Bakhshandeh, H | 3 |
| Sezavar, H | 1 |
| Dabbagh, A | 3 |
| Beigmohammadi, MT | 3 |
| Payandemehr, P | 3 |
| Yadollahzadeh, M | 3 |
| Riahi, T | 3 |
| Khalili, H | 3 |
| Jamalkhani, S | 3 |
| Rezaeifar, P | 3 |
| Abedini, A | 3 |
| Lookzadeh, S | 3 |
| Shahmirzaei, S | 3 |
| Tahamtan, O | 3 |
| Matin, S | 3 |
| Amin, A | 3 |
| Parhizgar, SE | 3 |
| Jimenez, D | 3 |
| Gupta, A | 3 |
| Madhavan, MV | 3 |
| Parikh, SA | 3 |
| Monreal, M | 4 |
| Hadavand, N | 3 |
| Hajighasemi, A | 3 |
| Maleki, M | 3 |
| Sadeghian, S | 3 |
| Mohebbi, B | 3 |
| Piazza, G | 3 |
| Kirtane, AJ | 3 |
| Krumholz, HM | 3 |
| Goldhaber, SZ | 3 |
| Sadeghipour, P | 5 |
| Cattelan, AM | 1 |
| Carrozzi, L | 1 |
| Leone, L | 1 |
| Filippi, L | 1 |
| De Gaudenzi, E | 1 |
| Villalta, S | 1 |
| Pesavento, R | 1 |
| Belcaro, G | 1 |
| Corsi, M | 1 |
| Agus, GB | 1 |
| Cesarone, MR | 1 |
| Cornelli, U | 1 |
| Cotellese, R | 1 |
| Feragalli, B | 1 |
| Hu, S | 1 |
| Dobbie, LJ | 1 |
| Lamb, A | 1 |
| Eskell, L | 1 |
| Ramage, IJ | 1 |
| Reynolds, BC | 1 |
| Arachchillage, DRJ | 1 |
| Shi, C | 1 |
| Saliu, D | 1 |
| Kozman, P | 1 |
| Mi, E | 1 |
| Buti, N | 1 |
| Kashef, E | 1 |
| Copley, SJ | 1 |
| Gomez, C | 1 |
| Leonard, R | 1 |
| Aziz, R | 1 |
| Shlebak, AA | 1 |
| Laffan, M | 1 |
| Kuhn, A | 1 |
| Steinbrenner, J | 1 |
| Tyrrell, L | 1 |
| Abdel-Rasoul, M | 1 |
| Dunn, A | 1 |
| Raffini, LJ | 1 |
| Hanson, SJ | 1 |
| Cholette, JM | 1 |
| Pinto, MG | 1 |
| Li, S | 1 |
| Kandil, SB | 1 |
| Nellis, ME | 1 |
| Shabanova, V | 1 |
| Silva, CT | 1 |
| Tala, JA | 1 |
| McPartland, T | 1 |
| Spinella, PC | 1 |
| Lv, Y | 1 |
| Bai, W | 1 |
| Li, K | 1 |
| Wang, Z | 1 |
| Guo, W | 1 |
| Luo, B | 1 |
| Wang, J | 1 |
| Wang, Q | 1 |
| Wang, E | 1 |
| Xia, D | 1 |
| Li, X | 1 |
| Yuan, J | 1 |
| Han, N | 1 |
| Niu, J | 1 |
| Yin, Z | 1 |
| Fan, D | 1 |
| Han, G | 1 |
| Bernard, AM | 1 |
| Alvarez, PA | 1 |
| Bream-Rouwenhorst, HR | 1 |
| Horner, KE | 1 |
| Briasoulis, A | 1 |
| Czerniak, LC | 1 |
| Kirkup, C | 1 |
| Pawlowski, C | 1 |
| Puranik, A | 1 |
| Conrad, I | 1 |
| O'Horo, JC | 1 |
| Gomaa, D | 1 |
| Banner-Goodspeed, VM | 1 |
| Mosier, JM | 1 |
| Zabolotskikh, IB | 1 |
| Daugherty, SK | 1 |
| Bernstein, MA | 1 |
| Zaren, HA | 1 |
| Bansal, V | 1 |
| Pickering, B | 1 |
| Badley, AD | 1 |
| Kashyap, R | 1 |
| Venkatakrishnan, AJ | 1 |
| Soundararajan, V | 1 |
| Sezavar, SH | 2 |
| Moghadam, KG | 2 |
| Rahmani, H | 2 |
| Zoghi, E | 2 |
| Mohammadi, K | 2 |
| Abri, H | 2 |
| Tabrizi, S | 2 |
| Mousavian, SM | 2 |
| Rafiee, F | 2 |
| Baghizadeh, E | 2 |
| Aliannejad, R | 2 |
| Eslami, V | 2 |
| Kashefizadeh, A | 2 |
| Kakavand, H | 2 |
| Hosseini, SH | 2 |
| Shafaghi, S | 2 |
| Ghazi, SF | 2 |
| Najafi, A | 2 |
| Sethi, SS | 2 |
| Van Tassell, BW | 2 |
| Dobesh, PP | 2 |
| Lopes, RD | 3 |
| de Barros E Silva, PGM | 1 |
| Furtado, RHM | 1 |
| Macedo, AVS | 1 |
| Ramacciotti, E | 2 |
| Damini, LP | 1 |
| Bronhara, B | 1 |
| Cavalcanti, AB | 1 |
| Rosa, RG | 1 |
| Azevedo, LCP | 1 |
| Veiga, VC | 1 |
| Machado, FR | 1 |
| Ritt, LE | 1 |
| Martins, PA | 1 |
| Alexander, JH | 1 |
| Avezum, A | 1 |
| Berwanger, O | 1 |
| Perepu, US | 1 |
| Chambers, I | 1 |
| Wahab, A | 1 |
| Ten Eyck, P | 1 |
| Wu, C | 1 |
| Dayal, S | 1 |
| Sutamtewagul, G | 1 |
| Bailey, SR | 1 |
| Rosenstein, LJ | 1 |
| Lentz, SR | 1 |
| Abdelwahab, HW | 1 |
| Shaltout, SW | 1 |
| Sayed Ahmed, HA | 1 |
| Fouad, AM | 1 |
| Merrell, E | 1 |
| Riley, JB | 1 |
| Salama, R | 1 |
| Abdelrahman, AG | 1 |
| Darling, E | 1 |
| Fadel, G | 1 |
| Elfar, MSA | 1 |
| Sabry, K | 1 |
| Shah, J | 1 |
| Amin, H | 1 |
| Nieman, GF | 1 |
| Mishriky, A | 1 |
| Aiash, H | 1 |
| Antunes de Brito, CA | 1 |
| de Oliveira Filho, JRB | 1 |
| Marques, DT | 1 |
| Lencastre, MDC | 1 |
| de Almeida, JR | 1 |
| Lopes, EP | 1 |
| Xiang, E | 1 |
| Ahuja, T | 1 |
| Raco, V | 1 |
| Cirrone, F | 1 |
| Green, D | 2 |
| Papadopoulos, J | 1 |
| Tognon, M | 1 |
| Darbellay Farhoumand, P | 1 |
| Blondon, M | 1 |
| Agoritsas, T | 1 |
| Kumar Jha, R | 1 |
| Bansal, S | 1 |
| S Issar, H | 1 |
| Chaudhary, M | 1 |
| Cao, F | 1 |
| Liu, G | 1 |
| Wang, W | 1 |
| Wang, B | 1 |
| Wei, X | 1 |
| Lu, F | 1 |
| Yang, F | 1 |
| Kang, K | 1 |
| Wang, Y | 1 |
| Yang, J | 1 |
| Qin, K | 1 |
| Zhao, D | 1 |
| Cosgrove, RH | 1 |
| Basken, RL | 1 |
| Smith, RG | 1 |
| Hsu, CH | 1 |
| Kazui, T | 1 |
| Martinez, BK | 1 |
| Burt, RW | 1 |
| Crawford, ES | 1 |
| Lick, SD | 1 |
| Khalpey, Z | 1 |
| Israel, EN | 1 |
| Thomas, CA | 1 |
| Mastropietro, CW | 1 |
| Peetermans, M | 1 |
| Liesenborghs, L | 1 |
| Peerlinck, K | 1 |
| Wijngaerden, EV | 1 |
| Gheysens, O | 1 |
| Goffin, KE | 1 |
| Hoylaerts, MF | 1 |
| Jacquemin, M | 1 |
| Verhaegen, J | 1 |
| Peetermans, WE | 1 |
| Vanassche, T | 1 |
| Lindquist, DE | 1 |
| Stewart, DW | 1 |
| Brewster, A | 1 |
| Waldroup, C | 1 |
| Odle, BL | 1 |
| Burchette, JE | 1 |
| El-Bazouni, H | 1 |
| Gill-Schuster, D | 1 |
| Bergold, M | 1 |
| Holzer, L | 1 |
| Jandial, A | 1 |
| Mishra, K | 1 |
| Kumar, S | 1 |
| Malhotra, P | 1 |
| Guimicheva, B | 1 |
| Patel, JP | 1 |
| Roberts, LN | 1 |
| Subramanian, D | 1 |
| Arya, R | 1 |
| Young, J | 1 |
| Sawyer, J | 2 |
| Jenkins, M | 1 |
| O'Brien, M | 1 |
| Luchtman-Jones, L | 1 |
| Breese, EH | 1 |
| Chamoun, N | 1 |
| Ghanem, H | 1 |
| Hachem, A | 1 |
| Hariri, E | 1 |
| Lteif, C | 1 |
| Mansour, H | 1 |
| Dimassi, H | 1 |
| Zalloum, R | 1 |
| Ghanem, G | 1 |
| Tadic, M | 1 |
| Belyavskiy, E | 1 |
| Cuspidi, C | 1 |
| Pieske, B | 1 |
| Haßfeld, S | 1 |
| Voudris, V | 1 |
| Georgiadou, P | 1 |
| Kalogris, P | 1 |
| Kostelidou, T | 1 |
| Karabinis, A | 1 |
| Gerotziafas, G | 1 |
| Gezelius, E | 1 |
| Bendahl, PO | 1 |
| Gonçalves de Oliveira, K | 1 |
| Ek, L | 1 |
| Bergman, B | 1 |
| Sundberg, J | 1 |
| Strandberg, K | 1 |
| Krämer, R | 1 |
| Belting, M | 1 |
| Brouwers, JRBJ | 1 |
| Roeters van Lennep, JE | 1 |
| Beinema, MJ | 1 |
| Guenther, F | 1 |
| Herr, N | 1 |
| Mauler, M | 1 |
| Witsch, T | 1 |
| Roming, F | 1 |
| Hein, L | 1 |
| Boeynaems, JM | 1 |
| Robaye, B | 1 |
| Idzko, M | 1 |
| Bode, C | 1 |
| Von Zur Muhlen, C | 1 |
| Robinson, S | 1 |
| Zincuk, A | 1 |
| Larsen, UL | 1 |
| Ekstrøm, C | 1 |
| Nybo, M | 1 |
| Rasmussen, B | 1 |
| Toft, P | 1 |
| Ladha, A | 1 |
| Alam, A | 1 |
| Idestrup, C | 1 |
| Choi, S | 1 |
| Seijo, S | 1 |
| Garcia-Pagan, JC | 1 |
| Grieco, A | 1 |
| Lombardo, A | 1 |
| Biolato, M | 1 |
| Kaeberich, A | 2 |
| Raaz, U | 3 |
| Vogt, A | 1 |
| Maedgefessel, L | 1 |
| Neuhart, E | 1 |
| Krezel, C | 1 |
| Drouget, L | 1 |
| Hauroeder, B | 5 |
| Buerke, M | 6 |
| Werdan, K | 5 |
| Schlitt, A | 6 |
| Bramham, K | 1 |
| Retter, A | 1 |
| Robinson, SE | 1 |
| Mitchell, M | 1 |
| Moore, GW | 1 |
| Hunt, BJ | 4 |
| Sinan, UY | 1 |
| Coskun, U | 1 |
| Balaban Kocas, B | 1 |
| Gultekin, N | 1 |
| Gurmen, T | 1 |
| Kucukoglu, S | 1 |
| Hiscock, RJ | 1 |
| Casey, E | 1 |
| Simmons, SW | 1 |
| Walker, SP | 1 |
| Newell, PA | 1 |
| Yusen, RD | 1 |
| Hull, RD | 1 |
| Schellong, SM | 1 |
| Tapson, VF | 1 |
| Samama, MM | 3 |
| Chen, M | 1 |
| Deslandes, B | 1 |
| Turpie, AG | 2 |
| Hirsh, J | 2 |
| Ginsberg, JS | 1 |
| Chan, N | 1 |
| Guyatt, G | 1 |
| Corder, A | 1 |
| Held, K | 1 |
| Oschman, A | 1 |
| Garcipérez de Vargas, FJ | 1 |
| Marcos, G | 1 |
| Moyano Calvente, SL | 1 |
| Giannini, EG | 1 |
| Stravitz, RT | 1 |
| Caldwell, SH | 1 |
| Bytsaĭ, AN | 1 |
| Chapelle, C | 1 |
| Bertoletti, L | 1 |
| Lega, JC | 1 |
| Cucherat, M | 1 |
| Zufferey, PJ | 1 |
| Darmon, JY | 1 |
| Hallbergson, A | 1 |
| Gillespie, MJ | 1 |
| Dori, Y | 1 |
| Connors, JM | 2 |
| Oliveira, SN | 2 |
| Santos, GR | 1 |
| Glauser, BF | 3 |
| Capillé, NV | 1 |
| Queiroz, IN | 1 |
| Pereira, MS | 3 |
| Pomin, VH | 1 |
| Mourão, PA | 3 |
| Tronina, O | 1 |
| Mikołajczyk, N | 1 |
| Pietrzak, B | 1 |
| Pacholczyk, M | 1 |
| Durlik, M | 1 |
| Kremers, RM | 1 |
| Peters, TC | 1 |
| Wagenvoord, RJ | 1 |
| Betancur-Gutiérrez, A | 1 |
| Bayón-Fernández, J | 1 |
| García-Rodríguez, MÁ | 1 |
| García-Egido, A | 1 |
| Garrote-Coloma, C | 1 |
| Fernández-Vázquez, F | 1 |
| Sauer, S | 1 |
| Goltz, JP | 1 |
| Gassenmaier, T | 1 |
| Kunz, AS | 1 |
| Bley, TA | 1 |
| Klein, D | 1 |
| Petritsch, B | 1 |
| Al-Sallami, HS | 1 |
| Medlicott, NJ | 1 |
| Vazquez, FJ | 1 |
| Paulin, P | 1 |
| Rodriguez, P | 1 |
| Lubertino, M | 1 |
| Gándara, E | 1 |
| White, DC | 1 |
| Grines, CL | 1 |
| Grines, LL | 1 |
| Marcovitz, P | 1 |
| Messenger, J | 1 |
| Schreiber, T | 1 |
| Vázquez-Alonso, E | 1 |
| Fábregas, N | 1 |
| Rama-Maceiras, P | 1 |
| Ingelmo Ingelmo, I | 1 |
| Valero Castell, R | 1 |
| Valencia Sola, L | 1 |
| Iturri Clavero, F | 1 |
| Baquero-Salamanca, M | 1 |
| Téllez-Arévalo, AM | 1 |
| Calderon-Ospina, C | 1 |
| Goldsmith, R | 1 |
| Chan, AK | 4 |
| Paes, BA | 1 |
| Bhatt, MD | 1 |
| Ardillon, L | 1 |
| Lambert, C | 1 |
| Eeckhoudt, S | 1 |
| Boon, LM | 1 |
| Hermans, C | 1 |
| Rousseau, A | 1 |
| Van Dreden, P | 1 |
| Mbemba, E | 1 |
| Elalamy, I | 1 |
| Larsen, A | 1 |
| Gerotziafas, GT | 1 |
| Boettcher, M | 1 |
| Fuchs, TA | 1 |
| Schäfer, H | 1 |
| Appl, B | 1 |
| Trochimiuk, M | 1 |
| Jiménez-Alcázar, M | 1 |
| Tiemann, B | 1 |
| Jung, R | 1 |
| Bergholz, R | 1 |
| Reinshagen, K | 1 |
| Eschenburg, G | 1 |
| Prieto-Torres, L | 1 |
| Gracia Cazaña, T | 1 |
| Pastushenko, I | 1 |
| Morales Moya, AL | 1 |
| Soria, J | 1 |
| Ara Martín, M | 1 |
| Kurtkoti, J | 1 |
| Bose, B | 1 |
| Hiremagalur, B | 1 |
| Sun, J | 1 |
| Cochrane, T | 1 |
| Mehta, AY | 1 |
| Mohammed, BM | 1 |
| Martin, EJ | 1 |
| Brophy, DF | 1 |
| Gailani, D | 1 |
| Desai, UR | 1 |
| Weishaupt, C | 1 |
| Strölin, A | 1 |
| Kahle, B | 1 |
| Kreuter, A | 1 |
| Schneider, SW | 1 |
| Gerss, J | 1 |
| Eveslage, M | 1 |
| Drabik, A | 1 |
| Goerge, T | 1 |
| Boon, IS | 1 |
| Boon, CS | 1 |
| Kalinin, RE | 1 |
| Suchkov, IA | 1 |
| Pshennikov, AS | 1 |
| Agapov, AB | 1 |
| Karapurkar, AP | 1 |
| Singh, R | 1 |
| Teelala, SM | 1 |
| Lalla, R | 1 |
| Gomez Gomez, E | 1 |
| Campos Hernandez, JP | 1 |
| Cazalilla, M | 1 |
| Triviño, F | 1 |
| Barbudo, J | 1 |
| Prieto, R | 1 |
| Requena Tapia, MJ | 1 |
| Krueger, K | 1 |
| Schmutz, A | 1 |
| Zieger, B | 2 |
| Kalbhenn, J | 1 |
| Akhtyamov, IF | 1 |
| Ziatdinov, BG | 1 |
| Shigaev, ES | 1 |
| Kalaska, B | 1 |
| Kaminski, K | 1 |
| Miklosz, J | 1 |
| Yusa, SI | 1 |
| Sokolowska, E | 1 |
| Blazejczyk, A | 1 |
| Wietrzyk, J | 1 |
| Kasacka, I | 1 |
| Szczubialka, K | 1 |
| Pawlak, D | 1 |
| Nowakowska, M | 1 |
| Mogielnicki, A | 1 |
| Curnutte, JT | 1 |
| Gold, A | 1 |
| Bronson, MD | 1 |
| Lu, G | 1 |
| Conley, PB | 1 |
| Goodman, S | 1 |
| Leeds, J | 1 |
| Wiens, BL | 1 |
| Siegal, DM | 1 |
| Zotova, E | 1 |
| Meeks, B | 1 |
| Nakamya, J | 1 |
| Lim, WT | 1 |
| Bos, S | 1 |
| Potze, W | 1 |
| Siddiqui, MS | 1 |
| Boyett, SL | 1 |
| Adelmeijer, J | 1 |
| Daita, K | 1 |
| Lisman, T | 1 |
| Sanyal, AJ | 1 |
| Maegdefessel, L | 4 |
| Schubert, S | 3 |
| Reindl, I | 2 |
| Michel, T | 1 |
| Carter, JM | 2 |
| Peetz, D | 3 |
| Bozcali, E | 1 |
| Tutpinar, Y | 1 |
| Scherr, D | 1 |
| Dalal, D | 1 |
| Chilukuri, K | 1 |
| Dong, J | 1 |
| Spragg, D | 1 |
| Henrikson, CA | 1 |
| Nazarian, S | 1 |
| Cheng, A | 1 |
| Berger, RD | 1 |
| Abraham, TP | 1 |
| Calkins, H | 1 |
| Marine, JE | 1 |
| Bauman, ME | 1 |
| Belletrutti, MJ | 1 |
| Bajzar, L | 1 |
| Black, KL | 1 |
| Kuhle, S | 1 |
| Bauman, ML | 1 |
| Patricia Massicotte, M | 1 |
| Stiefelhagen, P | 1 |
| Arellano-Rodrigo, E | 1 |
| Gironella, M | 1 |
| Nicolau, I | 1 |
| Vila, M | 1 |
| Alexander, KP | 1 |
| Manoukian, SV | 1 |
| Bertrand, ME | 1 |
| Feit, F | 1 |
| White, HD | 2 |
| Pollack, CV | 1 |
| Hoekstra, J | 1 |
| Gersh, BJ | 1 |
| Ohman, EM | 2 |
| Venkateswaran, L | 1 |
| Scaglia, F | 1 |
| McLin, V | 1 |
| Hertel, P | 1 |
| Shchelochkov, OA | 1 |
| Karpen, S | 1 |
| Mahoney, D | 1 |
| Yee, DL | 1 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
| Ruiz-Irastorza, G | 1 |
| Martinez-Berriotxoa, A | 1 |
| Egurbide, MV | 1 |
| Teixeira, OH | 1 |
| Mehta, AV | 1 |
| Viskov, C | 2 |
| Just, M | 1 |
| Laux, V | 3 |
| Mourier, P | 1 |
| Lorenz, M | 1 |
| Cage, TA | 1 |
| Lamborn, KR | 1 |
| Ware, ML | 1 |
| Frankfurt, A | 1 |
| Chakalian, L | 1 |
| Berger, MS | 1 |
| McDermott, MW | 1 |
| Díez, JG | 1 |
| Medina, HM | 1 |
| Cheong, BY | 1 |
| O'Meallie, L | 1 |
| Ferguson, JJ | 1 |
| Parsi, K | 1 |
| Exner, T | 1 |
| Low, J | 1 |
| Ma, DD | 1 |
| Joseph, JE | 1 |
| Busshardt, M | 2 |
| Plehn, A | 2 |
| Roffi, M | 1 |
| Eberli, FR | 1 |
| Barbetseas, J | 1 |
| Tsiachris, D | 1 |
| Chrysohoou, C | 1 |
| Brilli, S | 1 |
| Bonou, M | 1 |
| Stefanadis, C | 1 |
| Myers, DD | 1 |
| Wrobleski, SK | 1 |
| Deatrick, KB | 1 |
| Londy, FJ | 1 |
| Rectenwald, JE | 1 |
| Henke, PK | 1 |
| Schaub, RG | 1 |
| Wakefield, TW | 1 |
| Warkentin, TE | 2 |
| Cook, RJ | 1 |
| Marder, VJ | 1 |
| Greinacher, A | 2 |
| Shavit, L | 1 |
| Lifschitz, M | 1 |
| Lee, S | 1 |
| Slotki, I | 1 |
| Wallace, TW | 1 |
| Atwater, BD | 1 |
| Daubert, JP | 1 |
| Voora, D | 1 |
| Crowley, AL | 1 |
| Bahnson, TD | 1 |
| Hranitzky, PM | 1 |
| Russ, M | 2 |
| Ebelt, H | 2 |
| Sanchez de Toledo, J | 1 |
| Gunawardena, S | 1 |
| Munoz, R | 1 |
| Orr, R | 1 |
| Berry, D | 1 |
| Sonderman, S | 1 |
| Krallman, S | 1 |
| Shiderly, D | 1 |
| Wang, L | 1 |
| Wearden, P | 1 |
| Morell, VO | 1 |
| Chrysostomou, C | 1 |
| Tonbul, A | 1 |
| Uras, N | 1 |
| Tayman, C | 1 |
| Halici, T | 1 |
| Polat, A | 1 |
| Mansur Tatli, M | 1 |
| Schiele, F | 1 |
| Chin, SO | 1 |
| Lee, JJ | 1 |
| Hwang, YH | 1 |
| Han, JJ | 1 |
| Maeng, CH | 1 |
| Baek, SK | 1 |
| Choi, CW | 1 |
| Scholey, GM | 1 |
| Saayman, AG | 1 |
| Hingston, CD | 1 |
| Wise, MP | 1 |
| Al-Sallami, H | 1 |
| Jordan, S | 1 |
| Ferguson, R | 1 |
| Medlicott, N | 1 |
| Schollum, J | 1 |
| Duffull, S | 1 |
| Akcay, AB | 1 |
| Yuce, M | 1 |
| Akcay, M | 1 |
| Sen, N | 1 |
| Soydinc, HE | 1 |
| Davutoglu, V | 1 |
| Zhang, H | 1 |
| Löwenberg, EC | 1 |
| Crosby, JR | 1 |
| MacLeod, AR | 1 |
| Zhao, C | 1 |
| Gao, D | 1 |
| Black, C | 1 |
| Revenko, AS | 1 |
| Meijers, JC | 1 |
| Stroes, ES | 1 |
| Monia, BP | 1 |
| dos Reis Macedo, LG | 1 |
| de Oliveira, L | 1 |
| Pintão, MC | 1 |
| Garcia, AA | 1 |
| Leithäuser, B | 1 |
| Kasch, F | 1 |
| Broemel, T | 1 |
| Park, JW | 1 |
| Ilhan, E | 1 |
| Demirci, D | 1 |
| Güvenç, TS | 1 |
| Calık, AN | 1 |
| Ferres, MA | 1 |
| Olivarez, SA | 1 |
| Trinh, V | 1 |
| Davidson, C | 1 |
| Sangi-Haghpeykar, H | 1 |
| Aagaard-Tillery, KM | 1 |
| Pandey, V | 1 |
| Dummula, K | 1 |
| Parimi, P | 1 |
| Huang, L | 1 |
| Kanellis, J | 1 |
| Mulley, W | 1 |
| McKellar, SH | 1 |
| Abel, S | 1 |
| Camp, CL | 1 |
| Suri, RM | 1 |
| Ereth, MH | 1 |
| Schaff, HV | 1 |
| Allana, AM | 1 |
| Teo, LL | 1 |
| Chuah, BY | 1 |
| Liu, TC | 1 |
| Cheah, WK | 1 |
| Karow, A | 1 |
| Hainmann, I | 1 |
| Nakamura, L | 1 |
| Budde, U | 1 |
| Stock, SJ | 1 |
| Walker, MC | 1 |
| Edelshain, BT | 1 |
| Horn, L | 1 |
| Norman, JE | 1 |
| Denison, FC | 1 |
| Vairo, BC | 2 |
| Oliveira, CP | 1 |
| Cinelli, LP | 2 |
| Delbeck, M | 1 |
| Nickel, KF | 1 |
| Perzborn, E | 1 |
| Ellinghaus, P | 1 |
| Strassburger, J | 1 |
| Kast, R | 1 |
| Schäfer, S | 1 |
| Schermuly, RT | 1 |
| von Degenfeld, G | 1 |
| Gulati, A | 1 |
| Faed, JM | 1 |
| Isbister, GK | 1 |
| Duffull, SB | 1 |
| Clark, ER | 1 |
| English, JC | 1 |
| Yau, JW | 1 |
| Stafford, AR | 1 |
| Liao, P | 1 |
| Roberts, R | 1 |
| Kulik, A | 1 |
| Saltzman, MB | 1 |
| Morris, JJ | 1 |
| Iwatsuki, Y | 1 |
| Sato, T | 1 |
| Moritani, Y | 1 |
| Shigenaga, T | 1 |
| Suzuki, M | 1 |
| Kawasaki, T | 2 |
| Funatsu, T | 1 |
| Kaku, S | 1 |
| Argiriou, ME | 1 |
| Peled, E | 1 |
| Rovitsky, A | 1 |
| Axelman, E | 1 |
| Norman, D | 1 |
| Brenner, B | 3 |
| Lulic-Botica, M | 1 |
| Rajpurkar, M | 1 |
| Sabo, C | 1 |
| Tutag-Lehr, V | 1 |
| Natarajan, G | 1 |
| Yurttutan, S | 1 |
| Ozdemir, R | 1 |
| Erdeve, O | 1 |
| Calisici, E | 1 |
| Oncel, MY | 1 |
| Oguz, SS | 1 |
| Dilmen, U | 1 |
| Cakmak, HA | 1 |
| Değirmenci, E | 1 |
| Ikizceli, I | 1 |
| Manlhiot, C | 1 |
| Brandão, LR | 2 |
| Kwok, J | 1 |
| Kegel, S | 1 |
| Menjak, IB | 1 |
| Carew, CL | 1 |
| Schwartz, SM | 1 |
| Sivarajan, VB | 1 |
| Caldarone, CA | 1 |
| Van Arsdell, GS | 1 |
| McCrindle, BW | 1 |
| Stief, T | 1 |
| Yazbek, MA | 1 |
| Velho, P | 1 |
| Nadruz, W | 1 |
| Mahayri, N | 1 |
| Appenzeller, S | 1 |
| Costallat, LT | 1 |
| Shorr, AF | 2 |
| Eriksson, BI | 2 |
| Jaffer, AK | 1 |
| Smith, J | 1 |
| Zakrzewski, D | 1 |
| Michałek, P | 1 |
| Shin, JH | 1 |
| Kim, GN | 1 |
| Kil, HR | 1 |
| Chang, MY | 1 |
| D'Ippolito, S | 1 |
| Di Nicuolo, F | 1 |
| Marana, R | 1 |
| Castellani, R | 1 |
| Stinson, J | 1 |
| Tersigni, C | 1 |
| Scambia, G | 1 |
| Di Simone, N | 1 |
| Villa, E | 2 |
| Cammà, C | 2 |
| Marietta, M | 2 |
| Luongo, M | 1 |
| Critelli, R | 1 |
| Colopi, S | 1 |
| Tata, C | 1 |
| Zecchini, R | 1 |
| Gitto, S | 1 |
| Petta, S | 1 |
| Lei, B | 1 |
| Bernabucci, V | 1 |
| Vukotic, R | 1 |
| De Maria, N | 1 |
| Schepis, F | 1 |
| Karampatou, A | 1 |
| Caporali, C | 1 |
| Simoni, L | 1 |
| Del Buono, M | 1 |
| Zambotto, B | 1 |
| Turola, E | 1 |
| Fornaciari, G | 1 |
| Schianchi, S | 1 |
| Ferrari, A | 1 |
| Valla, D | 2 |
| Danguy, C | 1 |
| Biston, P | 1 |
| Carlier, E | 1 |
| Defrance, P | 1 |
| Piagnerelli, M | 1 |
| Barbarash, LS | 1 |
| Burkov, NN | 1 |
| Kudriavtseva, IuA | 1 |
| Anufriev, AI | 1 |
| Zhuravleva, IIu | 1 |
| Teoh, KC | 1 |
| Lingaratnam, S | 1 |
| Kirsa, S | 1 |
| Mellor, JD | 1 |
| Fontana, RJ | 1 |
| Yildiz, M | 1 |
| Karakoyun, S | 1 |
| Acar, RD | 1 |
| Gouya, G | 1 |
| Palkovits, S | 1 |
| Kapiotis, S | 2 |
| Madl, C | 1 |
| Locker, G | 1 |
| Stella, A | 1 |
| Wolzt, M | 1 |
| Heinz, G | 1 |
| Senzolo, M | 1 |
| Caldwell, S | 1 |
| Lima, MA | 1 |
| Herman, F | 1 |
| Gray, AL | 1 |
| de Farias, EH | 1 |
| Cavalheiro, RP | 1 |
| Sassaki, GL | 1 |
| Nader, HB | 1 |
| Bertesi, M | 1 |
| Rozzi, N | 1 |
| Cano, MC | 1 |
| Vallone, S | 1 |
| Cappi, C | 1 |
| Pozzi, S | 1 |
| Torelli, G | 1 |
| Kokkonen, L | 1 |
| Anttonen, O | 1 |
| Voutilainen, S | 1 |
| Bergmann, JF | 1 |
| Mouly, S | 1 |
| Paramo, JC | 1 |
| Sendzischew, H | 1 |
| Sivina, M | 1 |
| Olszowska, A | 1 |
| Zelichowski, G | 1 |
| Meurin, P | 2 |
| Renaud, N | 2 |
| Weber, H | 2 |
| Tabet, JY | 2 |
| Grosdemouge, A | 2 |
| Bourmayan, C | 2 |
| Ben Driss, A | 1 |
| Carp, H | 1 |
| Dolitzky, M | 1 |
| Inbal, A | 1 |
| Hundt, F | 1 |
| Bickel, C | 1 |
| Schaefer, I | 1 |
| Meyer, J | 1 |
| Rupprecht, HJ | 2 |
| Bosanquet, N | 1 |
| Jönsson, B | 1 |
| Fox, KA | 1 |
| Colwell, CW | 2 |
| Gramse, CA | 2 |
| Hingorani, A | 2 |
| Ascher, E | 2 |
| McLintock, C | 1 |
| North, RA | 2 |
| Revel-Vilk, S | 1 |
| Sharathkumar, A | 1 |
| Massicotte, P | 2 |
| Marzinotto, V | 2 |
| Daneman, A | 1 |
| Dix, D | 1 |
| Chan, A | 1 |
| Stouffer, GA | 1 |
| Pathak, A | 1 |
| Whinna, HC | 1 |
| Klingel, R | 1 |
| Schwarting, A | 1 |
| Lotz, J | 1 |
| Eckert, M | 1 |
| Hohmann, V | 1 |
| Hafner, G | 1 |
| Ho, SH | 1 |
| Wu, JK | 1 |
| Hamilton, DP | 1 |
| Dix, DB | 1 |
| Wadsworth, LD | 1 |
| Herishanu, Y | 1 |
| Misgav, M | 1 |
| Kirgner, I | 1 |
| Ben-Tal, O | 1 |
| Eldor, A | 1 |
| Naparstek, E | 1 |
| Karnicki, K | 1 |
| McBane, RD | 1 |
| Miller, RS | 1 |
| Leadley, RJ | 1 |
| Morser, J | 2 |
| Owen, WG | 1 |
| Chesebro, JH | 2 |
| Driss, AB | 1 |
| Janssen, D | 2 |
| Dalmora, SL | 1 |
| Junior, LB | 1 |
| Vaccari, SF | 1 |
| Fronza, M | 1 |
| Renato de Oliveira, P | 1 |
| Rolim, CM | 1 |
| Siddiqui, MA | 1 |
| Wagstaff, AJ | 1 |
| Madan, M | 1 |
| Radhakrishnan, S | 1 |
| Reis, M | 1 |
| Paradiso-Hardy, FL | 1 |
| Godin-Edgecombe, M | 1 |
| Sparling, C | 1 |
| Phillips, AM | 1 |
| Shanmugasegaram, S | 1 |
| Fort, S | 1 |
| Naqvi, SZ | 1 |
| Cohen, EA | 1 |
| Wells, J | 1 |
| Kossard, S | 1 |
| McGrath, M | 2 |
| Cavusoglu, E | 1 |
| Lakhani, M | 1 |
| Marmur, JD | 1 |
| Becker, RC | 1 |
| Ol'binskaia, LI | 1 |
| Kolosova, KIu | 1 |
| Nesterova, SG | 1 |
| Egorova, TD | 1 |
| Fedorova, AIu | 1 |
| Daykin, HJ | 1 |
| Sturgeon, SA | 1 |
| Jones, C | 1 |
| Wright, CE | 1 |
| Merkel, N | 1 |
| Gunther, G | 1 |
| Schobess, R | 1 |
| Le Feuvre, C | 1 |
| Batisse, A | 1 |
| Collet, JP | 1 |
| Batisse, JP | 1 |
| Choussat, R | 1 |
| Beygui, F | 1 |
| Helft, G | 2 |
| Montalescot, G | 2 |
| Metzger, JP | 1 |
| Buller, CE | 1 |
| Pate, GE | 1 |
| Armstrong, PW | 1 |
| O'Neill, BJ | 1 |
| Webb, JG | 1 |
| Gallo, R | 2 |
| Welsh, RC | 1 |
| O'Neill, WW | 1 |
| Casele, H | 1 |
| Haney, EI | 1 |
| James, A | 1 |
| Rosene-Montella, K | 1 |
| Carson, M | 1 |
| Jackson, WL | 1 |
| Moores, LK | 1 |
| Ganti, AK | 1 |
| Vose, JM | 1 |
| Haire, WD | 1 |
| Squizzato, A | 2 |
| Ageno, W | 2 |
| Cattaneo, A | 1 |
| Brumana, N | 1 |
| Byrne, GW | 1 |
| Davies, WR | 1 |
| Oi, K | 1 |
| Rao, VP | 1 |
| Teotia, SS | 1 |
| Ricci, D | 1 |
| Tazelaar, HD | 1 |
| Walker, RC | 1 |
| Logan, JS | 1 |
| McGregor, CG | 1 |
| Puértolas Ortega, M | 1 |
| Izquierdo Villarroya, B | 1 |
| Oliva Perales, P | 1 |
| Lafuente Ojeda, N | 1 |
| Izquierdo Villarroya, J | 1 |
| Ruiz Pérez, R | 1 |
| Renda, G | 1 |
| Di Pillo, R | 1 |
| D'Alleva, A | 1 |
| Sciartilli, A | 1 |
| Zimarino, M | 1 |
| De Candia, E | 1 |
| Landolfi, R | 1 |
| Di Giammarco, G | 1 |
| Calafiore, A | 1 |
| Criado, PR | 1 |
| Bernardelli, IM | 1 |
| Rivitti, EA | 1 |
| Sotto, MN | 1 |
| Vilella, MA | 1 |
| Valente, NY | 1 |
| Martins, JE | 1 |
| Cloonan, ME | 1 |
| DiNapoli, M | 1 |
| Mousa, SA | 1 |
| Dahl, OE | 4 |
| Ogren, M | 1 |
| Agnelli, G | 1 |
| Mouret, P | 1 |
| Rosencher, N | 1 |
| Bylock, A | 1 |
| Panfilov, S | 1 |
| Andersson, M | 1 |
| Dana, A | 1 |
| Nguyen, CM | 1 |
| Cloutier, S | 1 |
| Barbeau, GR | 1 |
| Marlovits, S | 1 |
| Striessnig, G | 1 |
| Schuster, R | 1 |
| Stocker, R | 1 |
| Luxl, M | 1 |
| Trattnig, S | 1 |
| Vécsei, V | 1 |
| Malowany, JI | 2 |
| Knoppert, DC | 2 |
| Pepelassis, D | 1 |
| Lee, DS | 2 |
| Haran, MZ | 1 |
| Lichman, I | 1 |
| Berebbi, A | 1 |
| Weinmann, E | 1 |
| Rosenberg, N | 1 |
| Lemos, PA | 1 |
| Langford, JR | 1 |
| Trokhan, S | 1 |
| Strauss, E | 1 |
| Wu, J | 1 |
| McCusker, P | 1 |
| Massicotte, MP | 1 |
| Williams, S | 1 |
| Naumnik, B | 1 |
| Pawlak, K | 1 |
| Myśliwiec, M | 1 |
| Tanne, D | 1 |
| Katzav, A | 1 |
| Beilin, O | 1 |
| Grigoriadis, NC | 1 |
| Blank, M | 1 |
| Pick, CG | 1 |
| Landenberg, Pv | 1 |
| Shoenfeld, Y | 1 |
| Chapman, J | 1 |
| Fernández-Meré, LA | 1 |
| Fernández Rogríguez, S | 1 |
| Alvarez-Blanco, M | 1 |
| Malek, LA | 1 |
| Chojnowska, L | 1 |
| Konka, M | 1 |
| Klopotowski, M | 1 |
| Skwarek, M | 1 |
| Maczynska, R | 1 |
| Hoffman, P | 1 |
| Ruzyllo, W | 1 |
| Kropff, SS | 1 |
| Schmidt, H | 1 |
| Abbruzzese, TA | 1 |
| Albadawi, H | 1 |
| Kang, J | 1 |
| Patel, VI | 1 |
| Yoo, JH | 1 |
| Lamuraglia, GM | 1 |
| Watkins, MT | 1 |
| Matthiasson, SE | 2 |
| Bergqvist, D | 2 |
| Lundell, A | 1 |
| Lindblad, B | 2 |
| Sternlo, JE | 1 |
| Hybbinette, CH | 1 |
| Menzin, J | 1 |
| Colditz, GA | 1 |
| Regan, MM | 1 |
| Richner, RE | 1 |
| Oster, G | 1 |
| Slunsky, R | 1 |
| Reach, I | 1 |
| Thébaud, HE | 1 |
| Dupuy, CA | 1 |
| Küntziger, H | 1 |
| Debure, A | 1 |
| Fievet, P | 1 |
| Thoumazou, G | 1 |
| de Groc, F | 1 |
| Teboulle, D | 1 |
| Combe, S | 1 |
| Rostoker, G | 1 |
| Durand-Zaleski, I | 1 |
| Petit-Phar, M | 1 |
| Ben Maadi, A | 1 |
| Jazaerli, N | 1 |
| Radier, C | 1 |
| Rahmouni, A | 1 |
| Mathieu, D | 1 |
| Vasile, N | 1 |
| Rosso, J | 1 |
| Przedlacki, J | 1 |
| Bogdańska-Straszyńska, B | 1 |
| Sawicka, B | 1 |
| Włodarczyk, D | 1 |
| Sladowska, B | 1 |
| Ajewski, M | 1 |
| Wasiak, K | 1 |
| Gellert, R | 1 |
| Ament, PW | 1 |
| Bertolino, JG | 1 |
| Wilson, BA | 1 |
| Phillips, JK | 1 |
| Majumdar, G | 1 |
| Savidge, GF | 1 |
| Grozovski, ES | 1 |
| Cohen, JD | 1 |
| Grunberg, G | 1 |
| Keslin, J | 1 |
| Gassner, S | 1 |
| Stassen, JM | 1 |
| Lambeir, AM | 1 |
| Vreys, I | 1 |
| Deckmyn, H | 1 |
| Matthyssens, G | 1 |
| Nyström, A | 1 |
| Vermylen, J | 1 |
| Levine, M | 1 |
| Gent, M | 1 |
| Leclerc, J | 1 |
| Anderson, D | 1 |
| Weitz, J | 1 |
| Ginsberg, J | 1 |
| Demers, C | 1 |
| Kovacs, M | 1 |
| Gibaldi, M | 1 |
| Wittkowsky, AK | 1 |
| Chen, LE | 2 |
| Seaber, AV | 2 |
| Korompilias, AV | 2 |
| Urbaniak, JR | 2 |
| Samama, CM | 1 |
| Gigou, F | 1 |
| Ill, P | 1 |
| Adams, M | 1 |
| Brooker, LA | 1 |
| Andrew, M | 1 |
| Kalodiki, EP | 1 |
| Hoppensteadt, DA | 2 |
| Nicolaides, AN | 1 |
| Gill, K | 1 |
| Regan, F | 1 |
| al-Kutoubi, A | 1 |
| Cunningham, DA | 1 |
| Birch, R | 1 |
| Harris, N | 1 |
| Hunt, D | 1 |
| Johnson, J | 1 |
| Marx, C | 1 |
| Stone, MH | 1 |
| Limb, D | 1 |
| Campbell, P | 1 |
| Stead, D | 1 |
| Culleton, G | 1 |
| Walsh-McMonagle, D | 1 |
| Horlocker, TT | 1 |
| Rader, CP | 1 |
| Kramer, C | 1 |
| König, A | 1 |
| Hendrich, C | 1 |
| Eulert, J | 1 |
| Gibson, JL | 1 |
| Ekevall, K | 1 |
| Walker, I | 1 |
| Greer, IA | 3 |
| Warwick, D | 1 |
| Harrison, J | 1 |
| Glew, D | 1 |
| Mitchelmore, A | 1 |
| Peters, TJ | 1 |
| Donovan, J | 1 |
| Kovacs, MJ | 2 |
| Weir, K | 1 |
| MacKinnon, K | 1 |
| Keeney, M | 1 |
| Brien, WF | 1 |
| Cruickshank, MK | 2 |
| Zidar, JP | 1 |
| Méndez, J | 1 |
| Sanchís, ME | 1 |
| de la Fuente, R | 1 |
| Stolle, R | 1 |
| Vega, JM | 1 |
| Martínez, C | 1 |
| Armentia, A | 1 |
| Sánchez, P | 1 |
| Fernández, A | 1 |
| Gikakis, N | 1 |
| Rao, AK | 1 |
| Miyamoto, S | 1 |
| Gorman, JH | 1 |
| Khan, MM | 1 |
| Anderson, HL | 1 |
| Hack, CE | 1 |
| Sun, L | 1 |
| Niewiarowski, S | 1 |
| Colman, RW | 1 |
| Edmunds, LH | 1 |
| Berger, PB | 1 |
| Bell, MR | 1 |
| Hasdai, D | 2 |
| Grill, DE | 1 |
| Melby, S | 1 |
| Holmes, DR | 1 |
| Panchenko, EP | 1 |
| Bara, L | 1 |
| Planes, A | 1 |
| Brennand, JE | 1 |
| Walker, ID | 2 |
| Cohen, M | 1 |
| Laifer, SA | 1 |
| Casele, HL | 1 |
| Mallory, R | 1 |
| Balcezak, T | 1 |
| Marwick, C | 1 |
| Lev-Ran, O | 1 |
| Kramer, A | 1 |
| Gurevitch, J | 1 |
| Shapira, I | 1 |
| Mohr, R | 1 |
| Dolenska, S | 1 |
| Younis, JS | 2 |
| Ohel, G | 1 |
| Haddad, S | 1 |
| Lanir, N | 1 |
| Ben-Ami, M | 1 |
| Sinha, U | 1 |
| Ku, P | 1 |
| Malinowski, J | 1 |
| Zhu, BY | 1 |
| Scarborough, RM | 1 |
| Marlowe, CK | 1 |
| Wong, PW | 1 |
| Lin, PH | 1 |
| Hollenbach, SJ | 1 |
| Hoffman, R | 1 |
| Blumenfeld, Z | 1 |
| Weiner, Z | 1 |
| Lindqvist, PG | 1 |
| Dahlbäck, B | 2 |
| Street, JT | 1 |
| O'Regan, K | 1 |
| Wakai, A | 1 |
| McGuinness, A | 1 |
| Redmond, HP | 1 |
| Berndt, N | 1 |
| Khan, I | 1 |
| Dunaway, KK | 1 |
| Gal, P | 1 |
| Ransom, JL | 1 |
| Busby, LT | 1 |
| Weyman, A | 1 |
| Rodgers, GM | 1 |
| Olmarker, K | 1 |
| Rydevik, B | 1 |
| Racine, E | 1 |
| Ellison, J | 2 |
| Thomson, AJ | 2 |
| Rowan, JA | 1 |
| McCowan, LM | 1 |
| Raudkivi, PJ | 1 |
| Cook, C | 1 |
| Callaway, M | 1 |
| McClanahan, TB | 1 |
| Hicks, GW | 1 |
| Morrison, AL | 1 |
| Peng, YW | 1 |
| Janiczek-Dolphin, N | 1 |
| Mertz, TE | 1 |
| Sullivan, ME | 1 |
| Juneau, PL | 1 |
| Leadley, R | 1 |
| Szczepański, M | 1 |
| Szostek, P | 1 |
| Pypno, W | 1 |
| Borówka, A | 1 |
| Conkie, JA | 1 |
| McCall, F | 1 |
| Walker, D | 1 |
| Greer, A | 1 |
| Pauzner, R | 1 |
| Dulitzki, M | 1 |
| Langevitz, P | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Many, A | 1 |
| Barragan, P | 1 |
| Teuma, X | 1 |
| Botosezzy, I | 1 |
| Bouvier, JL | 1 |
| Comet, B | 1 |
| Commeau, P | 1 |
| Macaluso, G | 1 |
| Roquebert, PO | 1 |
| Sarasin, FP | 1 |
| Bounameaux, H | 1 |
| Kormanová, K | 1 |
| Krska, Z | 1 |
| Trca, S | 1 |
| Pesková, M | 1 |
| Korínková, P | 1 |
| Shah, N | 1 |
| Shah, PS | 1 |
| De Giorgi, A | 1 |
| Giannarelli, C | 1 |
| De Negri, F | 1 |
| Carmassi, F | 1 |
| Jeske, W | 1 |
| Andrassy, K | 1 |
| Roqué, M | 1 |
| Rauch, U | 1 |
| Reis, ED | 1 |
| Badimon, JJ | 1 |
| Hiebert, LM | 2 |
| Wice, SM | 2 |
| Ping, T | 1 |
| Herr, D | 1 |
| Hach-Wunderle, V | 1 |
| Nakov, R | 1 |
| Stricker, H | 1 |
| Mombelli, G | 1 |
| Pechlaner, C | 1 |
| Gritsch, W | 1 |
| Donadini, MP | 1 |
| Guasti, L | 1 |
| Bischoff, A | 1 |
| Han, JM | 1 |
| Koh, Y | 1 |
| Kim, SH | 1 |
| Suh, SY | 1 |
| Cho, YS | 1 |
| Yu, SJ | 1 |
| Yoon, JH | 1 |
| Gwak, HS | 1 |
| McClelland, AF | 1 |
| Mandal, AKJ | 1 |
| Zakharious, F | 1 |
| Missouris, CG | 1 |
| Jonmarker, S | 1 |
| Hollenberg, J | 1 |
| Dahlberg, M | 1 |
| Stackelberg, O | 1 |
| Litorell, J | 1 |
| Everhov, ÅH | 1 |
| Järnbert-Pettersson, H | 1 |
| Söderberg, M | 1 |
| Grip, J | 1 |
| Schandl, A | 1 |
| Günther, M | 1 |
| Cronhjort, M | 1 |
| Iwanaga, T | 1 |
| Fukushima, R | 1 |
| Nagasato, T | 1 |
| Maruyama, I | 1 |
| Miura, N | 1 |
| Steenman, F | 1 |
| Vijlbrief, DC | 1 |
| Huisman, A | 1 |
| Bierings, M | 1 |
| Lutkin, M | 1 |
| Stronach, L | 1 |
| Yadav, P | 1 |
| Hothi, DK | 1 |
| Woodruff, S | 1 |
| Lee, AYY | 1 |
| Carrier, M | 1 |
| Feugère, G | 1 |
| Abreu, P | 1 |
| Heissler, J | 1 |
| Li, A | 1 |
| Manohar, PM | 1 |
| Garcia, DA | 1 |
| Lyman, GH | 1 |
| Steuten, LM | 1 |
| Connell, NT | 1 |
| DePaula, KM | 1 |
| deLaorcade, AM | 1 |
| King, RG | 1 |
| Hughs, H | 1 |
| Boudrieau, RJ | 1 |
| Lauzier, F | 1 |
| Arnold, DM | 1 |
| Rabbat, C | 1 |
| Heels-Ansdell, D | 2 |
| Zarychanski, R | 1 |
| Dodek, P | 1 |
| Ashley, BJ | 1 |
| Albert, M | 1 |
| Khwaja, K | 1 |
| Ostermann, M | 1 |
| Skrobik, Y | 1 |
| Fowler, R | 1 |
| McIntyre, L | 1 |
| Nates, JL | 1 |
| Karachi, T | 2 |
| Zytaruk, N | 2 |
| Finfer, S | 1 |
| Cook, D | 2 |
| Arabi, Y | 1 |
| Ferguson, N | 1 |
| Freitag, A | 1 |
| McDonald, E | 1 |
| Clarke, F | 1 |
| Keenan, S | 1 |
| Pagliarello, G | 1 |
| Plaxton, W | 1 |
| Herridge, M | 1 |
| Vallance, S | 1 |
| Cade, J | 1 |
| Crozier, T | 1 |
| Alves da Silva, S | 1 |
| Costa Filho, R | 1 |
| Brandao, N | 1 |
| Watpool, I | 1 |
| McArdle, T | 1 |
| Hollinger, G | 1 |
| Mandourah, Y | 1 |
| Al-Hazmi, M | 1 |
| Adhikari, NK | 1 |
| Babilonia, KM | 1 |
| Golightly, LK | 1 |
| Gutman, JA | 1 |
| Hassell, KL | 1 |
| Kaiser, JN | 1 |
| Kiser, TH | 1 |
| Klem, PM | 1 |
| Trujillo, TC | 1 |
| Shaya, SA | 1 |
| Saldanha, LJ | 1 |
| Vaezzadeh, N | 1 |
| Zhou, J | 1 |
| Ni, R | 1 |
| Gross, PL | 1 |
| Wackernagel, D | 1 |
| Obaya, S | 1 |
| Nydert, P | 1 |
| Gerdsen, F | 1 |
| Luxembourg, B | 1 |
| Langer, F | 1 |
| Bauersachs, R | 1 |
| Lindhoff-Last, E | 1 |
| Niemi, T | 1 |
| Silvasti-Lundell, M | 1 |
| Armstrong, E | 1 |
| Hernesniemi, J | 1 |
| De Cicco, M | 1 |
| Matovic, M | 1 |
| Balestreri, L | 1 |
| Steffan, A | 1 |
| Pacenzia, R | 1 |
| Malafronte, M | 1 |
| Fantin, D | 1 |
| Bertuzzi, CA | 1 |
| Fabiani, F | 1 |
| Morassut, S | 1 |
| Bidoli, E | 1 |
| Veronesi, A | 1 |
| Nassiri, AA | 1 |
| Hakemi, MS | 1 |
| Soulati, M | 1 |
| Marashian, M | 1 |
| Rahbar, K | 1 |
| Azizi, F | 1 |
| Uchikawa, Y | 1 |
| Ikegami, T | 1 |
| Masuda, Y | 1 |
| Ohno, Y | 1 |
| Mita, A | 1 |
| Urata, K | 1 |
| Nakazawa, Y | 1 |
| Terada, M | 1 |
| Miyagawa, S | 1 |
| Pehrsson, S | 1 |
| Johansson, K | 1 |
| Kjaer, M | 1 |
| Elg, M | 2 |
| Kunitada, S | 1 |
| Oursin, A | 1 |
| Depasse, F | 2 |
| Heptinstall, S | 1 |
| Pokrovskiĭ, AV | 1 |
| Gontarenko, VN | 1 |
| Titova, MI | 1 |
| Ilicki, J | 1 |
| Krauss, W | 1 |
| Andersson, SO | 1 |
| Nagathan, DS | 1 |
| Pahwa, HS | 1 |
| Kumar, A | 1 |
| Goel, A | 1 |
| Carlsson, S | 1 |
| Mattsson, C | 1 |
| Bick, RL | 4 |
| Alfar, H | 1 |
| Goedecke, C | 1 |
| Stone, S | 1 |
| Seed, PT | 1 |
| Parmar, K | 1 |
| Khamashta, MA | 1 |
| Poston, L | 1 |
| Malm, K | 1 |
| Arnljots, B | 1 |
| Pleil, AM | 1 |
| Arnesen, H | 2 |
| Aspelin, T | 2 |
| Seljeflot, I | 1 |
| Kierulf, P | 1 |
| Lyberg, T | 1 |
| Gattens, M | 1 |
| Khamashta, M | 1 |
| Nelson-Piercy, C | 1 |
| Almeida, A | 1 |
| Lersch, C | 1 |
| Kotowa, W | 1 |
| Fung, S | 1 |
| Hiller, E | 1 |
| Ezekowitz, MD | 1 |
| Tincani, E | 1 |
| Piccoli, M | 1 |
| Turrini, F | 1 |
| Crowther, MA | 1 |
| Melotti, G | 1 |
| Bondi, M | 1 |
| Ziai, F | 1 |
| Benesch, T | 1 |
| Kodras, K | 1 |
| Neumann, I | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Korenkov, M | 1 |
| Depta, A | 1 |
| Kentner, R | 1 |
| Beck, J | 1 |
| Junginger, T | 1 |
| Lapidus, LJ | 1 |
| Rosfors, S | 1 |
| Ponzer, S | 1 |
| Levander, C | 1 |
| Elvin, A | 1 |
| Lärfars, G | 1 |
| de Bri, E | 1 |
| Mätzsch, T | 1 |
| Holst, J | 1 |
| Bagge, L | 2 |
| Wahlberg, T | 2 |
| Holmer, E | 2 |
| Tydén, H | 2 |
| Nyström, SO | 2 |
| Malm, T | 1 |
| Kornowski, R | 1 |
| Glikson, M | 1 |
| Chernine, A | 1 |
| Ohad, D | 1 |
| Battler, A | 1 |
| Jeffrey, RF | 1 |
| Khan, AA | 1 |
| Douglas, JT | 1 |
| Will, EJ | 1 |
| Davison, AM | 1 |
| Tazawa, S | 1 |
| Ichikawa, K | 1 |
| Misawa, K | 1 |
| Fukuyama, J | 1 |
| Hamano, S | 1 |
| Miyata, H | 1 |
| Sakuragawa, N | 1 |
| Sigüenza, F | 1 |
| Maduell, F | 1 |
| Perella, M | 1 |
| Lopez-Menchero, R | 1 |
| Grau, E | 1 |
| Pastor, E | 1 |
| Schumacher, WA | 1 |
| Heran, CL | 1 |
| Steinbacher, TE | 1 |
| Luomanmäki, K | 1 |
| Grankvist, S | 1 |
| Hallert, C | 1 |
| Jauro, I | 1 |
| Ketola, K | 1 |
| Kim, HC | 1 |
| Kiviniemi, H | 1 |
| Koskivirta, H | 1 |
| Sörskog, L | 1 |
| Vilkko, P | 1 |
| Partsch, H | 1 |
| Kechavarz, B | 1 |
| Mostbeck, A | 1 |
| Köhn, H | 1 |
| Lipp, C | 1 |
| Lindmarker, P | 1 |
| Holmström, M | 1 |
| Andreassen, G | 1 |
| Müller, C | 1 |
| Mathiesen, P | 1 |
| Nyhus, S | 1 |
| Abdelnoor, M | 1 |
| Solhaug, JH | 1 |
| Kontny, F | 1 |
| Dale, J | 1 |
| Abildgaard, U | 1 |
| Pedersen, TR | 1 |
| Pan, M | 1 |
| Suárez de Lezo, J | 1 |
| Medina, A | 1 |
| Romero, M | 1 |
| Hernández, E | 1 |
| Segura, J | 1 |
| Melian, F | 1 |
| Wangüemert, F | 1 |
| Landin, M | 1 |
| Benítez, F | 1 |
| Amat, M | 1 |
| Velasco, F | 1 |
| Torres, A | 1 |
| Sato, K | 1 |
| Hisamichi, N | 1 |
| Taniuchi, Y | 1 |
| Hirayama, F | 1 |
| Koshio, H | 1 |
| Matsumoto, Y | 1 |
| Ting, SB | 1 |
| Ziegenbein, RW | 1 |
| Gan, TE | 1 |
| Catalano, JV | 1 |
| Silvers, J | 1 |
| Chambers, FE | 1 |
| Ng, S | 1 |
| McGrath, BP | 1 |
| Blombäck, M | 2 |
| Bremme, K | 2 |
| Hellgren, M | 2 |
| Siegbahn, A | 1 |
| Lindberg, H | 2 |
| Lassen, MR | 1 |
| Borris, LC | 1 |
| Anderson, BS | 1 |
| Jensen, HP | 1 |
| Skejø Bro, HP | 1 |
| Andersen, G | 1 |
| Petersen, AO | 1 |
| Siem, P | 1 |
| Hørlyck, E | 1 |
| Jensen, BV | 1 |
| Thomsen, PB | 1 |
| Hansen, BR | 1 |
| Erin-Madsen, J | 1 |
| Møller, JC | 1 |
| Rotwitt, L | 1 |
| Christensen, F | 1 |
| Nielsen, JB | 1 |
| Jørgensen, PS | 1 |
| Paaske, B | 1 |
| Tørholm, C | 1 |
| Hvidt, P | 1 |
| Jensen, NK | 1 |
| Nielsen, AB | 1 |
| Appelquist, E | 1 |
| Tjalve, E | 1 |
| Chillag, KJ | 1 |
| Hoek, KJ | 1 |
| Hofbauer, R | 1 |
| Moser, D | 1 |
| Frass, M | 1 |
| Oberbauer, R | 1 |
| Kaye, AD | 1 |
| Wagner, O | 1 |
| Druml, W | 1 |
| Pettilä, V | 1 |
| Kaaja, R | 1 |
| Leinonen, P | 1 |
| Ekblad, U | 1 |
| Kataja, M | 1 |
| Ikkala, E | 1 |
| Wong, PC | 1 |
| Quan, ML | 1 |
| Crain, EJ | 1 |
| Watson, CA | 1 |
| Wexler, RR | 1 |
| Knabb, RM | 1 |
| Nohe, N | 1 |
| Flemmer, A | 1 |
| Rümler, R | 1 |
| Praun, M | 1 |
| Auberger, K | 1 |
| Rice, J | 1 |
| Tinmouth, AH | 1 |
| Morrow, BH | 1 |
| Moore, PM | 1 |
| Olsson, E | 1 |
| Svartling, N | 1 |
| Asko-Seljavaara, S | 1 |
| Lassila, R | 1 |
| Akinosoglou, K | 1 |
| Savopoulos, C | 1 |
| Pouliakis, A | 2 |
| Triantafyllidis, C | 1 |
| Markatis, E | 1 |
| Golemi, F | 1 |
| Liontos, A | 1 |
| Vadala, C | 1 |
| Papanikolaou, IC | 1 |
| Dimakopoulou, V | 1 |
| Xarras, P | 1 |
| Varela, K | 1 |
| Kaiafa, G | 1 |
| Mitsianis, A | 1 |
| Chatzistamati, A | 1 |
| Randou, E | 1 |
| Savvanis, S | 1 |
| Pavlaki, M | 1 |
| Efraimidis, G | 1 |
| Samaras, V | 1 |
| Papazoglou, D | 1 |
| Konstantinidou, A | 1 |
| Panagopoulos, P | 1 |
| Milionis, H | 1 |
| Xynogalos, S | 1 |
| Simeonidis, D | 1 |
| Papageorgiou, G | 1 |
| Charalambakis, N | 1 |
| Lianos, E | 1 |
| Mazlimoglou, E | 1 |
| Liatsos, AN | 1 |
| Kosmas, C | 1 |
| Ziras, N | 1 |
| Frere, C | 1 |
| Crichi, B | 1 |
| Rueda-Camino, JA | 1 |
| Cajfinger, F | 1 |
| Spiess, N | 1 |
| Janus, N | 1 |
| Le Maignan, C | 1 |
| Marjanovic, Z | 1 |
| Farge, D | 1 |
| Amerali, M | 1 |
| Politou, M | 1 |
| Karathanos, C | 1 |
| Chatzis, D | 1 |
| Latzios, P | 1 |
| Papakostas, I | 1 |
| Goumas, K | 1 |
| Giannoukas, AD | 1 |
| Jara-Palomares, L | 1 |
| Solier-Lopez, A | 1 |
| Elias-Hernandez, T | 1 |
| Asensio-Cruz, M | 1 |
| Blasco-Esquivias, I | 1 |
| Marin-Barrera, L | 1 |
| de la Borbolla-Artacho, MR | 1 |
| Praena-Fernandez, JM | 1 |
| Montero-Romero, E | 1 |
| Navarro-Herrero, S | 1 |
| Serrano-Gotarredona, MP | 1 |
| Sánchez-Díaz, JM | 1 |
| Palacios, C | 1 |
| Otero, R | 1 |
| Musgrave, KM | 1 |
| Webber, K | 1 |
| Murphy, P | 1 |
| Avery, P | 1 |
| Biss, TT | 1 |
| Purnell, J | 1 |
| Abdulla, AN | 1 |
| Vasanthan, V | 1 |
| Harten, C | 1 |
| Kent, WDT | 1 |
| Wu, IQ | 1 |
| Tan, CW | 1 |
| Wong, WH | 1 |
| Ng, HJ | 1 |
| Kirwan, CJ | 1 |
| Baig, ZF | 1 |
| Platton, S | 1 |
| MacCullum, PK | 1 |
| Ashman, N | 1 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| Murphy, K | 2 |
| McAuliffe, F | 2 |
| Byrne, B | 1 |
| Matikas, A | 1 |
| Vardakis, N | 1 |
| Souglakos, J | 1 |
| Georgoulias, V | 1 |
| Higgins, M | 1 |
| Downey, R | 1 |
| Al-Saran, KA | 1 |
| Sabry, A | 1 |
| Taha, M | 1 |
| Ghafour, MA | 1 |
| Al Fawzan, F | 1 |
| Gouin-Thibault, I | 1 |
| Pautas, E | 2 |
| Andreux, JP | 2 |
| Siguret, V | 2 |
| Hainer, JW | 1 |
| Sprogel, P | 1 |
| Lindenstroem, E | 1 |
| Pinel, C | 1 |
| Norris, LA | 2 |
| Bonnar, J | 2 |
| Smith, MP | 1 |
| Steer, PJ | 1 |
| Savidge, G | 1 |
| Yoneda, M | 1 |
| Brosnan, JF | 1 |
| Stevenson, JL | 1 |
| Choi, SH | 1 |
| Varki, A | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Lausen, I | 1 |
| Jensen, R | 1 |
| Wille-Jørgensen, P | 1 |
| Jørgensen, LN | 1 |
| Rasmussen, MS | 1 |
| Lyng, KM | 1 |
| Andersen, M | 1 |
| Raaschou, HO | 1 |
| Hedner, U | 1 |
| Février, M | 1 |
| Wipff, C | 1 |
| Durand-Gasselin, B | 1 |
| Laurent, M | 1 |
| d'Urso, M | 1 |
| Gaussem, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)[NCT00203580] | Phase 4 | 910 participants | Interventional | 1994-12-31 | Completed | ||
| LITE Study, Appendix A (HOME-LITE), Amendment 6[NCT00203658] | Phase 4 | 400 participants | Interventional | 1997-04-30 | Completed | ||
| Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism[NCT02355548] | 200 participants (Anticipated) | Observational | 2012-12-31 | Completed | |||
| FREEDOM COVID Anticoagulation Strategy Randomized Trial[NCT04512079] | Phase 4 | 3,460 participants (Actual) | Interventional | 2020-09-08 | Completed | ||
| Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial[NCT04400799] | Phase 3 | 475 participants (Actual) | Interventional | 2020-06-15 | Terminated (stopped due to due to results from interim analysis) | ||
| Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study[NCT00571649] | Phase 3 | 8,101 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk[NCT02111564] | Phase 3 | 12,024 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| Prevention of Central Venous Catheter-associated Thrombosis in Critically Ill Children: A Multicenter Phase 2b Trial[NCT03003390] | Phase 2 | 51 participants (Actual) | Interventional | 2017-04-05 | Terminated (stopped due to Met protocol defined stopping rule for futility) | ||
| Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)[NCT04323787] | 100,000 participants (Anticipated) | Observational | 2020-03-30 | Recruiting | |||
| Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375] | 60 participants (Anticipated) | Interventional | 2021-04-20 | Not yet recruiting | |||
| Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial[NCT04394377] | Phase 4 | 615 participants (Actual) | Interventional | 2020-06-21 | Completed | ||
| Cellular Effects of SARS-CoV-2 in Mediating Thrombotic Susceptibility[NCT05334615] | 60 participants (Anticipated) | Observational | 2022-01-21 | Recruiting | |||
| Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function[NCT03158792] | Phase 4 | 32 participants (Actual) | Interventional | 2015-10-24 | Completed | ||
| Strategies for Anticoagulation During Venovenous ECMO: The SAFE-ECMO Pilot Trial[NCT04997265] | 30 participants (Anticipated) | Interventional | 2022-05-12 | Recruiting | |||
| Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial[NCT04273607] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | ||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)[NCT02329327] | Phase 3 | 479 participants (Actual) | Interventional | 2015-04-10 | Completed | ||
| Diagnostic Accuracy of the ATE Score for the Exclusion of Intra-atrial Thrombi Before Catheter Ablation of Atrial Fibrillation: a Confirmatory Study[NCT03455673] | 3,160 participants (Actual) | Observational | 2018-09-18 | Completed | |||
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523] | Phase 1 | 13 participants (Actual) | Interventional | 2012-02-09 | Completed | ||
| XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis[NCT02506985] | Phase 4 | 10 participants (Actual) | Interventional | 2015-07-31 | Terminated | ||
| Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis[NCT04874428] | Phase 1 | 24 participants (Anticipated) | Interventional | 2021-05-19 | Recruiting | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden[NCT04412304] | 166 participants (Actual) | Observational | 2020-03-06 | Completed | |||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958] | 150 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Metaxa's Thromboprophylaxis Program in Oncological & Surgical Patients[NCT04248348] | 600 participants (Anticipated) | Observational | 2018-12-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.4 |
| Enoxaparin | 5.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.6 |
| Enoxaparin | 9.2 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.7 |
| Enoxaparin | 2.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.0 |
| Enoxaparin | 3.1 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin | 3.9 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 9.4 |
| Enoxaparin | 7.8 |
Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin or transfusion of >=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.8 |
| Enoxaparin | 1.2 |
Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin; or transfusion of >= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.1 |
| Enoxaparin | 1.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.8 |
| Enoxaparin | 4.5 |
All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths. (NCT00571649)
Timeframe: Up to Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Any event | Death (cardiovascular) | Death (other) | VTE related death | |
| Enoxaparin | 6.2 | 1.4 | 3.7 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 6.7 | 1.4 | 4.3 | 1.0 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Symptomatic non-fatal PE | Symptomatic DVT in lower extremity | Asymptomatic proximal DVT in lower extremity | VTE related death | |
| Enoxaparin | 0.1 | 0.2 | 2.4 | 0.2 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 | 0.2 | 2.4 | 0.1 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Symptomatic non-fatal PE | Symptomatic DVT in lower extremity | Asymptomatic proximal DVT in lower extremity | VTE related death | |
| Enoxaparin | 0.5 | 0.5 | 4.4 | 1.0 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 | 0.4 | 3.5 | 0.6 |
Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category. (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any event-Day 10 | Ischemic stroke-Day 10 | Acute MI-Day 10 | Death (cardiovascular)-Day 10 | Any event-Day 35 | Ischemic stroke-Day 35 | Acute MI-Day 35 | Death (cardiovascular)-Day 35 | Any event-Day 90 | Ischemic stroke-Day 90 | Acute MI-Day 90 | Death (cardiovascular)-Day 90 | |
| Enoxaparin | 1.0 | 0.3 | 0.4 | 0.4 | 1.6 | 0.5 | 0.5 | 0.8 | 2.8 | 1.1 | 0.7 | 1.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 1.0 | 0.3 | 0.5 | 0.4 | 1.8 | 0.5 | 0.6 | 0.9 | 2.8 | 0.8 | 0.9 | 1.4 |
Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90 (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| symptomatic VTE (incl. VTE-related death)-Day 10 | symptomatic VTE (non fatal)-Day 10 | symptomatic VTE (incl. VTE-related death)-Day 35 | symptomatic VTE (non fatal)-Day 35 | symptomatic VTE (incl. VTE-related death)-Day 90 | symptomatic VTE (non fatal)-Day 90 | |
| Enoxaparin | 0.6 | 0.3 | 1.4 | 0.7 | 1.9 | 0.9 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | 0.5 | 1.0 | 0.6 | 1.7 | 0.7 |
Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.19 |
| Placebo | 1.49 |
Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.72 |
| Placebo | 0.77 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.31 |
| Placebo | 1.80 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.58 |
| Placebo | 2.03 |
Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.19 |
| Placebo | 0.42 |
A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days. (NCT02111564)
Timeframe: From randomization to 2 days after the last dose (Day 45)
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.28 |
| Placebo | 0.15 |
Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.84 |
| Placebo | 1.11 |
Duration of stay in the hospital from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the hospital, an average of 18 days
| Intervention | days (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 16 |
| Control Arm | 16 |
Duration of stay in the pediatric intensive care unit from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the pediatric intensive care unit, an average of 10 days
| Intervention | days (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 12 |
| Control Arm | 8 |
Number of children in whom ultrasound was not performed. (NCT03003390)
Timeframe: Up to 24 hours after removal of CVC
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled Children | 47 |
Number of eligible children enrolled in the study. (NCT03003390)
Timeframe: Up to 24 hours after insertion of CVC
| Intervention | Participants (Count of Participants) |
|---|---|
| Eligible Children | 51 |
Number of doses of enoxaparin that were not administered. This outcome measure was only applicable to the enoxaparin arm. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Doses of enoxaparin (Number) |
|---|---|
| Prophylaxis With Enoxaparin | 8 |
In-hospital mortality during the subject's admission (NCT03003390)
Timeframe: Up to day of discharge from the hospital, average of 18 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 5 |
| Control Arm | 2 |
Thrombus in the central vein where the CVC was inserted that is clinically suspected then confirmed radiologically, an incidental radiologic finding, or diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 7 |
| Control Arm | 13 |
Bleeding that is fatal, associated with a decrease in hemoglobin by ≥2 g/dl in 24 hours, requires medical or surgical intervention to restore hemostasis, or is in the retroperitoneum, pulmonary, intracranial or central nervous system as defined by International Society of Thrombosis and Haemostasis (NCT03003390)
Timeframe: Up to 30 hours after the last enoxaparin dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 1 |
| Control Arm | 0 |
Heparin-induced thrombocytopenia that is diagnosed with a positive serotonin release assay (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 0 |
| Control Arm | 0 |
Thrombus in the deep vein of any extremity or PE that is clinically suspected then confirmed radiologically, an incidental radiologic finding, excluding DVT diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 1 |
| Control Arm | 1 |
Time to first dose of enoxaparin (NCT03003390)
Timeframe: Up to 48 hours after insertion of CVC
| Intervention | hours from insertion of CVC (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 21.1 |
Time from insertion of the CVC to time that anti-Xa activity was within 0.2-0.5 IU/mL. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | hours from insertion of CVC (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 70.4 |
An established measure of coagulation status and is the best method to measure thrombin generation. It directly measures the amount of thrombin generation over time capturing the effects of natural (i.e., subject's coagulation status) and pharmacological (e.g., enoxaparin) pro- and anticoagulants. Endogenous thrombin potential is measured using thrombin generation assay. (NCT03003390)
Timeframe: Day of, day after and day 4 after insertion of the CVC
| Intervention | Nanomolar-minute (nM.min) (Median) | ||
|---|---|---|---|
| Day of CVC Insertion | Day After CVC Insertion | Day 4 After CVC Insertion | |
| Control Arm | 1035.6 | 896.58 | 969.89 |
| Prophylaxis With Enoxaparin | 919.7 | 851.19 | 826.97 |
Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| FXa Inhibitor: Apixaban | -93.3 |
| FXa Inhibitor: Rivaroxaban | -94.1 |
| FXa Inhibitor: Edoxaban | -71.3 |
| FXa Inhibitor: Enoxaparin | -75.41 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy. (NCT02329327)
Timeframe: 12 Hours (post infusion)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| Andexanet: High Dose | 54 | 17 |
| Andexanet: High Dose - Additional Participant | 1 | 0 |
| Andexanet: Low Dose | 218 | 51 |
| Andexanet: Low Dose - Additional Participant | 1 | 0 |
| Bleed Type: Gastrointestinal | 61 | 13 |
| Bleed Type: Intracranial Hemorrhage | 193 | 51 |
| Bleed Type: Intracranial Hemorrhage - Additional Participants | 2 | 0 |
| Bleed Type: Other | 18 | 4 |
| FXa Inhibitor: Apixaban | 134 | 35 |
| FXa Inhibitor: Edoxaban | 22 | 6 |
| FXa Inhibitor: Enoxaparin | 14 | 2 |
| FXa Inhibitor: Rivaroxaban | 102 | 25 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | 2 | 0 |
| Overall | 272 | 68 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| Excellent/Good | |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| FXa Inhibitor: Apixaban | -93.4 | -93.3 |
| FXa Inhibitor: Edoxaban | -75.8 | -65.2 |
| FXa Inhibitor: Enoxaparin | -75.20 | -78.44 |
| FXa Inhibitor: Rivaroxaban | -94.6 | -92.4 |
Patients with atrial thrombus diagnosed by pre-procedural transoesophageal echocardiography, without hypertension, heart failure, history of stroke and a plasma d-dimer level < 270 ng/ml ATE : Atrial Thrombus Exclusion minimum value = 0 maximum value = 4, patient at higher risk of atrial thrombus (NCT03455673)
Timeframe: at most 48 hours before ablation
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ATE = 0, thrombus | ATE = 0, No thrombus | ATE > 0, thrombus | ATE > 0, No thrombus | |
| Atrial Fibrillation | 2 | 816 | 27 | 2227 |
50 reviews available for dalteparin and Thrombosis
| Article | Year |
|---|---|
[Recurrent pulmonary embolism in the functional loss of an LGM cava filter after the recanalization of a caval thrombosis].
Topics: Aged; Combined Modality Therapy; Equipment Failure; Femoral Vein; Heparin; Humans; Iliac Vein; Male; | 1994 |
[The treatment of deep venous thrombosis using low-molecular heparin. Swiss Consensus Conference for the Application of Low-molecular Heparin].
Topics: Animals; Biological Availability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin; Heparin, Low | 1994 |
Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Topics: Blood Platelets; Capillary Permeability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; He | 1998 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; | 2001 |
Bemiparin in oncology.
Topics: Anticoagulants; Antineoplastic Agents; Chemotherapy, Adjuvant; Fibrinolytic Agents; Heparin, Low-Mol | 2010 |
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
Topics: Anticoagulants; COVID-19; Critical Care; Enoxaparin; Hospitalization; Humans; Pyrazoles; Pyridones; | 2022 |
Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review.
Topics: Adult; Anticoagulants; Brachiocephalic Veins; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Mal | 2022 |
Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Enoxaparin; | 2023 |
[Prevention of thrombosis among medical inpatients : should we adapt enoxaparin doses to the patient's weight ?]
Topics: Anticoagulants; Body Weight; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Inpatients; Thrombos | 2017 |
Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.
Topics: Anticoagulants; Biosimilar Pharmaceuticals; Drug Approval; Enoxaparin; Europe; Humans; Practice Guid | 2019 |
Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides.
Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Contrast Media; Enoxaparin; Fibrinolytic Agent | 2014 |
Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs.
Topics: Anticoagulants; Clinical Protocols; Clinical Trials as Topic; Drug Dosage Calculations; Enoxaparin; | 2014 |
The outcome of pulmonary vein thrombosis in non-surgical patients. A systematic review and case report.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle | 2015 |
[The antiphospholipid syndrome in the 21st century].
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Tri | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.
Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Enoxaparin; Fibrin Fibrinogen | 2010 |
Current enoxaparin dosing guidelines have dubious credibility.
Topics: Anticoagulants; Drug Prescriptions; Enoxaparin; Humans; Practice Guidelines as Topic; Thrombosis | 2010 |
Discoveries in thrombosis care for medical patients.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Critical Care; Drug Costs; Enoxaparin; Fibrinolytic | 2002 |
Thromboprophylaxis in medical patients: focus on France.
Topics: Acute Disease; Adult; Aged; Attitude of Health Personnel; Cardiovascular Diseases; Double-Blind Meth | 2002 |
[Enoxaparin in haemodialysis].
Topics: Anticoagulants; Enoxaparin; Fibrinolytic Agents; Humans; Kidney Failure, Chronic; Renal Dialysis; Th | 2002 |
Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary | 2003 |
Dosing and timing of low-molecular-weight heparin thromboprophylaxis in total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weigh | 2003 |
Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Centra | 2004 |
[Thrombosis prophylaxis with heparins in intensive care patients].
Topics: Age Factors; Anticoagulants; APACHE; Critical Care; Enoxaparin; Heparin; Heparin Antagonists; Hepari | 2005 |
Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Enoxaparin; Hemorrhage; Humans; Thr | 2005 |
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
Topics: Anticoagulants; Azetidines; Benzylamines; Dalteparin; Double-Blind Method; Enoxaparin; Fibrinolytic | 2005 |
A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients.
Topics: Adult; Anticoagulants; Cytomegalovirus Infections; Enoxaparin; Heparin, Low-Molecular-Weight; Humans | 2007 |
Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates.
Topics: Anticoagulants; Catheters, Indwelling; Enoxaparin; Humans; Infant, Newborn; Infant, Premature; Throm | 2008 |
Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Topics: Cost-Benefit Analysis; Decision Trees; Enoxaparin; Hip Prosthesis; Humans; Pulmonary Embolism; Sensi | 1995 |
Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.
Topics: Adult; Biopsy; Cohort Studies; Enoxaparin; Female; Humans; Incidence; Kidney; Male; Middle Aged; Nep | 1995 |
Enoxaparin in the prevention of deep venous thrombosis.
Topics: Clinical Trials as Topic; Drug Costs; Enoxaparin; Hip Prosthesis; Humans; Postoperative Complication | 1994 |
Contemporary use of and future roles for heparin in antithrombotic therapy.
Topics: Anticoagulants; Antithrombins; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; | 1995 |
[Enoxaparin: molecular structure aspects, pharmacokinetics, efficiency in internal medicine].
Topics: Adult; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Infarction; Thrombosis | 1998 |
Low molecular weight heparins in the cardiac catheterization laboratory.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Neuroaxial blocks and LMWH thromboprophylaxis.
Topics: Anesthesia, Epidural; Contraindications; Enoxaparin; Fibrinolytic Agents; Hematoma, Epidural, Crania | 1998 |
Differentiation of the low-molecular-weight heparins.
Topics: Dalteparin; Enoxaparin; Fibrinolytic Agents; Half-Life; Heparin, Low-Molecular-Weight; Humans; Molec | 2001 |
[Antithrombotic treatment protocols in interventional cardiology].
Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial | 2001 |
Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children.
Topics: Adolescent; Anticoagulants; Catheterization, Central Venous; Child; Child, Preschool; Heparin, Low-M | 2014 |
Pharmacological profile of reviparin-sodium.
Topics: Animals; Biological Availability; Blood Coagulation; Carbohydrate Sequence; Factor Xa Inhibitors; He | 1993 |
Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Topics: Biocompatible Materials; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Mol | 1993 |
Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis.
Topics: Anticoagulants; Cost-Benefit Analysis; Heparin, Low-Molecular-Weight; Humans; Postoperative Complica | 1996 |
Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies.
Topics: Clinical Trials as Topic; Drug Evaluation; Heparin, Low-Molecular-Weight; Humans; Thrombosis; Venous | 2013 |
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Factor Xa Inhibitors; Humans; Neoplasms; Pyridine | 2019 |
[Administration of dalteparin in reconstructive vascular surgery].
Topics: Anticoagulants; Arterial Occlusive Diseases; Arteries; Blood Coagulation; Blood Coagulation Factors; | 2011 |
Partial segmental thrombosis of the corpus cavernosum: a case report and a review of the literature.
Topics: Adult; Alcoholic Intoxication; Dalteparin; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; | 2012 |
Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.
Topics: Aged; Anticoagulants; COVID-19; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Pregnancy; T | 2022 |
Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review.
Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Renal Insufficiency; Thrombosis; Tinzaparin | 2022 |
Extending the role of antithrombotic agents: an example based on the low-molecular-weight heparin, tinzaparin.
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Thrombosis; Tinzaparin | 2004 |
An update on heparins at the beginning of the new millennium.
Topics: Cardiology; Clinical Trials as Topic; Fibrinolytic Agents; Heparin Lyase; Heparin, Low-Molecular-Wei | 2000 |
Development of tinzaparin: a heparinase-digested low-molecular-weight heparin.
Topics: Animals; Fibrinolytic Agents; Heparin; Heparin Lyase; Heparin, Low-Molecular-Weight; Humans; Thrombo | 2000 |
94 trials available for dalteparin and Thrombosis
| Article | Year |
|---|---|
Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation.
Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Heart Failure; Heart-Assist Devices; Heparin; Heparin, | 2008 |
Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
Topics: Aged; Anticoagulants; Catheterization, Central Venous; Female; Heparin, Low-Molecular-Weight; Humans | 2003 |
Low molecular weight heparin treatment in pregnant women with a mechanical heart valve prosthesis.
Topics: Adult; Coumarins; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Hydrocephalus; Nadro | 2007 |
Prevention of thromboses in human patients with Bothrops lanceolatus envenoming in Martinique: failure of anticoagulants and efficacy of a monospecific antivenom. Research Group on Snake Bites in Martinique.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antivenins; Blood Coagulation; Bothrops; Drug T | 1995 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi.
Topics: Anticoagulants; Capillaries; Colitis, Ulcerative; Humans; Intestinal Mucosa; Nadroparin; Prospective | 2001 |
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Topics: Aged; COVID-19; Enoxaparin; Female; Humans; Male; Middle Aged; Outpatients; SARS-CoV-2; Thrombosis; | 2022 |
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhag | 2023 |
Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.
Topics: Anticoagulants; Biosimilar Pharmaceuticals; Enoxaparin; Gastrointestinal Neoplasms; Humans; Postoper | 2023 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Topics: Anticoagulants; Betacoronavirus; Blood Coagulation; Coronavirus Infections; COVID-19; Enoxaparin; Eq | 2020 |
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID).
Topics: Adult; Aged; Anticoagulants; Brazil; COVID-19; COVID-19 Drug Treatment; Drug Administration Schedule | 2020 |
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Topics: Anticoagulants; Atorvastatin; COVID-19; COVID-19 Drug Treatment; Critical Illness; Double-Blind Meth | 2020 |
Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.
Topics: Anticoagulants; Catheterization, Central Venous; Child; Child, Preschool; Critical Illness; Enoxapar | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
Topics: Aged; Anticoagulants; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Critical Care; Dose-Respons | 2022 |
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
Topics: Administration, Oral; Anticoagulants; Brazil; COVID-19; Drug Administration Schedule; Enoxaparin; Fi | 2021 |
Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
Topics: Adult; Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Male; SARS-CoV-2; Thrombosis | 2021 |
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithro | 2018 |
Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Male; Re | 2019 |
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Blood Coagu | 2019 |
A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dose-Response Relationship, Drug; Double- | 2013 |
In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
Topics: Adolescent; Adult; Anticoagulants; Biotin; Cardiac Catheters; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
Topics: Age Factors; Aged; Anticoagulants; Canada; Enoxaparin; Europe; Female; Follow-Up Studies; Hemorrhage | 2013 |
[Prophylaxis of thrombotic complications in patients after reconstructive operations on the main arteries of the lower extremities, made for arteriosclerosis obliterans in a critical ischemia stage].
Topics: Aged; Anticoagulants; Arteriosclerosis Obliterans; Blood Coagulation; Enoxaparin; Female; Humans; Is | 2014 |
Comparison of the usefulness of enoxaparin versus warfarin for prevention of left ventricular mural thrombus after anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Anterior Wall Myocardial Infarction; Anticoagulants; Enoxaparin; Fem | 2015 |
Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: A randomized cross-over trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cross-Over Stud | 2016 |
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Enoxaparin; Factor Xa Inhibitors; Female; Germany; Humans; Male; | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Eptifibatide; Erythrocytes; Fibrin; Fi | 2008 |
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Aged; Aging; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Arter | 2009 |
Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa; Female; Glucuronidase; Hip; Humans; Knee; Male; Middle | 2012 |
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.
Topics: Anticoagulants; Bacterial Infections; Bacterial Translocation; Biomarkers; DNA, Bacterial; Enoxapari | 2012 |
Bioactivity of enoxaparin in critically ill patients with normal renal function.
Topics: Adult; Aged; Anticoagulants; Case-Control Studies; Critical Illness; Enoxaparin; Factor Xa Inhibitor | 2012 |
[Treatment of left intraventricular thrombosis with low molecular weight heparin].
Topics: Aged; Anticoagulants; Echocardiography; Enoxaparin; Feasibility Studies; Female; Heparin, Low-Molecu | 2003 |
Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia.
Topics: Abortion, Habitual; Adult; Birth Rate; Enoxaparin; Family Health; Female; Fibrinolytic Agents; Human | 2003 |
Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Kidney Failur | 2004 |
Treatment of left ventricular thrombi with a low molecular weight heparin.
Topics: Anticoagulants; Enoxaparin; Female; Heart Diseases; Heart Ventricles; Humans; Male; Middle Aged; Pro | 2005 |
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Therapy, Combination; Elective Surgical P | 2005 |
Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients.
Topics: Adolescent; Child; Child, Preschool; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Hum | 2006 |
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Contrast Media; Coronary Angio | 2006 |
Bone density changes in women who receive thromboprophylaxis in pregnancy.
Topics: Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Heparin; Humans; Pregnancy; Prospective Stu | 2006 |
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypass; | 2007 |
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplast | 2006 |
Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
Topics: Adult; Anterior Cruciate Ligament; Anticoagulants; Arthroscopy; Double-Blind Method; Drug Administra | 2007 |
Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Cross-Over Studies; Enoxaparin; Fe | 2009 |
Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female | 1995 |
Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Topics: Cost-Benefit Analysis; Decision Trees; Enoxaparin; Hip Prosthesis; Humans; Pulmonary Embolism; Sensi | 1995 |
[Optimization of enoxaparin dose in the prevention of coagulation in the circuits of hemodialysis: results of a multicenter study].
Topics: Adult; Aged; Enoxaparin; Female; Humans; Male; Middle Aged; Renal Dialysis; Thrombosis | 1994 |
Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.
Topics: Adult; Biopsy; Cohort Studies; Enoxaparin; Female; Humans; Incidence; Kidney; Male; Middle Aged; Nep | 1995 |
[Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure].
Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Enoxaparin; Extracorporeal Circulation; Female; He | 1994 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Vessel Prosthesis; Enoxaparin; Female; Heparin | 1995 |
Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial.
Topics: Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Enoxaparin; Female; | 1996 |
A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bandages; Enoxaparin; Female; Hip Prosthesis; Humans | 1996 |
Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; | 1998 |
Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Heparin; Heparin, Low-Molecular-Weight; Hu | 1998 |
Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Foot; Humans; Male; Middle | 1998 |
Low molecular weight heparin in coronary stenting.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pilot Proj | 1998 |
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra | 1999 |
Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitor | 1999 |
The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer.
Topics: Adult; Aged; Antithrombin III; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Fibrinoly | 2001 |
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Cesarean Section; Dalteparin; Enoxaparin; Facto | 2001 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal | 2002 |
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L | 2001 |
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N | 2019 |
Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.
Topics: Critical Care; Dalteparin; Double-Blind Method; Fibrinolytic Agents; Heparin; Humans; Informed Conse | 2013 |
Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies.
Topics: Acenocoumarol; Aged; Anticoagulants; Catheterization, Central Venous; Dalteparin; Female; Humans; Ma | 2009 |
Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
Topics: Adult; Aged; Anticoagulants; Aryldialkylphosphatase; Dalteparin; Drug Costs; Female; Heparin; Humans | 2009 |
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Anticoagulants; Antithrombins; Azetidines; Be | 2010 |
Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation Factors; Dalteparin; Female; | 2003 |
Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.
Topics: Adult; Cohort Studies; Dalteparin; Female; Fibrinolytic Agents; Humans; Middle Aged; Pregnancy; Preg | 2003 |
Video laparoscopic surgery: is out-of-hospital thromboprophylaxis necessary?
Topics: Adult; Aged; Cohort Studies; Dalteparin; Female; Fibrinolytic Agents; Humans; Laparoscopy; Male; Mid | 2005 |
The effect of oral anticoagulation on clotting during hemodialysis.
Topics: Administration, Oral; Aged; Anticoagulants; Blood Coagulation; Cross-Over Studies; Dalteparin; Drug | 2005 |
Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Ankle Injuries; Anticoagulants; Dalteparin; Double-Blind M | 2007 |
A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Dalteparin; Drug Administration Schedule; Female; Fibrinolytic Agent | 1996 |
Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.
Topics: Aged; Aged, 80 and over; Bandages; Chi-Square Distribution; Dalteparin; Female; Femoral Vein; Fibrin | 1996 |
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
Topics: Adult; Aged; Anticoagulants; Dalteparin; Double-Blind Method; Female; Hip; Hip Prosthesis; Humans; M | 1997 |
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.
Topics: Aged; Anticoagulants; Dalteparin; Double-Blind Method; Embolism; Female; Heart Diseases; Heart Ventr | 1997 |
In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Female; Femoral Artery; Hemorrhage; Heparin; Heparin A | 1997 |
Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study.
Topics: Adult; Dalteparin; Drug Administration Schedule; Female; Humans; Longitudinal Studies; Pregnancy; Pr | 1998 |
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Double-B | 1998 |
A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy.
Topics: Adult; Anticoagulants; Antithrombin III; Area Under Curve; Circadian Rhythm; Cross-Over Studies; Dal | 1998 |
Effect of anticoagulation on blood membrane interactions during hemodialysis.
Topics: Adult; Anticoagulants; Blood Coagulation; Cell Adhesion; Citrates; Dalteparin; Erythrocytes; Female; | 1999 |
Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy.
Topics: Adult; Dalteparin; Demography; Female; Fractures, Bone; Hemorrhage; Heparin; Heparin, Low-Molecular- | 1999 |
Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety--a preliminary report.
Topics: Adult; Dalteparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Outpatients; Thrombosis; | 1999 |
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
Topics: Adult; Aged; Anticoagulants; Antithrombin III; Cohort Studies; Dalteparin; Dose-Response Relationshi | 2000 |
Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Feasibility Studies; Female; Hemorrhage; Hospitalization; H | 2001 |
Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.
Topics: Aged; Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective | 2022 |
Anti-Xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Dose-Response Relationship, Drug; Drug M | 2013 |
Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic postoperative deep venous thrombosis.
Topics: Abdomen; Bandages; Elective Surgical Procedures; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Mol | 1995 |
332 other studies available for dalteparin and Thrombosis
| Article | Year |
|---|---|
Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.
Topics: Acute Kidney Injury; Anticoagulants; COVID-19; Critical Illness; Humans; Nadroparin; Prospective Stu | 2022 |
Unfractionated Heparin Versus Subcutaneous Nadroparin in Adults Supported With Venovenous Extracorporeal Membrane Oxygenation: a Retrospective, Multicenter Study.
Topics: Adult; Anticoagulants; Extracorporeal Membrane Oxygenation; Female; Heparin; Humans; Male; Middle Ag | 2021 |
[Prevention of thrombohemorrhagic postoperative complications in patients with benign prostatic hyperplasia].
Topics: Fibrinolytic Agents; Hemorrhage; Humans; Low-Level Light Therapy; Male; Nadroparin; Postoperative Co | 2017 |
Thrombogenesis in Thrombophilic Pregnancy: Evaluation of Low-Molecular-Weight Heparin Prophylaxis.
Topics: Adult; Anticoagulants; Case-Control Studies; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-We | 2017 |
Iatrogenic calcinosis cutis after subcutaneous LMW-heparin administration in a hemodialysis patient.
Topics: Biopsy, Needle; Calcinosis; Female; Humans; Iatrogenic Disease; Immunohistochemistry; Injections, Su | 2013 |
Effect of acetylsalicylic acid on microvascular thrombosis in autologous breast reconstruction.
Topics: Adult; Aspirin; Autografts; Fibrinolytic Agents; Humans; Mammaplasty; Middle Aged; Myocutaneous Flap | 2014 |
[Prophylaxis of thrombohemorrhagic complications in surgical treatment of chemoresistant pulmonary tuberculosis].
Topics: Adult; Anticoagulants; Antitubercular Agents; Female; Hemorrhage; Humans; Hydroxyethylrutoside; Indo | 2014 |
[Determination of anti-Xa activity in cancer patients].
Topics: Anticoagulants; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Humans; Nadroparin; Neoplasms; Thrombo | 2008 |
Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention.
Topics: Animals; Arteries; Clinical Trials as Topic; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Mal | 2010 |
Successful thrombolysis of late, non-obstructive mitral bioprosthetic valve thrombosis: case report and review of the literature.
Topics: Acenocoumarol; Aged; Bioprosthesis; Echocardiography, Transesophageal; Female; Fibrinolytic Agents; | 2011 |
Anti-thrombotic effect of a synthetic heparin mimetic in an arterial model of thrombosis in rats: comparison with unfractionated heparin and nadroparin.
Topics: Animals; Carotid Arteries; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Nadropari | 2002 |
Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin.
Topics: Arthroplasty, Replacement, Hip; Disseminated Intravascular Coagulation; Female; Humans; Immunoglobul | 2003 |
Thrombosis of a prosthetic aortic valve during pregnancy despite therapeutic dosage of Nadroparin.
Topics: Adult; Aortic Valve; Female; Heart Valve Prosthesis; Heparin; Heparin, Low-Molecular-Weight; Humans; | 2004 |
Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: results of a prospective study.
Topics: Angiography; Brain; Drug Administration Schedule; Humans; Nadroparin; Postoperative Hemorrhage; Pros | 2004 |
Evaluation of two experimental venous thrombosis models in the rat.
Topics: Animals; Blood Coagulation Tests; Chlorides; Disease Models, Animal; Female; Ferric Compounds; Hemos | 2005 |
Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Indomethacin; | 1995 |
Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Topics: Animals; Blood Coagulation; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrino | 1994 |
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
Topics: Animals; Antithrombin III; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Male; Nadroparin; Oli | 1994 |
[Antithrombotic properties of heparin independent of its anticoagulant activity].
Topics: Animals; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Heparin; Laser | 1994 |
Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties.
Topics: Animals; Anticoagulants; Bleeding Time; Disaccharides; Factor Xa Inhibitors; Fibrinolytic Agents; He | 1994 |
Successful treatment of catheter-related sepsis and extraluminal catheter thrombosis with vancomycin and fraxiparin without catheter removal.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Catheterization, Central Venous; Catheters | 1997 |
Calciphylaxis, thrombotic diathesis and defects in coagulation regulation.
Topics: Blood Coagulation Disorders; Calciphylaxis; Disease Susceptibility; Humans; Nadroparin; Protein C; P | 1997 |
[Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV Study].
Topics: Aged; Drug Administration Schedule; Female; Heart Ventricles; Heparin, Low-Molecular-Weight; Humans; | 1997 |
Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model.
Topics: Animals; Blood Coagulation Factors; Disease Models, Animal; Fibrinolytic Agents; Heparin; Heparinoid | 1999 |
No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients.
Topics: Bone Marrow Transplantation; Catheterization, Central Venous; Fibrinolytic Agents; Humans; Nadropari | 2000 |
[Ambulatory therapy of thrombosis with low molecular weight heparin. Further simplification by one-time administration].
Topics: Ambulatory Care; Clinical Trials as Topic; Drug Administration Schedule; Enoxaparin; Humans; Injecti | 2001 |
Clinical experiences with low-molecular weight heparins in pediatric patients.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Enoxaparin; Factor Xa Inhibitors; Female; Hepar | 2001 |
[Fraxiparin in the treatment of thrombophilia in angiopathy].
Topics: Adult; Anticoagulants; Female; Humans; Male; Middle Aged; Nadroparin; Peripheral Vascular Diseases; | 2001 |
[The use of parnaparin sodium (Fluxum) in the prevention of thromboembolic complications after surgical treatment of fractures associated with high risks of thrombosis].
Topics: Anticoagulants; Enoxaparin; Fracture Fixation; Fractures, Bone; Heparin, Low-Molecular-Weight; Human | 2020 |
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation; COVID-19; COVID-19 Drug Trea | 2020 |
Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
Topics: Carboxypeptidase B2; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Wei | 2004 |
Bemiparin vs enoxaparin in the prevention of thrombosis in microvascular head and neck reconstruction.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Post | 2022 |
Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy.
Topics: Animals; Anticoagulants; Antithrombins; Carotid Arteries; Cerebral Revascularization; Dabigatran; He | 2019 |
A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery.
Topics: Adult; Aged; Algorithms; Body Weight; Cohort Studies; Female; Follow-Up Studies; Heparin, Low-Molecu | 2009 |
[Hip fracture during pregancy in a woman with transient osteporosis].
Topics: Accidental Falls; Adult; Anticoagulants; Bone Screws; Cesarean Section; Female; Fracture Fixation, I | 2010 |
Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Hyperkalemia; Potassium; Thrombosis | 2005 |
Does low molecular weight heparin really protect against prosthetic valve thrombosis during pregnancy with strict anti-Xa monitoring?
Topics: Anticoagulants; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; Heparin, Low-Molec | 2021 |
Primary thromboprophylaxis to prevent thrombotic events in pediatric oncology patients with a malignant mediastinal mass.
Topics: Anticoagulants; Child; Enoxaparin; Humans; Neoplasms; Thrombosis; Vena Cava, Superior; Venous Thromb | 2021 |
Prophylaxis with low-molecular-weight heparin reduces thrombotic events and allows continuation of asparaginase containing regimens during intensification phase.
Topics: Anticoagulants; Asparaginase; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Thrombosis | 2022 |
Comparison of the injection of low-molecular weight heparin in the arterial vs. venous blood line for preventing extracorporeal circuit clotting during hemodialysis.
Topics: Anticoagulants; Enoxaparin; Hemodiafiltration; Heparin, Low-Molecular-Weight; Humans; Molecular Weig | 2022 |
Post-operative Anticoagulation Strategy Following Comprehensive Stage 2 Procedure for Single Ventricle Physiology.
Topics: Anticoagulants; Blood Coagulation; Child; Enoxaparin; Humans; Infant; Retrospective Studies; Thrombo | 2022 |
Investigating the experience of parents who have given their infants enoxaparin at home.
Topics: Anticoagulants; Child; Enoxaparin; Humans; Infant; Parents; Quality of Life; Thrombosis | 2022 |
Anti-Inflammatory Effects and Decreased Formation of Neutrophil Extracellular Traps by Enoxaparin in COVID-19 Patients.
Topics: Anti-Inflammatory Agents; COVID-19 Drug Treatment; Cytokines; DNA; Enoxaparin; Extracellular Traps; | 2022 |
The mechanism by which enoxaparin sodium-high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells.
Topics: Animals; Bone Cements; CD40 Antigens; Endothelial Cells; Enoxaparin; Humans; Materials Testing; Poly | 2022 |
An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pilot Projects; Pyraz | 2022 |
Prophylactic Enoxaparin Against Catheter-Associated Thrombosis in Postoperative Cardiac Children: An Interrupted Time Series Analysis.
Topics: Anticoagulants; Central Venous Catheters; Child; Enoxaparin; Humans; Infant; Interrupted Time Series | 2022 |
Enoxaparin to Prevent Catheter-Associated Thrombosis: Effective, But Is This a Tool We Need?
Topics: Anticoagulants; Catheters; Enoxaparin; Humans; Thrombosis | 2022 |
Assessment of BMI and Venous Thromboembolism Rates in Patients on Standard Chemoprophylaxis Regimens After Undergoing Free Tissue Transfer to the Head and Neck.
Topics: Anticoagulants; Body Mass Index; Chemoprevention; Cohort Studies; Enoxaparin; Female; Humans; Male; | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro.
Topics: Anticoagulants; Catheters; Enoxaparin; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; | 2023 |
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report.
Topics: Anticoagulants; Enoxaparin; Extracorporeal Membrane Oxygenation; Hemorrhage; Heparin; Heparin, Low-M | 2023 |
Comparison of edoxaban and enoxaparin in a rat model of AlCl
Topics: Animals; Enoxaparin; Factor Xa Inhibitors; Heparin; Humans; Male; Rats; Rats, Wistar; Superior Sagit | 2023 |
Practice patterns in the management of pediatric iliofemoral arterial thrombosis.
Topics: Adult; Blood Coagulation; Child; Enoxaparin; Heparin; Humans; Infant; Retrospective Studies; Thrombo | 2023 |
Thromboprophylaxis in pediatric patients with earthquake-related crush syndrome: a single centre experience.
Topics: Adolescent; Anticoagulants; Child; Crush Syndrome; Earthquakes; Enoxaparin; Female; Humans; Male; Th | 2023 |
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
Topics: Adult; Aged; Anticoagulants; Biomarkers; Enoxaparin; Gastrointestinal Neoplasms; Hemorrhage; Humans; | 2023 |
Transesophageal echocardiography-guided closure of electrically isolated left atrial appendage to constrain a rapidly growing thrombus despite anticoagulation and sinus rhythm.
Topics: Action Potentials; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial | 2020 |
A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aortic Valve; Aortic Valve Stenosis; Benzoates; Bi | 2020 |
Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clinical Decision-Making; Duration of T | 2020 |
Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report.
Topics: Adult; Anterior Wall Myocardial Infarction; Anticoagulants; Contraceptives, Oral, Combined; Contrace | 2020 |
Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin.
Topics: Anticoagulants; Biomarkers, Pharmacological; Blood Coagulation; Body Weight; Drug Dosage Calculation | 2020 |
Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.
Topics: Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Hemostasis; Humans; I | 2020 |
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.
Topics: Aged; Antithrombins; Arginine; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pipecolic Acids; Py | 2020 |
How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report.
Topics: Aged; Betacoronavirus; Blood Coagulation; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fibr | 2020 |
Priapism in a patient with coronavirus disease 2019 (COVID-19).
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Male; Middle Aged; Priapism; Thrombosis | 2021 |
Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset.
Topics: Aged; Anticoagulants; Computed Tomography Angiography; COVID-19; Dyspnea; Echocardiography; Enoxapar | 2020 |
COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis.
Topics: Anticoagulants; Betacoronavirus; Clinical Deterioration; Computed Tomography Angiography; Coronaviru | 2020 |
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.
Topics: Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Follow-Up Studies; H | 2021 |
Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial Infarction With Severe Left Ventricular Dysfunction.
Topics: Aged; Anterior Wall Myocardial Infarction; Anticoagulants; Dual Anti-Platelet Therapy; Echocardiogra | 2020 |
Rotational thromboelastometry in young, previously healthy patients with SARS-Cov2.
Topics: Adult; Anticoagulants; Blood Coagulation Disorders; COVID-19; Enoxaparin; Heparin; Humans; Pyrazoles | 2020 |
Inferior mesenteric vein thrombosis and COVID-19.
Topics: Adult; Analgesics; Anticoagulants; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; E | 2020 |
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Factor Xa In | 2020 |
Thrombo-prophylaxis prevents thrombotic events in home-managed COVID patients. A registry study.
Topics: Aged; Anticoagulants; Body Mass Index; Case-Control Studies; COVID-19; Enoxaparin; Female; Heparin, | 2020 |
Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort.
Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Nephrotic Syndrome; Thrombosis; Venous Thromb | 2021 |
Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19).
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; C-Reactive Protein; COVID-19; Dose-Response Re | 2021 |
Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
Topics: Anticoagulants; Child, Preschool; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Follow-Up Stu | 2021 |
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
Topics: Adult; Aged; Algorithms; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; | 2021 |
Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution.
Topics: Adolescent; Anticoagulants; Enoxaparin; Heart-Assist Devices; Hemorrhage; Humans; Outpatients; Prosp | 2022 |
Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry.
Topics: Anticoagulants; Blood Coagulation; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Healthcare | 2021 |
Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.
Topics: Anticoagulants; Aspirin; COVID-19; Enoxaparin; Humans; Respiration, Artificial; Retrospective Studie | 2021 |
COVID-19 and Hepatic Artery Thrombosis: A Case Report.
Topics: COVID-19; Enoxaparin; Female; Hepatic Artery; Humans; Middle Aged; SARS-CoV-2; Thrombosis | 2021 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle | 2018 |
Treatment of Prosthetic Valve Thrombosis with Bolus Dose Tenecteplase: An Experience from a Developing Country.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Aortic Valve; Developing Countries; Echocar | 2017 |
Combined Treatment with an Anticoagulant and a Vasodilator Prevents Steroid-Associated Osteonecrosis of Rabbit Femoral Heads by Improving Hypercoagulability.
Topics: Animals; Anticoagulants; Bone Morphogenetic Protein 2; Disease Models, Animal; Enoxaparin; Femur Hea | 2017 |
Anticoagulant Bridge Comparison in Mechanical Circulatory Support Patients.
Topics: Anticoagulants; Enoxaparin; Female; Fondaparinux; Heart-Assist Devices; Humans; International Normal | 2019 |
Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Topics: Anticoagulants; Central Venous Catheters; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; F | 2018 |
Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asp | 2018 |
Topics: Aged, 80 and over; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Intraoperativ | 2018 |
Pulmonary saddle thrombus.
Topics: Computed Tomography Angiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Pulmona | 2018 |
Women's views, adherence and experience with postnatal thromboprophylaxis.
Topics: Adult; Anticoagulants; Cesarean Section; Delivery, Obstetric; Enoxaparin; Female; Humans; Intermitte | 2019 |
Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Antithrombin III Deficiency; Asparaginase; Chil | 2019 |
Right heart masses in a patient with endometrial stromal sarcoma.
Topics: Echocardiography; Endometrial Neoplasms; Enoxaparin; Female; Fibrinolytic Agents; Heart Diseases; Hu | 2020 |
Missed Heparin-Induced Thrombocytopenia (HIT) Diagnosis in a Patient with Acute Stent Thrombosis.
Topics: Aged; Anticoagulants; Coronary Artery Disease; Enoxaparin; Heparin; Humans; Male; Percutaneous Coron | 2019 |
Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition.
Topics: Adenosine; Animals; Anticoagulants; Chlorides; Contrast Media; Enoxaparin; Ferric Compounds; Male; M | 2013 |
Spinal haematoma after removal of a thoracic epidural catheter in a patient with coagulopathy resulting from unexpected vitamin K deficiency.
Topics: Aged; Analgesia, Epidural; Anesthesia, General; Anticoagulants; Blood Coagulation Disorders; Blood C | 2013 |
Anticoagulation in cirrhosis: ready … set … wait!
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2013 |
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; | 2013 |
How I treat heterozygous hereditary antithrombin deficiency in pregnancy.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Drug Administration Schedule; Enoxaparin; Fema | 2013 |
Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI.
Topics: Anticoagulants; Enoxaparin; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Thro | 2014 |
Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
Topics: Adult; Anticoagulants; Body Mass Index; Cesarean Section; Cohort Studies; Enoxaparin; Factor Xa Inhi | 2013 |
Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Topics: Age Factors; Anticoagulants; Antithrombin III; Critical Illness; Dose-Response Relationship, Drug; D | 2014 |
Pulmonary embolism as a first manifestation of intracardiac extension of an endometrial stromal sarcoma.
Topics: Anticoagulants; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Endometrial Neoplasms; E | 2014 |
Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis.
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2014 |
A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator.
Topics: Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Vessel Anomalies; Coronary V | 2015 |
Anticoagulation management of left ventricular assist devices.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Heart Failure; Heart Transplantation; Heart Ventricles; | 2015 |
Structural and functional analyses of biosimilar enoxaparins available in Brazil.
Topics: Animals; Anticoagulants; Biosimilar Pharmaceuticals; Blood Coagulation; Blood Coagulation Tests; Bra | 2015 |
Pregnancy in a patient with hepatic artery thrombosis after liver transplantation: a case report.
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Collateral Circulation; Enoxaparin; Female; H | 2014 |
The balance of pro- and anticoagulant processes underlying thrombin generation.
Topics: alpha-Macroglobulins; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Computational Biolo | 2015 |
Thrombosis of a mechanical tricuspid valve prosthesis resolved with fibrinolysis.
Topics: Drug Therapy, Combination; Echocardiography, Three-Dimensional; Enoxaparin; Female; Fibrinolytic Age | 2014 |
Partial segmental thrombosis of the corpus cavernosum (PSTCC) diagnosed by contrast-enhanced ultrasound: a case report.
Topics: Adult; Anticoagulants; Aspirin; Contrast Media; Edema; Enoxaparin; Humans; Male; Pain; Penile Diseas | 2014 |
Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.
Topics: Anticoagulants; Antithrombin III; Enoxaparin; Factor Xa; Freezing; Hemolysis; Humans; Male; Thrombos | 2015 |
National survey on thromboprophylaxis and anticoagulant or antiplatelet management in neurosurgical and neurocritical patients.
Topics: Anesthesiology; Anticoagulants; Critical Care; Enoxaparin; Health Care Surveys; Humans; Intermittent | 2015 |
Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Female; Hematuria; Hemorrhage; Humans; | 2015 |
Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Infant, Newborn; Male; | 2015 |
Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations.
Topics: Adult; Anticoagulants; Blood Platelets; Dabigatran; Disseminated Intravascular Coagulation; Enoxapar | 2016 |
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Topics: Anticoagulants; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Enoxaparin; Factor Xa; Female; | 2015 |
Modulation of Thrombosis Significantly Reduces Testicular Damage after Testicular Torsion in Rats: Anti-Thrombotic Treatment and Testicular Torsion.
Topics: Animals; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Male; Random Allocation; Rats; Rats, Wista | 2016 |
[Bullous haemorrhagic dermatosis at distant sites due to enoxaparin: An uncommon secondary effect in an anticoagulated oncology patient].
Topics: Aged; Anticoagulants; Antineoplastic Agents; Enoxaparin; Female; Humans; Skin Diseases, Vesiculobull | 2016 |
Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
Topics: Allosteric Site; Animals; Anticoagulants; Binding Sites; Bleeding Time; Blood Coagulation; Blood Coa | 2016 |
In the nick of time: arterial thrombosis on starting combination chemotherapy in metastatic gastric adenocarcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Enoxaparin; Humans; Male; Pall | 2016 |
[Ultrasound dynamics lysis apex thrombus as an objective criterion of effectiveness of anticoagulation therapy in venous thrombosis].
Topics: Aged; Anticoagulants; Drug Monitoring; Enoxaparin; Female; Humans; International Normalized Ratio; L | 2016 |
Free-floating thrombus in a stenotic supraclinoid left internal carotid artery.
Topics: Aged; Anticoagulants; Aphasia; Carotid Artery, Internal; Carotid Stenosis; Enoxaparin; Female; Human | 2016 |
Partial thrombosis of the corpus cavernosum: should we dig deeper into coagulopathy disorders?
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; Humans; Magnetic Resonance | 2016 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation | 2016 |
Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
Topics: Adult; Animals; Anticoagulants; Bleeding Time; Cell Survival; Enoxaparin; Fondaparinux; Heparin; Hum | 2016 |
Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease.
Topics: Adult; Alcoholism; Anticoagulants; Dabigatran; Enoxaparin; Female; Hemostasis; Humans; Liver Cirrhos | 2017 |
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombo | 2016 |
Images in cardiovascular medicine. Regression of thrombus and electrocardiographic changes with thrombolytic therapy in acute massive pulmonary embolism.
Topics: Coronary Angiography; Creatine Kinase; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; | 2008 |
Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Catheter A | 2009 |
Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Dosage Calculations; Dru | 2009 |
[Leg venous thrombosis after work accident: serious surprise in echocardiography].
Topics: Accidents, Occupational; Adult; Casts, Surgical; Critical Care; Echocardiography, Doppler, Color; En | 2008 |
Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Drug Monitoring; Enoxaparin; Factor VII Defi | 2009 |
Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis.
Topics: Anticoagulants; Compartment Syndromes; Enoxaparin; Humans; Infant; Infant, Newborn; Male; Ornithine | 2009 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |
Aortic thrombosis in infancy.
Topics: Anticoagulants; Aortic Diseases; Aspirin; Echocardiography, Doppler; Enoxaparin; Female; Humans; Inf | 2009 |
Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026.
Topics: Animals; Anticoagulants; Chromatography, Affinity; Chromatography, Gel; Dogs; Enoxaparin; Factor Xa | 2009 |
Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Chemotherapy, Adjuvant; Enoxaparin; Female; Humans; | 2009 |
Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Enoxaparin; Eptifi | 2009 |
In vitro effects of detergent sclerosants on antithrombotic mechanisms.
Topics: Anticoagulants; Antithrombins; Blood Coagulation; Detergents; Dose-Response Relationship, Drug; Enox | 2009 |
Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.
Topics: Cardiac Catheterization; Dalteparin; Enoxaparin; Heart Diseases; Heparin, Low-Molecular-Weight; Huma | 2010 |
Paraprosthetic leak unmasked by combined enoxaparin/warfarin therapy for thrombosed mitral valve.
Topics: Anticoagulants; Drug Therapy, Combination; Echocardiography, Transesophageal; Enoxaparin; Fibrinolyt | 2009 |
Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.
Topics: Antibodies; Anticoagulants; Body Mass Index; Drug Administration Schedule; Enoxaparin; Evidence-Base | 2010 |
Use of enoxaparin to diminish the incidence of vascular access stenosis/thrombosis in chronic hemodialysis patients.
Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Enoxaparin; Female; Humans; | 2011 |
Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation.
Topics: Adult; Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Chi-Square Di | 2010 |
The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Topics: Anticoagulants; Antithrombin III; Arginine; Blood Coagulation; Blood Platelets; Cardiac Catheterizat | 2010 |
Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Topics: Anticoagulants; Creatinine; Critical Illness; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; H | 2010 |
Thrombocytosis associated with enoxaparin: A very rare cause in newborns.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Humans; Infant, Newborn; Infant, Newborn, Dis | 2010 |
Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.
Topics: Acute Coronary Syndrome; Anticoagulants; Catheterization; Enoxaparin; Fondaparinux; Hirudins; Humans | 2010 |
Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer.
Topics: Anticoagulants; Antineoplastic Agents; Aorta; Cisplatin; Enoxaparin; Humans; Lung Neoplasms; Male; M | 2010 |
Renal function and thromboprophylaxis in critically ill patients.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Humans; Kidney; Kidney Function Tests; Thrombosis | 2010 |
Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis.
Topics: Adult; Echocardiography, Transesophageal; Enoxaparin; Female; Fibrinolytic Agents; Heart Valve Prost | 2011 |
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mi | 2010 |
Error in body weight estimation leads to inadequate parenteral anticoagulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Chi-Square Distribution; Em | 2011 |
[Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Atrial Fibrillation; Drug T | 2010 |
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid | 2010 |
Rate of wound complications with enoxaparin use among women at high risk for postpartum thrombosis.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Humans; Puerperal Disorders; Retrospect | 2011 |
Do sick preterm babies need adult levels of AntiXa units for thrombolysis?
Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Agents; Humans; Infant, Newborn; I | 2011 |
Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous; | 2011 |
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Blood Co | 2011 |
Effort thrombosis in a young triathlete: an unusual presentation of painless neck swelling secondary to right brachiocephalic vein thrombosis.
Topics: Adult; Anticoagulants; Arm; Athletes; Brachiocephalic Veins; Enoxaparin; Humans; Male; Thrombosis; T | 2011 |
Progressive thrombosis in a 13-year-old girl with trisomy 21 under therapy with low molecular weight heparin.
Topics: Adolescent; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; | 2011 |
Fixed dosing regimes of enoxaparin for thromboprophylaxis do not reliably achieve target anti-Xa levels in women of normal weight during pregnancy.
Topics: Adult; Anticoagulants; Body Weight; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Comp | 2011 |
Generic versions of enoxaparin available for clinical use in Brazil are similar to the original drug.
Topics: Animals; Anticoagulants; Brazil; Drugs, Generic; Enoxaparin; Hemorrhage; Magnetic Resonance Spectros | 2011 |
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Topics: Animals; Blood Coagulation; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Familial Primary Pulmonary | 2011 |
Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
Topics: Anticoagulants; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Drug Monitoring; Enoxaparin; | 2012 |
Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency.
Topics: Anetoderma; Antithrombin III Deficiency; Enoxaparin; Humans; Leg Ulcer; Thrombosis | 2011 |
Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Catheters; Dis | 2011 |
Dabigatran after cardiac surgery: caution advised.
Topics: Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Enoxaparin; Fibrinolytic Agent | 2011 |
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Azepines; Benzamides; Bleeding Time; Disease Models, | 2011 |
Dabigatran etexilate in mechanical valve thromboprophylaxis.
Topics: Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Enoxaparin; Fibrinolytic Agent | 2011 |
Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Topics: Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fema | 2012 |
Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Topics: Animals; Anticoagulants; Blood Coagulation; Brazil; Disease Models, Animal; Drugs, Generic; Enoxapar | 2012 |
Intrauterine upper extremity thrombosis successfully treated with recombinant tissue plasminogen activator, enoxaparin and collagenase.
Topics: Collagenases; Enoxaparin; Fetal Diseases; Fibrinolytic Agents; Humans; Infant, Newborn; Male; Necros | 2012 |
A giant tumor thrombi filling right ventricle in a thrombocytopenic patient with renal cell carcinoma.
Topics: Anticoagulants; Carcinoma, Renal Cell; Chest Pain; Dyspnea; Echocardiography; Enoxaparin; Heart Vent | 2012 |
Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation.
Topics: Anticoagulants; Cross-Sectional Studies; Enoxaparin; Female; Fontan Procedure; Heart Defects, Congen | 2012 |
LMWH - action-monitoring for all patients.
Topics: Enoxaparin; Factor Xa; Female; Fibrinolytic Agents; Humans; Infant, Premature, Diseases; Male; Throm | 2012 |
Extensive skin necrosis induced by low-molecular-weight heparin in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Aspirin; Drug Eruptions; Drug Therapy, Combination; Enoxaparin; Female; F | 2012 |
Impact of stage 3B chronic kidney disease on thrombosis and bleeding outcomes after orthopedic surgery in patients treated with desirudin or enoxaparin: insights from a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Drug Adm | 2012 |
[Early asymptomatic pacemaker lead thrombosis successfully treated with pharmacotherapy].
Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Equipment Failure; Female; Humans; Pacemaker, Artific | 2012 |
Successful use of low molecular weight heparin in intracardiac thrombus of an extremely low birth weight infant.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography; Enoxaparin; Female | 2013 |
Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression.
Topics: Abortion, Habitual; Anticoagulants; Cell Differentiation; Cell Movement; Cells, Cultured; Cysteine-R | 2012 |
Severe hyperkalemia in critically ill patients treated with prophylactic doses of enoxaparin.
Topics: Aged; Enoxaparin; Female; Fibrinolytic Agents; Humans; Hyperkalemia; Intensive Care Units; Male; Mid | 2012 |
[Comparative analysis of arterial bioprostheses with various antithrombotic modification].
Topics: Biological Availability; Bioprosthesis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantatio | 2012 |
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facili | 2013 |
Prophylactic anticoagulation in cirrhotics: a paradox for prime time?
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2012 |
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Topics: Acute Disease; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Drug Substitution; Em | 2013 |
Portal vein thrombosis in cirrhosis: ignore, prevent, or treat?
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2013 |
Reply: To PMID 22819864.
Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re | 2013 |
Ultra-low-molecular-weight heparins: precise structural features impacting specific anticoagulant activities.
Topics: Anticoagulants; Carbohydrate Sequence; Circular Dichroism; Enoxaparin; Glucosamine; Heparin; Heparin | 2013 |
Low-molecular-weight heparin for vertebral artery dissection.
Topics: Child; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Male; Thrombosis; Treatment Outcome; Verte | 2002 |
[Prosthetic valve thrombosis].
Topics: Anticoagulants; Aortic Valve; Enoxaparin; Fibrinolytic Agents; Heart Valve Diseases; Heart Valve Pro | 2001 |
Regarding "Anticoagulation with enoxaparin versus intravenous unfractionated heparin in postoperative vascular surgery patients".
Topics: Anticoagulants; Enoxaparin; Heparin; Humans; Infusions, Intravenous; Injections, Subcutaneous; Posto | 2003 |
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin | 2003 |
Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.
Topics: Animals; Anticoagulants; Blood Coagulation Tests; Enoxaparin; Fondaparinux; Heart Valve Prosthesis; | 2003 |
Postoperative anticoagulation in vascular surgery--Part two: A summary of lessons learned in our successful discharge planning experience using enoxaparin after vascular surgery.
Topics: Anticoagulants; Drug Monitoring; Enoxaparin; Humans; Length of Stay; Nurse's Role; Patient Care Team | 2003 |
Prosthetic heart valves and pregnancy.
Topics: Abnormalities, Drug-Induced; Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Humans; Pre | 2003 |
Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound.
Topics: Adolescent; Arteries; Child; Child, Preschool; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infa | 2004 |
Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Eptifibatide; Factor Xa; Female; Humans; Male; Middle Aged; Peptid | 2004 |
An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Dose-Response Relationship, Drug; Enoxaparin; F | 2004 |
Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition.
Topics: Amidines; Animals; Anticoagulants; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Dos | 2004 |
Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Topics: Anticoagulants; Clinical Trials as Topic; Dalteparin; Drug Approval; Enoxaparin; France; Heparin, Lo | 2005 |
Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations.
Topics: Anticoagulants; Chemistry, Pharmaceutical; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-W | 2005 |
Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.
Topics: Abdominal Wall; Adjuvants, Immunologic; Chondroitin Sulfates; Dermatan Sulfate; Enoxaparin; Female; | 2005 |
The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
Topics: Angina Pectoris; Anticoagulants; Blood Coagulation; Cardiac Catheterization; Coronary Angiography; D | 2005 |
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibito
Topics: Anticoagulants; Coronary Disease; Drug Interactions; Endothelium, Vascular; Enoxaparin; Fibrinolytic | 2005 |
Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
Topics: Animals; Anticoagulants; Aspirin; Bleeding Time; Carotid Arteries; Clopidogrel; Dose-Response Relati | 2006 |
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2006 |
Safer alternative to heparin identified.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Humans; Leg; Polysaccharides; Thrombosis | 2006 |
Risk of bleeding after elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Cause of Death; Enoxaparin; Hemorrhage; Heparin; Hum | 2006 |
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
Topics: Body Weight; Costs and Cost Analysis; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-W | 2007 |
Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis.
Topics: Adult; Anticoagulants; Enoxaparin; Factor VIII; Fibrinogen; Fibrinogens, Abnormal; Graft Survival; H | 2007 |
Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival.
Topics: Animals; Anticoagulants; Blood Coagulation; Enoxaparin; Graft Rejection; Graft Survival; Heart Trans | 2006 |
[Analgesia for childbirth in a patient with factor V Leiden mutation].
Topics: Activated Protein C Resistance; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants; | 2007 |
Childhood-onset skin necrosis resulting from protein C deficiency.
Topics: Blood Component Transfusion; Child, Preschool; Enoxaparin; Fibrinolytic Agents; Follow-Up Studies; H | 2007 |
[The best of thrombosis in 2006].
Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Coronary Disease; Enoxaparin; Humans; Myocardi | 2007 |
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
Topics: Alanine; Cell Line, Tumor; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weight; Hum | 2007 |
Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxaparin; Equipment | 2007 |
Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Topics: Anticoagulants; Bone Diseases, Metabolic; Catheters, Indwelling; Dose-Response Relationship, Drug; E | 2007 |
Unbalanced protein S deficiency due to warfarin treatment as a possible cause for thrombosis.
Topics: Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; International Normalized Ratio; Middl | 2007 |
Catheter induced clot formation during angioplasty: an enoxaparin side effect?
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxaparin; Equipment Failur | 2007 |
External iliac artery thrombosis after open reduction of an acetabular fracture: a case report.
Topics: Acetabulum; Adult; Angiography; Anticoagulants; Enoxaparin; Female; Fracture Fixation, Internal; Fra | 2008 |
Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome.
Topics: Alprostadil; Analysis of Variance; Animals; Antiphospholipid Syndrome; Aspirin; Behavior, Animal; be | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
Cardioverter-defibrillator lead-related thrombus treated with prolonged anticoagulation in patient with prothrombotic disorder.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Defibrillators, Implantable; Echocardiography; Eno | 2008 |
In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus.
Topics: Cardiac Catheterization; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin; Humans; In Vitro Te | 2008 |
Enoxaparin does not ameliorate limb ischemia-reperfusion injury.
Topics: Animals; Anticoagulants; Biomarkers; Enoxaparin; Hindlimb; Inflammation; Male; Mice; Mice, Inbred C5 | 2008 |
Effect of dextran and enoxaparin on early ePTFE graft thrombogenicity in sheep.
Topics: Animals; Blood Vessel Prosthesis; Carotid Artery, Common; Dextrans; Double-Blind Method; Drug Therap | 1995 |
Spinal subdural bleeding after attempted epidural and subsequent spinal anaesthesia in a patient on thromboprophylaxis with low molecular weight heparin.
Topics: Aged; Anesthesia, Epidural; Anesthesia, Spinal; Enoxaparin; Female; Hematoma, Epidural, Cranial; Hem | 1995 |
[Histologic changes in ligated stumps of ovarian blood vessels in preoperative low-molecular weight preventive heparin administration].
Topics: Endothelium, Vascular; Enoxaparin; Female; Humans; Hysterectomy; Injections, Subcutaneous; Ligation; | 1995 |
Enoxaparin and a new look at clot prevention.
Topics: Enoxaparin; Humans; Thrombosis | 1994 |
Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)
Topics: Adult; Dalteparin; Drug Eruptions; Enoxaparin; Erythema; Female; Femoral Vein; Humans; Iliac Vein; P | 1993 |
Heparin-induced thrombocytopenia and paradoxical venous thromboses.
Topics: Aged; Axillary Vein; Coronary Disease; Diabetes Mellitus, Type 2; Enoxaparin; Female; Femoral Vein; | 1993 |
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Topics: Animals; Anticoagulants; Aprotinin; Arthropod Proteins; Cattle; Cricetinae; Drug Evaluation, Preclin | 1995 |
Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries.
Topics: Administration, Topical; Anastomosis, Surgical; Animals; Enoxaparin; Femoral Artery; Fibrinolytic Ag | 1995 |
Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
Topics: Adolescent; Anticoagulants; Blood Coagulation Tests; Case-Control Studies; Catheters, Indwelling; Ch | 1996 |
Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses.
Topics: Administration, Topical; Anastomosis, Surgical; Animals; Anticoagulants; Disease Models, Animal; Dos | 1997 |
Low-molecular-weight heparin in the management of Trousseau's syndrome.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Neoplasms; Paraneoplastic Synd | 1997 |
Low-molecular-weight heparins.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Enoxaparin; Hematoma; Humans; Spinal Diseases; Thrombosis | 1998 |
Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Body Weight; | 1998 |
Delayed-type hypersensitivity to subcutaneous enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Hypersensitivity, Delayed; Injections, Subcutaneou | 1998 |
Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons.
Topics: Animals; Anticoagulants; Bleeding Time; Cardiopulmonary Bypass; Complement Activation; Enoxaparin; F | 1998 |
Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Complications, He | 1999 |
Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
Topics: Enoxaparin; Factor Xa Inhibitors; Heparin; Humans; Thrombolytic Therapy; Thrombosis | 1999 |
Treatment of mobile left ventricular thrombus with low-molecular-weight heparin.
Topics: Enoxaparin; Fibrinolytic Agents; Heart Diseases; Heart Ventricles; Humans; Male; Middle Aged; Thromb | 1999 |
Better control coming for clotting and bleeding.
Topics: Anticoagulants; Blood Coagulation Factors; Enoxaparin; Genetic Therapy; Hemophilia A; Hemostasis; Hu | 1999 |
Low-molecular-weight heparin for prosthetic heart valves: treatment failure.
Topics: Adult; Aged; Anticoagulants; Aortic Valve; Contraindications; Echocardiography; Enoxaparin; Female; | 2000 |
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; | 2000 |
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Antithrombins; Arteriovenous Shunt, Surgic | 2000 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
Topics: Anemia; Anticoagulants; Dalteparin; Delivery, Obstetric; Dextrans; Enoxaparin; Female; Hemorrhage; H | 2000 |
Thromboprophylaxis using a low molecular weight heparin delays fracture repair.
Topics: Animals; Anticoagulants; Biomechanical Phenomena; Bone and Bones; Bony Callus; Disease Models, Anima | 2000 |
A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report.
Topics: Adult; Anticoagulants; Dilatation and Curettage; Enoxaparin; Female; Heart Valve Prosthesis; Heart V | 2000 |
Use of enoxaparin in a preterm infant.
Topics: Anticoagulants; Enoxaparin; Humans; Infant, Newborn; Infant, Premature, Diseases; Thrombosis | 2000 |
Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
Topics: Adult; Anticoagulants; Creatine; Drug Monitoring; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec | 2001 |
Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica.
Topics: Animals; Antibodies, Monoclonal; Anticoagulants; Antirheumatic Agents; Cauda Equina; Edema; Enoxapar | 2001 |
Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Transfusion; Drug Monitoring; Enoxaparin; Fema | 2001 |
Use of enoxaparin in a pregnant woman with a mechanical heart valve prosthesis.
Topics: Administration, Cutaneous; Adult; Anticoagulants; Aortic Valve; Contraindications; Enoxaparin; Femal | 2001 |
Enoxaparin treatment in women with mechanical heart valves during pregnancy.
Topics: Adult; Antibodies; Anticoagulants; Aspirin; Enoxaparin; Factor Xa; Female; Heart Valve Diseases; Hea | 2001 |
Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen.
Topics: Aged; Biopsy, Needle; Carcinoma, Endometrioid; Enoxaparin; Female; Hemorrhage; Humans; Iliac Vein; I | 2001 |
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
Topics: Amidines; Animals; Anticoagulants; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; E | 2001 |
[Heparin-induced thrombocytopenia in patients and prevention with low molecular weight heparin].
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; | 2001 |
Thromboprophylaxis with reviparin in a patient with acquired hemophilia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Carcinoma, Renal Cell; Factor VIII; Hemophilia | 2005 |
Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury.
Topics: Adenosine Diphosphate; Animals; Arteries; Blood Coagulation Tests; Blood Flow Velocity; Collagen; Di | 2000 |
Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.
Topics: Administration, Oral; Animals; Aorta; Blood Coagulation Tests; Dose-Response Relationship, Drug; End | 2001 |
Low-molecular-weight heparin in patients with deep-vein thrombosis.
Topics: Anticoagulants; Heparin; Heparin, Low-Molecular-Weight; Humans; Partial Thromboplastin Time; Seconda | 2001 |
Low-molecular-weight heparin in patients with deep-vein thrombosis.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Thromboembolism; Thrombosis | 2001 |
[Facilitated patient management with low molecular weight heparin].
Topics: General Practice; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Thrombosis | 2016 |
[Internist patients are strongly thrombosis endangered. CERTIFY study has arrived].
Topics: Age Factors; Aged; Anticoagulants; Antifibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; | 2007 |
[LMWH and UFH in direct comparison. Consent: CERTIFY].
Topics: Age Factors; Aged; Anticoagulants; Antifibrinolytic Agents; Double-Blind Method; Follow-Up Studies; | 2007 |
Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients.
Topics: Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Portal Vein; Rec | 2023 |
A Man with a Clot on his Platelets: Adrenal Carcinoma and Dynamic Right Ventricular Inflow Obstruction.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged, 80 and over; Anticoagulants; Dalteparin; H | 2020 |
Word Thrombosis Day-5 years on.
Topics: Anniversaries and Special Events; Anticoagulants; Dalteparin; Global Burden of Disease; Humans; Risk | 2019 |
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Topics: Aged; Anticoagulants; APACHE; COVID-19; Critical Illness; Dalteparin; Female; Humans; Intensive Care | 2020 |
Analysis of blood clotting with the total thrombus analysis system in healthy dogs.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Coagulation Tests; Dalteparin; Dogs; Fema | 2021 |
Dalteparin in Newborn Thrombosis, Time for a New Starting Dose.
Topics: Anticoagulants; Dalteparin; Humans; Infant; Infant, Newborn; Retrospective Studies; Thrombosis; Trea | 2021 |
Dalteparin anticoagulation in paediatric home haemodialysis.
Topics: Adolescent; Age Factors; Anticoagulants; Blood Coagulation; Child; Child, Preschool; Dalteparin; Dos | 2018 |
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Gastrointestinal Neoplasms; Humans; Markov Chains | 2019 |
Arterial thrombosis after vehicular trauma and humeral fracture in a dog.
Topics: Accidents, Traffic; Animals; Anticoagulants; Clopidogrel; Dalteparin; Dog Diseases; Dogs; Female; Fo | 2013 |
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
Topics: Adult; Aged; Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Hospital Mor | 2013 |
Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.
Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Dalteparin; Female; Fibrinolytic Agents; Hospital | 2014 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Prog | 2016 |
Dalteparin-sodium induced drug fever in a neonate.
Topics: Anticoagulants; Dalteparin; Fever; Heart Diseases; Humans; Infant, Newborn; Infant, Premature; Infan | 2016 |
A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin.
Topics: Adult; Antibody Specificity; Antigens, Human Platelet; Autoantibodies; Autoantigens; Dalteparin; Dos | 2008 |
The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Topics: Aged; Atrial Fibrillation; Cerebral Hemorrhage; Coronary Artery Disease; Dalteparin; Fatal Outcome; | 2009 |
Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation.
Topics: Adult; Antithrombin III; Blood Coagulation; Blood Component Transfusion; Dalteparin; Female; Fibrino | 2009 |
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Topics: Amidines; Animals; Antithrombin III; Antithrombins; Azetidines; Blood Coagulation; Chlorides; Daltep | 2010 |
Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication!
Topics: Adult; Anticoagulants; Brachial Artery; Dalteparin; Drug Therapy, Combination; Gangrene; Hemopneumot | 2012 |
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response R | 2002 |
Thrombophilic causes of retinal vascular thrombosis: etiology and treatment outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clinical Laboratory Techniques; Clopidogrel; Da | 2002 |
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F | 2003 |
Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury.
Topics: Animals; Carotid Artery Thrombosis; Dalteparin; Dose-Response Relationship, Drug; Endarterectomy, Ca | 2003 |
Cancer-associated thrombosis.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasms; Pulmonary Embolism; Risk Factors; Secondary Preventio | 2003 |
Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement.
Topics: Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Cost-Benefit Analysis; Dalteparin; Economi | 2003 |
Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Catheterization, Central Veno | 2004 |
[Initial trials give hope. Anticoagulants against cancer?].
Topics: Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Fibrinolytic Agents; Heparin; Human | 2003 |
Anticoagulation interruptus: not without risk.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Loss, Surgical; Carotid Arteri | 2004 |
[Paraneoplastic lupus anticoagulans syndrome].
Topics: Anticoagulants; Antiphospholipid Syndrome; Dalteparin; Female; Fibrinolytic Agents; Follow-Up Studie | 2005 |
Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits.
Topics: Animals; Dalteparin; Dextrans; Drug Synergism; Drug Therapy, Combination; Female; Fibrinolytic Agent | 1994 |
Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model.
Topics: Animals; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Dalteparin; Dise | 1994 |
Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting.
Topics: Adult; Blood Coagulation; Blood Donors; Cardiopulmonary Bypass; Dalteparin; Female; Hemostasis; Hepa | 1994 |
Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
Topics: Animals; Dalteparin; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination | 1994 |
Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.
Topics: Acute Kidney Injury; Adult; Aged; Blood Coagulation; Critical Care; Dalteparin; Female; Fibrinopepti | 1993 |
Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
Topics: Animals; Anticoagulants; Antithrombin III; Dalteparin; Disease Models, Animal; Disseminated Intravas | 1995 |
Low molecular weight heparin ('fragmin') in haemodialysis: is laboratory monitoring worthwhile?
Topics: Anticoagulants; Dalteparin; Female; Humans; Male; Middle Aged; Renal Dialysis; Thrombosis | 1995 |
Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Bleeding Time; Dalteparin; Dose-Response Relationship, Drug; Fibri | 1996 |
Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
Topics: Aged; Ambulatory Care; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Drug Administration Schedu | 1996 |
Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Proteins; Dal | 1998 |
Dalteparin for deep venous thrombosis: a hospital-in-the-home program.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Dalteparin; Female; Hom | 1998 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul | 1998 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul | 1998 |
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Topics: Animals; Anticoagulants; Arteriovenous Shunt, Surgical; Blood Coagulation; Dalteparin; Dose-Response | 2000 |
The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases.
Topics: Adolescent; Age Factors; Anticoagulants; Child; Child, Preschool; Dalteparin; Dose-Response Relation | 1999 |
Activation of coagulation and fibrinolysis in microsurgical reconstructions in the lower extremities.
Topics: Adult; Aged; Analysis of Variance; Blood Coagulation; C-Reactive Protein; Dalteparin; Enzyme-Linked | 2001 |
Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.
Topics: Aged; Anticoagulants; COVID-19 Drug Treatment; Female; Hospital Mortality; Humans; Male; Middle Aged | 2022 |
Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study.
Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective Studies; Thrombosis; Tinzaparin; Venou | 2022 |
Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study - The SeVEN EXTension study.
Topics: Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Thrombosis; Tinzaparin; Treat | 2021 |
Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
Topics: Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pr | 2017 |
Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cohort Studies; Drug Administration Schedule; Fact | 2017 |
Case report: ischemic priapism secondary to tinzaparin.
Topics: Adult; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Priapism; Thrombosis; Tinza | 2018 |
Mechanical Mitral Valve Thrombosis Secondary to Tinzaparin as an Anticoagulation Bridging Strategy.
Topics: Anticoagulants; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valv | 2018 |
Utility of global hemostatic assays in the management of anticoagulation in a haemophilia patient.
Topics: Anticoagulants; Coronary Angiography; Factor VIII; Hemophilia A; Hemorrhage; Humans; International N | 2018 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Mol | 2013 |
Tinzaparin failure in a pregnant patient with a mitral metal valve.
Topics: Adult; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; P | 2008 |
Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
Topics: Adult; Anticoagulants; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Female; Heparin, Low-Mo | 2010 |
Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days.
Topics: Aged; Aged, 80 and over; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Lipoproteins; Male; | 2003 |
Orally administered heparins prevent arterial thrombosis in a rat model.
Topics: Administration, Oral; Animals; Blood Flow Velocity; Carotid Artery Thrombosis; Disease Models, Anima | 2004 |
Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Topics: Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight | 2004 |
The effect of LMWH (tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis.
Topics: Adult; Blood Coagulation; Factor Xa; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; F | 2006 |
Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Topics: Animals; Anticoagulants; Cell Line, Tumor; Disaccharides; Factor Xa; Fibrinolytic Agents; Fondaparin | 2005 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
Topics: Age Factors; Aged; Aged, 80 and over; Factor Xa; Female; Fibrinolytic Agents; Hemorrhage; Heparin, L | 2000 |